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General introduction, aim and outline of this thesis
GENERAL INTRODUCTION
Vaccination
The advent of disease prevention by vaccination, introduced by pioneers such as Edward 
Jenner (1749-1823) and Louis Pasteur (1822-1895), started a revolution in medicine that 
is unparalleled to date. Vaccination strongly reduces disease burden, disability and death 
resulting from a variety of infectious diseases [1]. In fact, common (pediatric) diseases of 
the 20th century were reduced by 90% to 99% by modern vaccination programs in the 
United States [2, 3]. The success of vaccination even led to the eradication of smallpox, 
while an endgame strategic plan for polio eradication was drafted by the World Health 
Organization [4, 5]. Moreover, by preventing diseases, vaccination programs reduce 
healthcare costs drastically [6, 7]. 
Vaccination not only protects the vaccinated individuals, but in case of sufficiently high 
vaccination coverage also prevents the spread of disease, thereby indirectly protecting 
non-vaccinated individuals and those who do not respond to vaccination [8]. A successful 
vaccine must be highly effective, safe and have high vaccination coverage within the 
population [1, 8]. However, hesitance or refusal to vaccination is growing [9-11]. Religious 
views [12] and fear for side-effects [1] are cited as causes for growing refusal to vaccination. 
Furthermore, pain, fear and distress during vaccination leads to refusal, especially within 
the pediatric population [13].
Vaccine administration routes
Vaccination is usually performed via intramuscular and subcutaneous administration 
routes. These routes have the downsides of requiring trained personnel and painful 
injections by using hypodermic needles. Hypodermic needles also carry a risk for re-
use and needle-stick injuries. Therefore, alternative administration routes have been 
investigated, including the intradermal and mucosal routes [14-19]. These alternative 
administration routes are easily accessible, potentially remove the requirement for 
trained personnel for administration and may enable painless administration of the 
vaccine. Vaccination via the skin is of high interest, owing to the presence of high 
numbers of immune cells in the skin [14, 20-24], which may enable increased immune 
responses at equal or lower doses. For example, intradermal rabies vaccination has been 
reported to result in a 60-80% dose reduction compared to intramuscular vaccination 
[25-27]. Dose sparing has also been reported for intradermal vaccination as compared to 
intramuscular vaccination against hepatitis B [28, 29], influenza [30-35] and polio [36, 37].
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Intradermal vaccination: skin anatomy
An important role of the skin is to protect the body from pathogens in the environment 
[14, 24, 38]. Protection against invading pathogens is provided by two factors: 1) physical 
obstruction to invading pathogens and 2) a highly complex defense mechanism provided 
by the immune cells present in the skin.
The physical obstruction to invading pathogens by the skin is provided by the stratum 
corneum, which is the outermost layer of the epidermis (in human skin ca. 15-20 μm 
thickness) [39]. Underneath the stratum corneum is the viable epidermis. The viable 
epidermis is densely populated with keratinocytes and supplemented with melanocytes, 
Merkel cells and Langerhans Cells (LCs). The epidermis in human skin has a thickness of 
ca. 50-100 μm [14, 24, 38, 40]. The dermis is located below the epidermis, consists of a dense 
fibroelastic connective tissue and has a thickness of ca. 1-2 mm in human skin. Nerves, 
blood and lymphatic vessels, fibroblasts and a variety of immune cells are present 
throughout the dermis. The inner most layer of the skin is the subcutis, which consists 
of subcutaneous fat cells.
Intradermal vaccination: skin immunobiology
When an antigen from a pathogen or vaccine enters the skin, it can be taken up by 
(professional) antigen presenting cells (APCs), such as dendritic cells (DCs). After antigen 
uptake, DCs will process the antigen and subsequently migrate from the skin towards 
draining lymph nodes [24, 41, 42]. This process is facilitated by unspecific innate immune 
responses, which mainly function to induce inflammation and recruitment of immune 
cells. An example of this principle is the release of cytokines from the keratinocytes (the 
major cell type in the epidermis). Alternatively, the antigen itself migrates to a draining 
lymph node, after which the antigen is taken up by DCs residing in the lymph node 
[43-45]. Within draining lymph nodes, DCs present the antigen to B and T cells, initiating 
the adaptive immune response [24, 41, 42]. The adaptive immune response is capable of 
adapting and tailoring an immune response very specifically to the antigens of the 
invading pathogen or vaccine administered. The adaptive immune responses depend 
on antigen-specific B and T cells. Naïve B cells are inactive, until they encounter their 
specific antigen and are further activated by T helper cells. Upon activation, B cells 
proliferate into plasma cells, which produce high numbers of antibodies against the 
antigen. Antibodies provide a number of helpful functions to the immune system, which 
help neutralize and eliminate the invading pathogen. T cells may be divided into T helper 
(CD4+) T cells and cytotoxic (CD8+) T cells. Upon encountering their specific antigen, 
T helper cells are activated and help other immune cells, such as B cells, and help 
maximize the bactericidal activity of phagocytes (such as macrophages). Cytotoxic T 
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cells recognize and attack infected cells, effectively eliminating the pathogen.
Keratinocytes and LCs are present in the epidermis. As the human epidermis is only 
50-100 μm in thickness, these immune cells are very close to the surface of the skin. 
Logically, they provide the first line of defense against invading pathogens. Keratinocytes 
function as sentries, providing key innate immune functions [46-48]. LCs are a special 
subset of DCs and provide a unique role to skin homeostasis and immunobiology. LCs 
form a high-density network, with their dendrites almost completely covering the skin 
surface [24, 41]. LCs are more specialized in cellular immunity than other skin DCs [49-54]. LCs 
react to viruses [49, 52-54], but weakly to bacteria [51, 55, 56]. This selective reactivity of LCs is 
most likely due to reduced expression of TLR2 [50, 51, 56] TLR4 [51, 56] and TLR5 [50, 51, 56], which 
are involved in recognition of bacterial ligands. Without the presence of antigens, LCs 
are known to be stationary in the skin for a long period of time [38].
Within the dermis, fibroblasts, subpopulations of dermal dendritic cells (DDCs), mast 
cells, macrophages, gamma-delta T cells and memory T cells (both CD4+ and CD8+) 
are present [57]. Fibroblasts play a role in the skin’s innate immunity [38]. DDCs are also 
professional APCs and in human skin are comprised of two subsets, namely the CD1a+ 
DDCs and the CD14+ DDCs [24, 41, 50]. CD14+ DDCs are more efficient in initiating humoral 
immunity than LCs or CD1a+ DDCs. Naïve CD4+ T cells are polarized by CD14+ DDCs to 
develop into (follicular) helper T cells, which in turn induce naïve B cells to produce 
antibodies and to proliferate into plasma cells [49, 50, 58]. In comparison to LCs and CD14+ 
DDCs, CD1a+ DDCs are intermediately efficient in inducing humoral and cellular immune 
responses [49, 50, 59, 60]. Macrophages survey the dermis and have a critical role in innate 
immunity through phagocytosis and scavenging [61], and are involved in tissue repair [62]. 
Macrophages also bridge the innate and adaptive immunity by recruiting immune cells 
[61]. As the dermis is highly vascularized with blood- and lymph vessels, various immune 
cells may be recruited upon inflammation [63, 64].
After encounter and combating a pathogen, DCs perform antigen-imprinting on T cells 
specific for that pathogen [65], which marks them as memory T cells to be harbored in the 
skin. Upon re-encounter of the pathogen, memory T cells boost the immune responses 
to more effectively eliminate the pathogen. Thus, the skin is not only involved in local 
pathogen defense, but also on a systemic level, as the skin is home to twice the total 
number of circulating T cells in the blood. About 95% of T cells found in the skin is of the 
memory phenotype, while the other 5% is of the “revertant” memory phenotype [66, 67]. 
The epidermis houses mostly CD8+ T cells in close proximity to the LCs [68].
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Intradermal vaccination: methods of administration
The major hurdle to administer vaccines into the skin is to overcome the physical 
obstruction of the skin, provided by the stratum corneum [14]. Several techniques are 
developed to bypass the physical obstruction provided by the stratum corneum. The use 
of a conventional needle and syringe to inject vaccines into the skin, developed by Mendel 
and Mantoux in the early 1900s [69], is still being used today. However, such injections are 
hard to perform and require well-trained physicians. Therefore, alternative administration 
techniques are explored for safe and effective administration of vaccines into the skin.
Techniques explored to administer vaccines into the skin are nano-carriers (such as 
nanoparticles and liposomes) or micro-carriers, which are directly applied to the intact 
skin and may enter the hair follicles or are injected into the skin. Other administration 
techniques include the needle-free disruption of the stratum corneum by tape-
stripping [70-74], abrasion [75-82], low-frequency ultrasound [83], electroporation [84-87] and 
thermo-ablation [88]. Jet injections of dry powder [89-96] or liquid formulations [97-99] have 
been investigated as well. Especially for polio vaccination, liquid jet injections were 
popular until the 1985 hepatitis outbreak [100], but have gained renewed interest [101-106]. 
However, of the novel administration techniques, microneedle-mediated administration 
of vaccines is regarded as highly promising and is widely explored [14, 107-109].
Microneedles
Microneedles are needles at a micrometer scale, usually with a length between 50-
1000 μm [108]. Different types of microneedles exist, which can be classified into hollow 
microneedles and solid microneedles. 
Hollow microneedles are hollow-bore needles at micrometer scale and can be used in 
the “poke and flow” approach to administer vaccine into the skin [108]:
1. In the “poke and flow” approach, either a single hollow microneedle or an array of 
hollow microneedles is used. The microneedle (array) is pierced into the skin, after 
which a liquid formulation flows through the bore of the microneedle(s), effectively 
injecting the liquid formulation into the skin.
As the name suggests, solid microneedles are solid needles at micrometer scale. Solid 
microneedles are usually utilized in arrays, which can be used in three distinctive 
approaches to administer vaccine into the skin:
2. In the “poke and patch” approach, an array of solid microneedles is pierced into the 
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skin, thereby creating microchannels. After removal of the (array of) microneedles, 
a patch containing a vaccine is applied onto the disrupted skin, allowing the vaccine 
to diffuse along the microchannels into the skin.
3. In the “poke and release” approach, vaccine is encapsulated in an array of 
dissolving microneedles. After piercing the (array of) microneedles into the skin, 
the microneedles start to dissolve, thereby releasing the vaccine. The “poke and 
release” approach can also be applied by using (array of) porous microneedles, 
allowing to release the encapsulated vaccine into the skin by a diffusion process.
4. In the “coat and poke” approach, the vaccine is coated onto the surface(s) of (an 
array of) solid microneedles. Upon piercing the skin, the vaccine is released from 
the coated microneedle surface(s).
In this thesis, studies have been described further exploring the “poke and flow” and 
“coat and poke” approaches, as detailed in the following section.
AIM AND OUTLINE OF THIS THESIS
The main goals of this research were to:
1. Investigate the dependency of immune responses on the depth at which the antigen 
is administered in skin by a single hollow microneedle by using the “poke and flow” 
approach.
2. Determine whether immune responses resulting from intradermal injections of 
repeated fractional doses differ from immune responses resulting from a single 
intradermal bolus injection. In these studies, the “poke and flow” approach has 
been explored by using a single hollow microneedle.
3. Evaluate the possibilities to create pH-sensitive surfaces on gold surfaces.
4. To examine whether a layer-by-layer vaccine-coating approach on pH-sensitive 
modified silicon surfaces of microneedles can be used for intradermal immunization 
purposes. In these studies, the “coat and poke” approach has been explored by 
using a high-density solid microneedle array.
In chapter 2, the performance of a single hollow microneedle together with an applicator 
system to perform depth-controlled minimally-invasive intradermal microinjections 
is described. The single hollow microneedle injection system allowed for precisely 
controlling the injection depth, injection rate and injection volume. By using this single 
hollow microneedle injection system, monovalent inactivated polio vaccine serotype 
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1 (IPV1) was injected intradermally at different depths in rats in vivo. The relationship 
between the intradermal injection depth and IPV1-specific immune responses was 
investigated. In addition, the potential of the adjuvants CpG oligodeoxynucleotide 1826 
(CpG) and cholera toxin (CT) to enhance intradermal IPV1-specific immune responses 
was investigated. The results were compared against classic subcutaneous IPV1 injection 
using a conventional needle and syringe.
In chapter 3, a human skin DC crawl-out model was utilized to investigate responses 
of human skin DCs in relation to the depth at which vaccine was injected intradermally 
by using the single hollow microneedle injection system or a conventional needle and 
syringe. In this chapter, it was investigated whether the fraction and maturation of 
LCs and DDCs and the internalization of model antigen ovalbumin (OVA) by LCs and 
DDCs differs in response to the OVA dose or the depth at which OVA was administered 
intradermally.
Besides intradermal administration depth, the influence of repeated fractional 
intradermal dosing of IPV1 on IPV1-specific immune responses was investigated in 
chapter 4. The IPV1 dose was fractionated and administered over multiple days. The 
repeated fractional dosing schedules were compared to the classic (single) bolus dosing 
schedule and to CpG adjuvanted IPV1 bolus dosing. IPV1 was intradermally administered 
by using the single hollow microneedle injection system or subcutaneously administered 
by using a conventional needle and syringe.
A benefit of using solid microneedle arrays in the “coat and poke” approach, is that 
the vaccine is in a solid state and therefore is expected to be more stable at room 
temperature as compared to liquid vaccine formulations. To make use of the “coat and 
poke” approach, pH-sensitive microneedle surfaces provide a method to adhere antigen 
to the microneedle surface and to release antigen upon piercing the skin. The amount of 
antigen that can be coated in a single layer onto pH-sensitive surfaces of microneedle 
arrays is limited. In an effort to increase the amount of antigen that can be coated onto 
pH-sensitive silicon surfaces of microneedle arrays, two approaches were examined.
In chapter 5, the development of a layer-by-layer coating approach on pH-sensitive 
silicon microneedles is described. This layer-by-layer coating approach effectively 
enlarges the surface area available for coating, thereby increasing the amount of antigen 
that can be coated onto the microneedle array. In the layer-by-layer coating approach, 
a negatively charged antigen (diphtheria toxoid (DT)) was coated alternatingly with a 
positively charged polymer (N,N,N-trimethyl chitosan (TMC)) onto pH-sensitive silicon 
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surfaces of microneedle arrays. The coating and release properties of these layer-
by-layer DT-TMC coated microneedle arrays were characterized. Furthermore, the 
potential of these DT-TMC coated microneedle arrays to induce immunization against 
diphtheria toxin was investigated, by using an in vivo mouse model. In these studies, 
immunization via the skin by using DT-TMC coated microneedle arrays was compared 
against intradermal or subcutaneous immunization with DT alone or in combination with 
TMC. Intradermal immunization was performed by using the single hollow microneedle 
injection system and subcutaneous immunization was performed by using a conventional 
needle and syringe.
Sponge-like surfaces can be created by sputtering gold-ions onto silicon surfaces, 
to enlarge the surface area available for coating. In chapter 6, chemical gold surface 
modifiers were used to create self-assembled pH-sensitive monolayers on gold surfaces. 
This pH-sensitivity depends on the surface pKa. Therefore, the surface pKa of these 
pH-sensitive modified gold surfaces was determined using a fluorescent nanoparticle 
adhesion assay as well.
Lastly, the results and conclusions of this thesis are summarized in chapter 7. 
Additionally, this chapter contains the prospects of intradermal immunization making 
use of microneedle-mediated administration of vaccines.
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The aim of this study was to investigate the depth-dependent intradermal immunogenicity 
of inactivated polio vaccine (IPV) delivered by depth-controlled microinjections via 
hollow microneedles (HMN) and to investigate antibody response enhancing effects of 
IPV immunization adjuvanted with CpG oligodeoxynucleotide 1826 (CpG) or cholera toxin 
(CT).
METHODS
A novel applicator for HMN was designed to permit depth- and volume-controlled 
microinjections. The applicator was used to immunize rats intradermally with monovalent 
IPV serotype 1 (IPV1) at injection depths ranging from 50-550 μm, or at 400 μm for CpG 
and CT adjuvanted immunization, which were compared to intramuscular immunization.
RESULTS
The applicator allowed accurate microinjections into rat skin at predetermined injection 
depths (50-900 μm), -volumes (1-100 μL) and -rates (up to 60 μL/min) with minimal 
volume loss (±1-2%). HMN-mediated intradermal immunization resulted in similar IgG 
and virus-neutralizing antibody titers as conventional intramuscular immunization. No 
differences in IgG titers were observed as function of injection depth, however IgG 
titers were significantly increased in the CpG and CT adjuvanted groups (7-fold).
CONCLUSION
Intradermal immunogenicity of IPV1 was not affected by injection depth. CpG and CT 
were potent adjuvants for both intradermal and intramuscular immunization, allowing 
effective vaccination upon a minimally-invasive single intradermal microinjection by 
HMN.
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INTRODUCTION
Poliomyelitis can be prevented through vaccination by either oral polio vaccine (OPV) or 
inactivated polio vaccine (IPV). Although OPV is an inexpensive and easy to administer 
vaccine, it may cause outbreaks of vaccine-derived polioviruses [1]. Therefore, the World 
Health Organization aims to eliminate the use of OPV and substitute it by IPV in its goal 
towards worldwide polio eradication [2]. However, IPV vaccination is more costly because 
of higher production costs and a higher dose requirement in comparison to OPV. 
Therefore, several strategies for dose sparing to reduce the cost of IPV vaccination have 
been proposed, including intradermal immunization and IPV adjuvantation [3].
Although intradermal IPV immunization at reduced doses in human resulted in 
seroconversion, [4] intradermal injection by the Mantoux technique is difficult to perform. 
Therefore, there is an urgent need for novel intradermal injection methods. Intradermal 
IPV immunization via jet injectors resulted in seroconversion at reduced doses [5, 6]. 
Another novel strategy for intradermal injection is microneedles, which are micron-
sized needles [7]. Microneedles were investigated on their ability to induce protective 
immune responses upon intradermal IPV delivery on rats and rhesus macaques [8-12]. 
Hollow microneedle (HMN) mediated intradermal IPV immunization at reduced doses 
was also investigated in humans, which resulted in similar seroconversion rates in 
comparison to a full intramuscular dose [13].
Although intradermal immunization is a promising immunization strategy, it is unknown 
whether the immunogenicity of intradermally administered IPV is affected as a function 
of injection depth. This is of interest, as several classes of dendritic cells (DCs) reside 
in either the epidermis or the dermis. Langerhans cells (LCs) reside in the epidermis 
(topmost skin layer) and dermal dendritic cells (DDCs) reside in the dermis (lower 
layer) [14]. Both LCs and DDCs have distinct immune functions and may therefore have a 
different role in immunization [14]. Therefore, targeting different skin depths may affect 
the efficiency of intradermal IPV immunization. Hence, the objective of the present study 
is to investigate intradermal IPV immunization efficiency as function of skin injection 
depth by using a HMN system. To this end, precise and reproducible injection of IPV 
into the skin at a predefined depth is a requirement. This requirement can be fulfilled 
by using our previously developed in-house applicator [8]. However, this applicator only 
allowed a maximum flow rate of 2 μL/min without leakage in the microinjection system. 
Therefore, the system was thoroughly redesigned to allow increased pressures, resulting 
in increased ranges of injection rates, -volumes and -depths without leakages.
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Besides establishing the potential effect of intradermal injection depth on the immune 
response, the use of adjuvants can improve IPV immunization efficiency and therefore 
may result in IPV dose sparing and thus cost reduction [3, 15]. Although colloidal aluminum 
hydroxide or aluminum phosphate salts have been used with IPV for intramuscular 
immunization [16-20], they are not for intradermal use as they cause severe side effects. 
Therefore, in this study we examined the immune potentiating effects of CpG 
oligodeoxynucleotide 1826 (CpG) and cholera toxin (CT) as potentially suitable adjuvants 
for intradermal IPV immunization.
In this study we demonstrate a HMN applicator that allows for injection depth, -rate 
and -volume controllable minimally-invasive intradermal microinjections. This applicator 
allowed to investigate the dependence of intradermal immunogenicity to the injection 
depth of IPV1. To our knowledge this is the first systematic study where the influence of 
injection depth on antigen-specific immune responses is investigated. Additionally, the 
potential of adjuvants CpG and CT to enhance intradermal IPV immunization for dose 
sparing was investigated.
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MATERIALS
Polyimide coated fused silica capillary (375 μm outer diameter, 100 and 20 μm inner 
diameter) was obtained from Polymicro, Phoenix, USA. Silicone oil AK 350 was purchased 
from Boom Chemicals, Meppel, the Netherlands. CapTite™ connections were obtained 
from Labsmith, USA. Parafilm M® was purchased from Bemis, Monceau-sur-Sambre, 
Belgium. Tissue-Tek O.C.T. compound was ordered at Sakura Finetek, Alphen aan den 
Rijn, the Netherlands. Phosphate buffered saline, pH 7.4 (PBS pH 7.4: 163.9 mM Na+, 
140.3 mM Cl-, 8.7 mM HPO4
2- and 1.8 mM H2PO4
-, pH 7.4) was purchased from B. Braun 
Melsungen, Melsungen, Germany. IsoFlo® (isoflurane 100% w/w) was obtained from 
Abbott Laboratories, Maidenhead, UK. CpG was purchased from Invivogen, Toulouse, 
France. Hydrofluoric acid (49% w/w), concentrated sulfuric acid (95-98%), fluorescein, 
trypan blue, CT (holotoxin) and 3,3’5,5’-tetramethylbenzidine (TMB) were obtained 
from Sigma-Aldrich, Zwijndrecht, the Netherlands. Polystyrene 96 well microtiter plates 
and 2.5 mL Vacuette® Z serum separator clot activator premium tubes were ordered 
at Greiner Bio-One, Alphen aan den Rijn, the Netherlands. Tween 80 and 30% w/w 
hydrogen peroxide were obtained from Merck, Amsterdam, the Netherlands. PBS pH 
7.2 (160.6 mM Na+, 155.2 mM Cl-, 2.7 mM HPO4
2-, 1.5 mM H2PO4
- and 1.5 mM K+, pH 7.2) 
was purchased from Gibco (Life Technologies), Bleiswijk, the Netherlands. Protifar was 
obtained from Nutricia, Zoetermeer, the Netherlands. Bovine anti-poliovirus type 1 
serum, monovalent IPV vaccine serotype 1 (IPV1), 1.1 M sodium acetate and 2M sulfuric acid 
were kindly provided by Intravacc, Bilthoven, the Netherlands. Horseradish peroxidase-
conjugated goat-anti-rat IgG was obtained from Southern Biotech, Birmingham, AL, USA. 
Female Wistar Han IGS rats (Crl:WI(Han), strain code 273) of 175-225 g were ordered 
from Charles River Laboratories, Saint-Germain-sur-l’Arbresle, France.
METHODS
Fabrication of HMN
HMN were produced by an in-house process as described previously [8]. In short, the 
inner lumen of 20 μm inner diameter polyimide coated fused silica capillaries were filled 
overnight with silicone oil AK 350 by use of a vacuum oven at 100 °C. These silicone 
oil-filled capillaries were subsequently wet etched into HMN by immersing the ends in a 
container with hydrofluoric acid (49% w/w) for 4 h. To expose the microneedle tips, the 
polyimide coating at the etched ends of the capillaries was removed by immersing them 
in concentrated sulfuric acid (95-98%) at 250 °C for 5 min.
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HMN applicator
The HMN applicator that was previously developed in-house [8] was thoroughly redesigned 
to enable better depth-controlled intradermal microinjections. This HMN applicator is 
depicted in Fig. 1A and 1B. Optimization was dedicated to improve accuracy, precision 
and reproducibility of microinjections, to allow for increased injection rates to decrease 
the injection time, to allow for higher injection volumes and to achieve skin depth-
controlled injections. To achieve these improvements, high-pressure resistance in the 
fluidics system was required. Therefore, flexible materials were replaced by non-flexible 
rigid materials and all previous connectors in the fluidics system were replaced by high-
pressure resistant CapTite™ connectors. For the fluidics system, an 100 μL Hamilton 
gas-tight Luer-Lock syringe (model 1710 TLL, Hamilton Robotics, Bonaduz, Switzerland) 
with a barrel inner diameter of 1.46 mm was used in conjunction with a syringe pump 
(NE-300, Prosense, Oosterhout, the Netherlands) and 100 μm inner diameter polyimide 
coated fused silica capillaries.
HMN applicator performance validation with ex vivo rat skin
Microinjections into ex vivo rat skin were performed to determine the range of injection 
rates, -volumes and –depths that can be used for leakage-free microinjections. Ex 
vivo shaved rat skin was isolated from sacrificed female Wistar Han rats. The skin was 
stretched on Styrofoam covered with parafilm. Subsequently, microinjections of a 
solution of 10 μg/mL fluorescein in PBS pH 7.4 were performed at various injection 
rates, -volumes and -depths. To determine the accuracy and repeatability of the 
microinjections, volume loss that occurred at i) connections of the fluidics system, ii) on 
the skin surface at the injection site or iii) due to retained volume on the microneedle 
after its withdrawal from the injection site was measured by pipetting the lost volume 
with a 0.2-2 μL pipette. A pipetted volume below 0.2 μL was measured as a volume loss 
of 0.2 μL. The percentage volume loss was calculated as the percentage of volume loss 
(as measured by pipetting) from the digitally-displayed dispensed volume (as indicated 
by the syringe pump).
In the first series of experiments, the injection rate performance was investigated by 
varying injection rates from 1 – 60 μL/min, while both the injection volume and -depth 
were kept constant at 10 μL and at 500 μm, respectively. The maximum injection rate of the 
syringe pump for the 1.46 mm inner diameter 100 μL Hamilton syringe was 62 μL/min. In the 
second series of experiments, the injection volume was investigated by varying injection 
volumes from 1 – 100 μL, while both the injection rate and -depth were kept constant at 
20 μL/min and at 500 μm, respectively. Finally, injection depths ranging from 50 to 900 μm 
were investigated by performing 10 μL microinjections at an injection rate of 20 μL/min.
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Visualization of depth-controlled microinjections in ex vivo rat skin
In order to visualize microinjections at different preselected depths in ex vivo rat skin, 
trypan blue solution (0.4% w/v in PBS pH 7.4) was used. Ex vivo rat skin was isolated and 
prepared as described above. Next, trypan blue solution was injected at 250, 400 and 
550 μm depths with an injection volume of 10 μL and at an injection rate of 20 μL/min. 
The microinjections in ex vivo rat skin were photographed on outer and inner skin sides 
by utilizing a stereo microscope at 2.5x magnification (Zeiss Stemi 2000-c, paired with 
a Zeiss AxioCam ICc5 camera).
Furthermore, ex vivo rat skin injected with 0.5 μL trypan blue solution at the same 
injection depths and at an injection rate of 1 μL/min was embedded in Tissue-Tek O.C.T. 
compound and subsequently snap-frozen in liquid nitrogen, from which 10 μm thick 
cryosections were made on a Leica CM3050s cryostat. Subsequently, unstained and 
hematoxylin and eosin (H&E) stained images were made to visualize the injection depth 
of the microinjections. Images were made with a Zeiss 10x plan-Apochromat objective 
mounted onto a Zeiss Axio Imager D2 microscope coupled with a MRc5 camera.
Investigation of depth-dependent intradermal immunogenicity
Two immunization studies were performed under the guidelines and regulations 
enforced by the animal ethic committee of the Netherlands, and were approved by 
the “Dierexperimentencommissie Universiteit Leiden (UDEC)” under number 12084. 
Female Wistar Han rats with a weight of 175-225 g on arrival were accommodated 
under standardized conditions in the animal facilities of the Leiden Academic Centre 
for Drug Research, Leiden University. The animals were housed in groups of five and 
were assigned to different immunization groups (10 rats per immunization group). Prior 
to blood withdrawal or immunization, the rats were anaesthetized with isoflurane. 
Anaesthetized animals that were assigned to the intradermal injection groups were 
shaved minimally (an area of 4 cm2 on the left flank) prior to the intradermal injection.
To investigate the depth-dependent intradermal immunogenicity of IPV1, the rats were 
immunized intradermally via HMN mediated microinjections of 10 μL containing 5 DU 
of IPV1 at an injection rate of 20 μL/min and at injection depths of 250, 400, 550 μm 
for animal study 1, and 50, 150, 250 μm for animal study 2. As a control in both animal 
studies, 5 DU of IPV1 in 200 μL PBS pH 7.4 was administered intramuscularly divided 
over each hind leg (100 μL per hind leg). Furthermore, both animal studies contained a 
mock treated group via the intramuscular route (100 μL PBS pH 7.4 per hind leg). In the 
first animal study the immunogenicity enhancing effects of adjuvants were investigated: 
two groups were immunized intradermally via HMN mediated microinjections of 10 μL 
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(injection rate 20 μL/min and injection depth 400 μm) and two groups were immunized 
intramuscularly (100 μL per hind leg) with 5 DU IPV1 adjuvanted with either CpG or CT. 
These previously described immunization procedures were performed at day 1 (prime 
immunization) and were repeated at day 21 (booster immunization). Collection of blood 
samples were performed at day 1, day 21 (prime) and day 42 (boost). Blood samples were 
collected in 2.5 mL Vacuette® tubes and stored on ice before centrifugation at 2000g 
for 10 min to isolate serum.
Serum IgG titers
To measure serum IgG titers, a capture ELISA was performed. Bovine anti-poliovirus type 
1 serum in PBS pH 7.2 was used to coat polystyrene 96 well microtiter plates overnight 
at 4 °C. Subsequently, washing was performed with 0.05% Tween 80 in tap water. 
Afterwards, assay buffer consisting of PBS pH 7.2, 0.5% (w/v) Protifar and 0.05% (v/v) 
Tween 80 was used to add 4.5 DU IPV1/well (100 μL/well). Plates were incubated at 37 
°C for 2 h before a wash step was performed. Afterwards, threefold serial dilutions of 
serum samples in assay buffer were added at 100 μL/well and subsequently incubated 
at 37 °C for 2 h. Plates were washed before horseradish peroxidase-conjugated goat-
anti-rat IgG was added to the wells (4000-fold dilution, 100 μL/well) and subsequently 
incubated at 37 °C for 1 h. Subsequently, plates were thoroughly washed before adding 
TMB substrate solution (100 μL/well) which consisted of 1.1 M sodium acetate, 100 mg/
mL TMB and 0.006% (v/v) hydrogen peroxide. 2 M sulfuric acid was used after 10 min to 
stop the reaction (100 μL/well). Finally, sample absorbance was measured at 450 nm by 
a Biotek ELx808 plate reader (Winooski, VT, USA).
The Biotek Gen5 2.0 data analysis software was used to determine endpoint titers by 
4-parameter analysis. The endpoint titer was defined as the reciprocal of the serum 
dilution producing a 450 nm absorbance equal to that of the mean 450 nm absorbance 
with addition of three times the standard deviation of eight samples of IPV1-specific-
antibody negative serum samples.
Virus-neutralizing antibodies
Determination of the antibody titers able to neutralize wildtype poliovirus serotype 1 
was outsourced to Bilthoven Biologicals and performed as previously described [21, 22]. 
In short, average virus-neutralizing (VN) antibody titers were measured after pooling 
of the serum samples of all rats per immunization group. Subsequently, two-fold serial 
dilutions of the pooled sera were made (211-222) after inactivation of sera at 56 °C for 30 
min prior to testing. 100TCID50 of the Mahoney wild-type strain (poliovirus type 1) was 
added to the resulting serum dilutions and these virus/serum mixtures were incubated 
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for 3 h at 36 °C and 5% CO2 before incubation at 4 °C overnight. Subsequently, to each 
sample 1x104 Vero cells were added and the resulting mixtures were incubated for 7 days 
at 36 °C and 5% CO2. Finally, samples were fixed with formalin, stained with crystal violet 
and were analyzed macroscopically. VN titers were displayed as the last serum dilution 
which did not exhibit cytopathogenic effects.
Statistical analysis
Statistics were performed using GraphPad Prism (v.6.00, GraphPad Software, LaJolla, 
CA, USA). Kruskall-Wallis tests with Dunn’s post-hoc tests were performed as IgG titers 
were non-normally distributed and considered significant at p < 0.05.
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RESULTS
HMN applicator optimization and performance
To allow for increased injection rates and thereby short injection times, connections 
in the fluidics system of the HMN applicator were optimized by applying high-pressure 
resistant CapTite™ connectors and high-pressure resistant polyimide fused silica 
capillaries, as shown in Fig. 1A and 1B. Furthermore, the dead volume in the fluidics 
system was kept to a minimum to maximize injection volume accuracy and minimize 
the loss of vaccine formulation. The hydrofluoric acid etching procedure of polyimide 











Fig. 1 Images of the HMN applicator (A and B) and a scanning electron microscopy image of a HMN 
(C, bar represents 50 μm). The microneedle insertion speed (1 to 3 m/s) is controlled by an 
electromagnet (1). Angled injections are possible via a guided rail (2). The injection depth of the 
microneedle into the skin is accurately controlled by a micrometer actuator (10) and a guide plate 
(9). Fluid flow starts with a 100 μL Hamilton gas-tight Luer-Lock syringe (3) which is driven by a 
controllable syringe pump (5) that is connected to a 100 μm inner diameter capillary (6) via a Luer-
Lock-CapTite adapter (4). This capillary feeds the fluid flow via a specially designed connection 
piece (7) into a HMN (8) that enables the intradermal injections. Because the syringe pump is 
programmable, injection rates and -volumes can be accurately controlled.
The performance of the fluidics system was examined by varying the injection rate 
during intradermal microinjections into ex vivo rat skin, mimicking back pressure during 
actual microinjections on live animals. As shown in Fig. 2A, the volume loss was ±1-2% for 
all investigated injection rates at an injection volume and -depth of 10 μL and 500 μm, 
respectively. Volume loss was only observed at the skin surface of the microinjection 
sites or on the HMN after retracting the microneedle from the skin. No additional 
volume loss was observed. Owing to the achieved increase in injection rate, a significant 
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reduction in injection time was achieved.
As shown in Fig. 2B, volumes up to 100 μL could be injected into ex vivo rat skin with 
volume loss that was ±1-2%, independent of injection volume, at an injection depth and 
-rate of 500 μm and 20 μL/min, respectively. This volume loss was observed on the skin 
surface at the microinjection sites.
Finally, variation in injection depth was studied by injecting 10 μL in ex vivo rat skin at 
different injection depths. As shown in Fig. 2C, microinjections were performed between 
50 to 900 μm injection depths. At all investigated injection depths, all microinjections 
resulted in ±1-2% volume loss. Moreover, there was no increase in volume loss at any 
particular injection depth.
Visualization of depth-controlled microinjections in ex vivo rat skin
To obtain evidence that skin layers at different preselected depths were targeted, 
microinjections of a trypan blue solution were performed on ex vivo rat skin, which 
was then photographed at both sides (Fig. 3A). Whereas the trypan blue spot of the 
shallower microinjection at a skin injection depth of 250 μm was more clearly visible at 
the outer side of the skin, the trypan blue spot of the deeper injection at 550 μm was 
hardly visible. Contrarily, the trypan blue spot of the deeper microinjection at a skin 
injection depth of 550 μm was more clearly visible at the inner side of the skin than 
the trypan blue spot of the shallower injection (250 μm). Moreover, as shown in Fig. 
3B, visualization of the skin injection depth in cross-sectioned skin indicated that the 
microinjections were indeed performed at different pre-defined skin injection depths.





































































Fig. 2 Accuracy of the HMN applicator, expressed as percent volume loss, as function of (A) injection 
rate (1-60 μL/min (pump-syringe combination maximum)) at constant injection depth (500 μm) and 
volume (10 μL); (B) injection volume (5-100 μL) at constant injection depth (500 μm) and rate (20 
μL/min); and (C) injection depth (50-900 μm) at constant injection volume (10 μL) and rate (20 μL/
min). Bars represent mean ± SEM (n = 6).































Fig. 3 Visualization of depth-controlled microinjections of trypan blue solution by HMN into rat skin 
at 10 μL and 20 μL/min (A), visualized by light microscopy at 4x magnification; bars represent 500 
μm. Visualization of cross-sections of cryofixed rat skin after depth-controlled microinjections of 
trypan blue solution into rat skin at 0.5 μL at 10 μL/min were performed (B), visualized either before 
or after H&E staining by bright-field microscopy at 10x magnification; bars represent 200 μm.
Injection depth-dependent intradermal immunogenicity
To assess whether injection of IPV1 at different injection depths in the skin affects 
IPV1-specific antibody responses, two immunization studies in rats were conducted. 
Intradermal immunization was performed using the HMN applicator in a depth-controlled 
manner and this was compared to intramuscular immunization with a conventional 26G 




hypodermic needle. IPV1-specific IgG titers obtained after intradermal immunization with 
non-adjuvanted IPV1 at injection depths ranging between 50 and 550 μm are shown in 
Fig. 4. Three weeks after prime immunization (Fig. 4A) and boost immunization (Fig. 4B), 
no significant differences in IPV1-specific IgG titers were observed at different injection 
depths. Moreover, IPV1-specific IgG titers obtained after intradermal immunization 
were similar to those obtained after intramuscular IPV1 immunization. No IPV1-specific 
antibody responses were observed in the mock treated group.
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Fig. 4 IPV1-specific IgG antibody responses measured in serum obtained in study 1 or 2, after 
prime immunization (A, day 21) or boost immunization (B, day 42) with PBS pH 7.4, 5 DU IPV1 or 5 
DU IPV1 adjuvanted with either CpG or CT. Formulations were injected intradermally via HMN at the 
indicated injection depths or intramuscularly via conventional 26G needles. Aqua or orange rounds 
represent animals from study 1 or 2, respectively. Bars represent mean ± 95% confidence interval 
(n = 10) and stars represent a significant increase (p < 0.05).




Immunogenicity enhancing effects of adjuvants CpG and CT
To assess the potential increase in antibody responses and the applicability for use 
as intradermal adjuvants, CpG and CT were used as adjuvants in intradermal and 
intramuscular IPV immunization (Fig. 4A and 4B). Intradermal IPV1 immunization 
adjuvanted with CpG led to statistically significant increased IgG titers in comparison to 
non-adjuvanted 400 and 550 μm injection depths and intramuscular IPV1 group after 
prime immunization. Contrarily, intramuscular IPV1 immunization adjuvanted with CpG 
did not result in any significant increase in IgG titer after prime immunization. After boost 
immunization however, IPV1 immunization adjuvanted with CpG via both the intradermal 
and intramuscular route resulted in significantly increased IgG titers in comparison to 
the non-adjuvanted intramuscular IPV1 group.
Intradermal IPV1 immunization adjuvanted with CT led to statistically significant increased 
IgG titers after prime immunization (non-adjuvanted 400 μm injection depth) and 
booster immunization (non-adjuvanted intramuscular control group). Intramuscular IPV1 
immunization adjuvanted with CT resulted in statistically significant increased IgG titers 
in comparison to all non-adjuvanted groups (250, 400 and 550 μm injection depths and 
intramuscular IPV1 group) after prime immunization. However, after boost immunization 
there were no significant differences for intramuscular IPV1 immunization adjuvanted 
with CT.
Furthermore, there were no statistically significant differences in IgG titers between CpG 
or CT adjuvanted groups, neither for the intradermal or the intramuscular immunization 
routes and neither after prime or boost immunization. However, some differences 
were observed between CpG and CT, when they were compared against non-
adjuvanted groups. After prime intradermal immunization, CpG and CT adjuvanted IPV1 
immunization resulted in 6.9 and 7.3 fold increased IgG titers on average, respectively, in 
comparison to the non-adjuvanted intradermal IPV1 groups. After prime intramuscular 
immunization, CpG and CT adjuvanted IPV1 immunization resulted in 2.7 and 12.1 fold 
increased IgG titers, respectively, in comparison to the non-adjuvanted intramuscular 
IPV1 group. Thus in prime immunization, CpG enhanced IgG titers more in intradermal 
immunization in comparison to intramuscular immunization, whereas CT enhanced IgG 
titers in both immunization routes. After the booster intradermal immunization, CpG 
and CT adjuvanted IPV1 immunization resulted in 1.9 and 2.2 fold increased IgG titers 
on average, respectively, in comparison to the non-adjuvanted intradermal IPV1 groups. 
After the booster intramuscular immunization, CpG and CT adjuvanted IPV1 immunization 
resulted in 5.5 and 2.4 fold increased IgG titers, respectively, in comparison to the non-
adjuvanted intramuscular IPV1 group. Thus, the IgG titer enhancing effect was more 
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pronounced in prime immunization than in booster immunization. Intramuscular IPV1 
immunization adjuvanted with CpG resulted in the strongest increase in IgG titers in 
booster immunization.
Besides increasing IgG titers, intradermal IPV1 immunization adjuvanted with CpG and 
both intradermal and intramuscular IPV1 immunization adjuvanted with CT, resulted 
in less low-responders in comparison to the non-adjuvanted groups after prime 
immunization. Moreover, these adjuvanted groups resulted in IPV1-specific IgG titers 
after a single immunization that were comparable to the ones obtained after two non-
adjuvanted immunizations.
Virus-neutralizing antibodies
In addition to the determination of the IPV1-specific IgG antibody responses by ELISA, 
protectivity of these antibodies against wildtype poliovirus was measured in a wildtype 
poliovirus-neutralizing antibody assay. VN antibody titers were observed in all IPV1 
immunization groups (Table 1). No VN antibody titer was observed in the mock treated 
group. Although the VN titers were measured on pooled serum samples, some slight 
differences in mean VN titer per immunization group were observed. For example, 
for the 400 μm injection depth, a VN titer of 13 was observed, which was higher 
than those of the other injection depths and the intramuscular IPV1 immunization. 
Moreover, this VN titer was similar to the VN titers of intradermal and intramuscular 
IPV1 immunization adjuvanted with CpG, however lower than the VN titer of intradermal 
IPV1 immunization adjuvanted with CT, which had the highest VN titer. VN titers of non-
adjuvanted intradermal and intramuscular IPV1 immunization were similar. Intramuscular 
IPV1 immunization adjuvanted with CT resulted in a similar VN titer as non-adjuvanted 
intradermal and intramuscular immunization and was lower in comparison to intradermal 
IPV1 immunization adjuvanted with CT. Thus, CpG enhanced VN antibody titers in both 
intradermal and intramuscular IPV1 immunization, whereas CT only in intradermal IPV1 
immunization.
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Table 1 Virus neutralizing (VN) antibody titers measured in serum obtained in study 1 and 2 after 
prime and boost immunization (day 42) with PBS pH 7.4, 5 DU IPV1 or 5 DU IPV1 adjuvanted with 
either CpG or CT. Formulations were injected intradermally via HMN at indicated injection depths 
or intramuscularly via conventional 26G needles. Presented data represents VN titers which were 
measured on pooled serum samples of all rats per immunization group.
VN antibody titers (log2)
Intradermal Intramuscular
Depth (µm) 50 150 250 400 550 400 400
IPV1 + + + + + + + + + + -
CpG + +
CT + +
VN titer study 1 11 13 11 13 14 12 13 11 0
VN titer study 2 11 12 12 11 0
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Both during and immediately after intradermal immunization with HMN, a small bleb was 
observed on the skin. This bleb disappeared within 5 min after injection. No erythema 
was observed during and after intradermal injections with HMN, with one exception. 
Mild erythema was observed after intradermal injection of IPV1 with CT. This effect 
was only observed after the prime immunization and started 60 min post injection and 
lasted up to 7 days. Other adverse effects were not observed.
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DISCUSSION
The relationship between injection depth and intradermal immunization has not been 
studied before, because this requires accurate, precise and reproducible depth-
controlled intradermal injections with small injection volumes. For these reasons, an HMN 
applicator was thoroughly redesigned and improved in this study. This improved HMN 
applicator allowed for accurately controllable injection rates, -volumes and -depths, 
which allowed to investigate the depth-dependent intradermal immunogenicity of IPV1, 
in an effort for IPV1 dose sparing.
Skin resistance during injection might significantly inhibit injection rate and accuracy [23]. 
However, the redesigned applicator allowed for a 30-fold increased injection rate (60 
μL/min) compared to previously achieved rates (2 μL/min) [8]. Increased injection rates 
were needed to increase injection accuracy and shorten injection duration. Achieved 
injection rates were higher than those reported in literature for rat skin with a single 
HMN (0.17 μL/min/HMN, 1 μL/min/HMN after needle retraction, [24]) or with HMN arrays 
(0.001 μL/min/HMN, [25]) and for human skin with a single HMN (0.25-1.6 μL/min/HMN), 
which required hyaluronidase and needle retraction to increase rates to 18.83 μL/min/
HMN [23]. In contrast, by using the improved applicator, no additional methods were 
required to achieve even higher injection rates. Therefore, the utilization of non-flexible 
materials allowed increased pressure during injection, which allowed to easily overcome 
skin resistance and to achieve increased injection rates.
In addition, injection volumes achieved with this improved applicator were increased 
11-fold in comparison to those previously achieved in rat skin (9 μL/HMN) [8]. These 
volumes were also much higher as those reported for single HMN in human skin (20 μL/
HMN) [23] or HMN arrays in mice skin (0.22 μL/HMN) [26]. Additionally, achieved volumes 
were comparable to HMN arrays in porcine skin (83.33 μL/HMN) [27]. Furthermore, a 
single hollow needle design reduces the risk of volume loss (dose loss) compared to 
HMN arrays, as in arrays all needles need to be penetrated and unclogged to ensure an 
accurate injection and prevent leakage [28, 29]. 
The improved applicator allowed for an increased injection depth range (50-900 μm) 
compared to the previously reported range (100-400 μm) [8]. This injection depth range 
was larger than the previously reported depth range in hairless rat skin (150-770μm, 
[24]) and smaller than the previously reported depth range in human skin (180-1080 μm, 
[23]). However, these studies do not report the influence of injection depth on antigen-
specific immune responses. 
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In contrast to our hypothesis, there was no injection depth-dependent intradermal 
immunogenicity observed for IPV1. However, the limited thickness (20-30 μm) of rat 
epidermis prevented injection into the epidermis where LCs reside [30]. The attempt to 
inject IPV1 as close to the epidermis as possible did not result in a significant change in 
IPV1-specific IgG titers. It is not known whether the distribution of the injected volume 
in the skin influences the targeting of intradermal injection depths. Furthermore, it is 
unclear whether local changes in innate immunity can be expected, as antigen-bearing 
DCs will migrate to lymph nodes, where lymph node-residing DCs may influence any 
immunological effect [14, 30]. This behavior, chemotaxis and chemoattraction of other 
DCs and the complex interplay between different DC classes, may explain the absence 
of differences in immune response as function of the injection depth. Contrarily to 
rat skin though, in human skin the epidermis has a thickness of 50-100 μm [30]. As the 
redesigned applicator is able to inject at a depth of 50 μm, injection directly into the 
human epidermis is possible. This allows to study LC function in intradermal immunity in 
the future. In conclusion, our applicator could provide a method to investigate depth-
dependent intradermal vaccine immunogenicity in human. 
Furthermore, results presented in this study are important in microneedle patch design 
for intradermal IPV immunization as the independence of IPV1 immunization on skin 
depth suggests that microneedle length will not affect the immune response and thus 
precise dosing at a certain skin depth is not required. This may put a smaller burden on 
the design specifications of microneedle applicators.
Besides, an effort was made to find a dose sparing strategy for IPV immunization. 
However, intradermal and intramuscular immunization without use of adjuvants led 
to similar results, likewise as reported for other microneedle strategies: HMN in rats 
[8, 11] or humans [13], coated microneedles in rats, [9] dissolving microneedles in rats [10] or 
rhesus macaques [12]. Furthermore, clinical trials in humans have been performed to 
investigate IPV dose sparing, by comparison of a 80% reduced IPV dose (20% of full dose) 
administered intradermally against a full IPV dose administered intramuscularly. For polio 
prime immunization in newborn infants, intradermal 20% IPV dose resulted in similar [4, 
5] or inferior [31-33] seroconversion rates compared to a full intramuscular dose. Similarly, 
for polio booster immunization, intradermal 20% IPV dose resulted in either similar [6, 13] 
or inferior [34, 35] seroconversion rates in comparison to full intramuscular dose. However, 
intradermal immunization generally resulted in significantly lowered antibody titers [5, 6, 
31-35]. These findings were seemingly not dependent on the intradermal immunization 
method used, because jet injectors [5, 6, 31, 32, 34, 35], the Mantoux technique [4, 35] or HMN 
arrays [13, 33] evenly resulted in either similar or inferior results to full intramuscular dose. 
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In this study, it is shown that the depth at which the antigen was administered by these 
different intradermal immunization techniques cannot explain this phenomenon either. 
However, the 80% dose-reduction goal may be unrealistic, as a 60% dose-reduction 
was achieved by HMN mediated intradermal immunization without use of adjuvants [11, 13].
Adjuvants may be used as another strategy for IPV dose sparing [3]. For example, aluminum 
hydroxide [16, 17] and aluminum phosphate [18, 19] have been successfully used as an adjuvant 
for intramuscular IPV immunization. Because aluminum salts cannot be administered 
intradermally due to local adverse effects, adjuvants CpG and CT were assessed for 
intradermal IPV1 immunization. Both CpG and CT have shown to be safe as adjuvant 
in intradermal immunization in humans [36, 37]. In the present study, immune-enhancing 
effects on IPV1-specific IgG responses by the adjuvants CpG and CT were significant, 
which indicates that CpG and CT might be potential adjuvant candidates for intradermal 
IPV1 immunization and may lead to dose sparing. Indeed, CpG was reported by others 
to be an effective immune enhancing adjuvant for IPV immunization [38]. Although this 
latter study utilized mice and a different CpG motif (ODN2006), both studies report on 
the potential for CpG as adjuvant in IPV immunization. Furthermore, we have reported 
a 6.9- and 7.3-fold increase in IPV1-specific IgG serum titers for intradermally IPV co-
administered with CpG and CT, respectively. This increase was larger as reported for 
intradermal IPV immunization in mice in combination with CpG-ODN2006 (4-fold) or 
double mutant heat-labile enterotoxin from E. coli LT (R192G/L211A) (2.5-fold) [38, 39]. 
Contrarily, a 10-fold increase was achieved by CAF01 liposomal IPV formulation for 
intradermal IPV immunization in mice [40].
CONCLUSION
In this study, an unique dose sparing strategy for IPV1 was investigated by intradermal 
microinjections of small volumes of IPV1 formulation at different pre-determined 
depths in rat skin in vivo. To enable this, a HMN applicator controllable in injection 
rate, -volume and –depth was developed that allowed for intradermal microinjections. 
Results indicated however, that intradermal immunogenicity was not dependent on 
the injection depth. Nonetheless, IPV1 immunization by minimally-invasive intradermal 
microinjections resulted in similar IPV1-specific antibody responses in comparison to 
IPV1 immunization by more invasive and painful intramuscular injections. Moreover, 
intradermal IPV1 immunization antibody responses were significantly increased (7-fold) 
by adjuvants CpG and CT, such that a single minimally-invasive intradermal immunization 
by HMN resulted in comparable antibody responses to two intramuscular immunizations.
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ABSTRACT
The skin is an attractive administration route for vaccines, as the skin is rich in dendritic 
cells (DCs) and is easily accessible. Multiple subsets of DCs with distinct roles reside at 
different depths in the skin. The aim of this study was to determine whether migration 
of, maturation of and antigen uptake by the different DC subsets in skin differ as a result 
of administration of antigen at various doses (1-50 μg) or injection depths (50-1000 
μm) in ex vivo human skin. Ovalbumin (OVA) was selected as model antigen. Migrated 
skin cells were collected by using a skin explant model and the migration, maturation 
and OVA uptake were determined per DC subset by using flow cytometric analysis. An 
increase in OVA dose decreased the percentage of CD1a+ and CD14+ dermal DCs (DDCs) 
within the migrated HLA-DR+ DC population. Moreover, with increasing OVA doses, only 
CD1a+ DDCs demonstrated increased maturation, determined as increased expression 
of costimulatory molecule CD86. Furthermore, with increasing dose the amount 
of OVA taken up and percentage of OVA-containing cells increased for Langerhans 
cells (12-99%) and CD1a+ DDCs (91-99%). CD14+ DDCs were most efficient in antigen 
uptake, as demonstrated by a seemingly saturated amount of OVA uptake and very high 
percentage of OVA-containing cells (±99%), even at the lowest dose tested. Intradermal 
administration of OVA at various depths in skin did not result in differences in migration, 
maturation and OVA uptake, most likely due to a high diffusion coefficient of OVA in 
human skin. However, intradermal microinjection by using a single hollow microneedle 
using a 50x reduced injection volume resulted in similar antigen uptake as compared to 
using a conventional hypodermic needle-and-syringe. Thus using hollow microneedles, 
the injection volume for intradermal injections may be strongly reduced, avoiding 
discomfort associated with intradermal injections.
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INTRODUCTION
The skin is an attractive immunization route, owing to the presence of high numbers 
of dendritic cells (DCs) within the skin, allowing for the induction of a potent immune 
response [1-4]. Previous studies have shown that an equally effective immune response 
was induced by intradermal rabies immunization using a 60-80% dose reduction, as 
compared to intramuscular immunization [5-7]. Furthermore, dose sparing has been 
reported for intradermal immunization (compared to conventional intramuscular 
immunization) for hepatitis B [8, 9], influenza [10-15] and polio [16, 17], making intradermal 
immunization an attractive alternative to conventional intramuscular immunization.
DCs are key immune cells for (intradermal) immunization [18-20]. However, to administer 
a sufficient amount of antigen to DCs located in the skin, the physical barrier of the 
skin (i.e., the stratum corneum) must be bypassed [1]. Several techniques are available 
to administer a sufficient amount of antigen into the skin. One of the more attractive 
approaches are the use of hollow and solid microneedles, which are able to disrupt 
the stratum corneum effectively and potentially without pain sensation [21, 22]. Upon 
administration of the antigen into the skin, DCs will take up and process the antigen and 
migrate from the skin towards draining lymph nodes [23-25]. Alternatively, the antigen itself 
migrates to draining lymph nodes after which it is taken up by lymph node residing DCs. 
Within the draining lymph nodes, DCs present the antigen to B- and T-cells, initiating the 
adaptive immune response [23-25].
Three phenotypically and functionally distinct subsets of DCs are known to reside in 
human skin [24, 26-34]. LCs reside in the epidermis, forming a tight knit network with their 
dendrites just below the surface of the skin [23, 24, 33]. Human LCs are recognized by their 
expression of Langerin and CD1a, but lack of expression of CD14 on the cell surface. LCs 
are more efficient in inducing cytotoxic T-lymphocyte (CTL) responses [29, 32, 35-38] than 
other skin DCs. LCs are known to respond to viruses [29, 36-38], but not to bacteria [35, 39, 
40], probably due to reduced expression of TLR 2, 4 and 5 [35]. Dermal DCs (DDCs) reside 
in the dermis and are comprised of CD1a+ DDCs and CD14+ DDCs [23, 24, 32-34]. CD14+ DDCs 
lack expression of Langerin and CD1a, but do express CD14 on the cell surface. CD14+ 
DDCs are reported to be more efficient in initiating humoral immunity than LCs or CD1a+ 
DDCs. CD14+ DDCs polarize naïve CD4+ T cells to develop into follicular helper T cells, 
which in turn induce naïve B cells to produce antibodies and to proliferate into plasma 
cells [29, 32, 41]. CD1a+ DDCs lack expression of Langerin and CD14, but do express CD1a on 
the cell surface. CD1a+ DDCs are intermediately efficient in inducing humoral and cellular 
immune responses, in comparison to LCs and CD14+ DDCs [28, 29, 32, 42].
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Due to differences in immunological function and location in skin, it is important to 
examine to which extent LCs, CD1a+ and CD14+ DDCs are involved in antigen uptake. 
Therefore, the aim of this study was to determine the effects of administration of 
antigen at various doses and injection depths in skin on antigen uptake by human LCs, 
CD1a+ and CD14+ DDCs.
Ovalbumin (OVA) was selected as model protein antigen and a human skin explant model 
was used, to examine the antigen uptake, migration and maturation by/of LCs, CD1a+ and 
CD14+ DDCs [43-45]. To be able to perform intradermal depth-controlled microinjections, 
a single hollow microneedle and an applicator system was used [46-49]. In addition, a 
combination of fluorescence recovery after photobleaching (FRAP) experiments with 
finite element analysis was used to determine the diffusion coefficient of OVA in various 
depths in skin.
In this study, we demonstrated that the amount and efficiency of OVA uptake differs 
between LCs, CD1a+ and CD14+ DDCs, but that the intradermal injection depth did not 
result in different uptake. We also demonstrated that OVA uptake was similar at equal 
dose for intradermal administration by using a conventional hypodermic needle-and-
syringe (standard volume of 10 μL) and by using a single hollow microneedle using a 50x 
reduced injection volume.
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MATERIALS
OVA conjugated with Alexa Fluor® 488 (OVA) or FITC (OVA-FITC), Hoechst 33342, 
Iscove’s Modified Dulbecco’s Medium (IMDM), Hank’s balanced salt solution and anti-
human CD11c-PE-Cy7 antibodies (catalogue number 25-0116-42) were purchased from 
Thermo Fisher Scientific (Bleiswijk, the Netherlands). Cholecalciferol (vitamin D3) and 
ethanol 96% (v/v) were obtained from Sigma Aldrich (Zwijndrecht, the Netherlands). 
Sterile phosphate buffered saline (PBS) (163.9 mM Na+, 140.3 mM Cl-, 8.7 mM HPO4
2- 
and 1.8 mM H2PO4
-, pH 7.4) was ordered at B. Braun Melsungen (Oss, the Netherlands). 
Skin biopsy punches were purchased from Kai Europe (Solingen, Germany). BD Micro-
Fine™+ 30G 0.3 mL needle-syringes and anti-human CD1a-APC, CD86-PE and HLA-
DR-PerCP antibodies (catalogue numbers 559775, 555665 and 347364, respectively) 
were obtained from Becton Dickinson (Breda, the Netherlands). Anti-human CD14-
APC-Cy7 antibodies (catalogue number 301820) were ordered at Biolegend (Koblenz, 
Germany). HyClone™ Fetal calf serum (FCS) was purchased from GE Healthcare Life 
Sciences (Eindhoven, the Netherlands). GM-CSF was obtained from Schering-Plough 
(Uden, the Netherlands). Costar® 48-well plates were ordered at Corning Life Sciences 
(Amsterdam, the Netherlands). Styrofoam were purchased from a local hardware store.
METHODS
Preparation of human skin for intradermal injections
Abdominal ex vivo human skin was obtained from local hospitals after cosmetic surgery 
and after obtaining informed consent from the donors, which was handled according 
to the ethical principles of the Declaration of Helsinki. The skin was stored at 4 °C until 
use within 24 h after surgery. To clean the skin, the epidermal side of the skin was 
sequentially rinsed with sterile PBS, 70% (v/v) ethanol and sterile PBS again. The skin was 
slightly pre-stretched by pinning the skin on a flat piece of Styrofoam, in an effort to 
simulate the stretch conditions of skin in normal conditions.
Dose-dependent antigen uptake
For each experiment, sterile formulations of OVA and vitamin D3 were prepared. To 
determine the effect of the administered OVA dose on antigen uptake, migration and 
maturation by/of LCs, CD1a+ and CD14+ DDCs, 1, 5, 25, or 50 μg OVA in 10 μL PBS was 
injected intradermally using a conventional hypodermic needle-and-syringe (30G 
needle-syringes). As controls, 1.25·10-9 mole Vitamin D3 in 10 μL PBS (positive control) 
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or 10 μL PBS alone (negative control) were injected intradermally using a conventional 
hypodermic needle-and-syringe (30G needle-syringes). Additionally, plain biopsies of 
untreated skin were included (negative control).
System for single hollow microneedle-mediated depth-controlled intradermal 
microinjections
To allow for intradermal microinjections at an accurate depth, intradermal microinjections 
were performed using a digitally-controlled single hollow microneedle injection system 
(DC-shMN-iSystem). This system comprises of a single hollow microneedle, which 
is fixed in an applicator, as explained in detail elsewhere [47, 49]. Accurate intradermal 
microinjections of very low volumes were feasible by controlling the microneedle 
applicator and syringe pump (NE-300, Prosense, Oosterhout, the Netherlands) via a 
microneedle applicator controller unit (uPRAX Microsolutions, Delft, The Netherlands) 
[46, 50]. Single hollow microneedles were fabricated using hydrofluoric acid etching as 
previously described [49]. Prior to use, the fluidics part of the DC-shMN-iSystem was 
sterilized by flushing it with 70% ethanol.
Depth-controlled intradermal microinjections
To maximize the accuracy of the depth at which an antigen is administered intradermally, 
very low volumes have to be injected, due to possible perfusion. Therefore, the 
microinjection volume was reduced to 0.2 μL (as compared to the 10 μL intradermal 
injections using a conventional hypodermic needle-and-syringe), and contained 0.1 μg 
OVA. Intradermal microinjections were performed at a pre-selected depth of 50, 500 or 
1000 μm using the DC-shMN-iSystem. As control, 0.1 μg OVA in 10 μL PBS was injected 
intradermally using a conventional hypodermic needle-and-syringe (30G needle-
syringes).
Culturing of human skin explants
A skin biopsy was harvested immediately after intradermal injection and was cultured 
to observe the immunological behavior of migrating cells, as reported earlier [44, 45]. A 
full thickness skin biopsy of 6 mm in diameter was taken from the ex vivo skin at the 
injection site, whilst simultaneously removing the subcutaneous fat. For each treatment, 
12 biopsies were harvested. Each biopsy was floated with the epidermal side up for 1 
hour in 0.5 mL IMDM containing 1% FCS in a 48-well plate. Subsequently, the biopsies 
were transferred to 1 mL of IMDM containing 10% FCS and 100 ng/mL GM-CSF in a new 
48-well plate and were cultured with the epidermal side up at 37 °C and 5% CO2 for 
3 days. After removal of the biopsies, migrated cells (crawled out the biopsies) were 
harvested and pooled for flow cytometric analysis.
58 | CHAPTER 3
3
Analysis by flow cytometry
The percentage of specific subsets of total migrated HLA-DR+ DCs, maturation and uptake 
of OVA by migrated LCs, CD1a+ and CD14+ DDCs were analyzed by using flow cytometry. 
Migrated DCs were isolated and stained with fluorescently labeled antibodies. During 
flow cytometric analysis, migrated DCs were distinguished by their forward and sideward 
scatter properties, in combination with high expression levels of HLA-DR and CD11c, 
after which LCs (defined as CD1ahigh), CD1a+ and CD14+ DDCs were discriminated from 
this population, see Supplementary Materials. Absolute cell counts and percentages of 
specific subsets of total migrated HLA-DR+ DCs and relative changes in comparison to 
PBS treatment (%cells treatment group / %cells PBS group * 100) of LCs, CD1a+ and 
CD14+ DDCs were calculated. Subsequently, OVA uptake by LCs, CD1a+ and CD14+ DDCs 
was quantified by measuring the median fluorescence intensity (MFI) of (fluorescently 
labeled) OVA within each LC, CD1a+ or CD14+ DDC. Moreover, the percentage of cells 
within the LC, CD1a+ and CD14+ DDC subpopulations which had taken up OVA was 
determined. Additionally, maturation of LCs, CD1a+ or CD14+ DDCs was analyzed by 
measuring the MFI of the markers HLA-DR and CD86. Multicolor flow cytometry was 
performed on a FACS Canto II (Becton Dickinson) and FlowJo v10.3 (Tree Star, Ashland, 
OR, USA) was used for data analysis.
Determination of the diffusion coefficient of OVA in skin
A method combining FRAP experiments with finite element analysis was used to 
determine the diffusion coefficient of OVA at various depths in the skin, as described 
in detail elsewhere [51]. In short, human skin samples were prepared by cutting slices 
perpendicular to the skin surface using a cutting device to create a flat cutting plane. 
Subsequently, the skin samples were immerged in 1 mg/mL OVA-FITC in Hank’s balanced 
salt solution with 20 μg/mL Hoechst 33342 and stored at 4 °C for at least 20 h. After 
equilibrating the skin samples to room temperature (15-25 °C) for at least 30 min, the 
skin samples were prepared for FRAP experiments, so that dehydration during the 
experiments was prevented. During FRAP experiments, the fluorescent molecules in a 
spot in the skin were bleached with a high laser power. Due to diffusion of bleached 
and unbleached molecules, the fluorescence level of the bleached spot recovers. This 
recovery is recorded with a confocal microscope with low laser power. The locations 
tested in FRAP experiments were at 50% of the epidermal thickness, 50% of the papillary 
dermal thickness and at the upper 10% of the reticular dermis, corresponding to average 
depths in skin of approximately 90, 300 and 1000 μm, respectively. The resulting images 
of the FRAP experiments were processed using MATLAB (2013a, The MathWorks Inc., 
Natick, MA, USA). Using Abaqus/Standard (v6-11.2, Dassault Systèmes Simulia Corp., 
Providence, RI, USA), a two-dimensional finite element model was designed simulating 
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the FRAP experiments, to solve the diffusion equation for OVA. Finally, the results of 
the finite element simulation were fitted to results of the processed data from the 
microscopy images of the FRAP experiments, whereby the diffusion coefficient of OVA 
at various depths in skin was estimated.
Statistical analysis
Graphs were plotted as mean ± SEM by using GraphPad Prism (v.7.00, GraphPad 
Software, LaJolla, CA, USA). The data was considered to be non-parametric paired 
data with multiple test groups. Therefore, statistical analysis was performed using linear 
mixed models (covariance type: compound symmetry) on rank transformed data with 
donor as covariate, followed by the post-hoc least significant difference (LSD) test for 
pairwise comparisons. Effects of the combination of the injected formulations and type 
of injection (single hollow microneedle, conventional hypodermic needle-and-syringe 
or no injection) were measured by assessing markers related to five different outcome 
groups: cell counts, percentage of specific subsets of total migrated HLA-DR+ DCs, 
relative changes in comparison to PBS treatment, DC maturation marker expression 
and OVA uptake. The linear mixed model was adjusted for 5 outcome groups and was 
considered to be statistically significant at p < 0.01. The LSD was considered to be 
statistically significant at p < 0.05. Statistical analyses were performed using IBM SPSS 
Statistics (version 23, International Business Machines Corporation, Armonk, NY, USA).




Antigen uptake by skin DCs may be influenced by the amount of antigen that is 
administered into the skin. Therefore, various amounts of model antigen OVA were 
administered intradermally using a conventional hypodermic needle-and-syringe.
Migration of skin DC subsets
Increasing OVA doses (1-50 μg) resulted in a trend of enhanced migration of LCs out of 
the skin, as determined in absolute cell counts (Fig. 1A), percentage of total migrated 
HLA-DR+ DCs (Fig. 1B) and relative changes in comparison to PBS treatment (Fig. 1C). 
When focusing on CD1a+ DDCs, the migration was independent of the OVA dose when 
determined in absolute cell counts (Fig. 1A). Contrarily, increasing OVA doses resulted in 
decreased CD1a+ DDC migration, taking into account the percentage of total migrated 
HLA-DR+ DCs (Fig. 1B) and relative changes in comparison to PBS treatment (Fig. 1C). 
Furthermore, a dose-dependent decrease in CD14+ DDC migration was also found, 
expressed as absolute cell counts (Fig. 1A), percentage of total migrated HLA-DR+ DCs 
(Fig. 1B) and relative changes in comparison to PBS treatment (Fig. 1C). Summarizing, 
intradermal administration of increasing OVA doses resulted in a trend in enhanced 
migration of LCs, whilst it resulted in statistically significant decreased migration of 
CD1a+ and CD14+ DDCs.
Vitamin D3 was selected as a positive control, as it is known to influence the migration of 
skin DCs [45]. Intradermal administration of vitamin D3 resulted in decreased migration of 
CD1a+ DDCs, but increased migration of CD14+ DDCs, expressed as absolute cell counts 
(Fig. 1A), percentage of total migrated HLA-DR+ DCs (Fig. 1B) and in relative changes in 
comparison to PBS treatment (Fig. 1C).
PBS treatment and biopsy alone were selected as negative controls. By comparing PBS 
treatment with biopsy alone, it was possible to determine whether the migration of 
skin DCs is affected by intradermal injection. After intradermal injection of PBS, in 
comparison to biopsy alone, only an enhanced migration of CD1a+ DDCs was observed, 
expressed as increase in percentage of total migrated HLA-DR+ DCs (Fig. 1B) and in 
relative changes in comparison to PBS treatment (Fig. 1C).
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Fig. 1 Migration of LCs, CD1a+ and CD14+ DDCs is independent of administered OVA dose.
For LCs, CD1a+ and CD14+ DDCs, the absolute cell count (A), the percentage of total migrated 
HLA-DR+ DCs (B) and the relative changes in comparison to PBS treatment (C) was analyzed as 
function of OVA dose, vitamin D3 or PBS after intradermal administration by using a conventional 
hypodermic needle-and-syringe or as function of biopsy alone. The data represents mean ± SEM 
(n = 3). Statistical significant differences (p < 0.05) are indicated with an asterisk (*).The statistical 
significant differences for the vitamin D3 group are omitted and are as follows: Fig. 1A CD14+ DDCs 
(vitamin D3 against all other treatments, except PBS), Fig. 1B CD1a+ DDCs and Fig. 1B CD14+ DDCs 
(vitamin D3 against all other treatments), Fig. 1C CD1a+ DDCs (vitamin D3 against 5 and 1 μg OVA and 
biopt) and Fig. 1C CD14+ DDCs (vitamin D3 against all other groups).
Maturation
DCs must activate and maturate after antigen uptake, in order to be able to induce 
adaptive immune responses, important to immunization. Maturation is characterized 
by an increase in expression of HLA-DR and co-stimulatory molecule CD86 on the cell 
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the expression of HLA-DR and CD86 on LCs, CD1a+ and CD14+ DDCs. Representative 
histograms of flow cytometric analysis after administration of 50 μg OVA or PBS is shown 
in Fig. 2A and 2B for HLA-DR and CD86, respectively.
The expression of HLA-DR (Fig. 2C) by LCs, CD1a+ and CD14+ DDCs was independent of 
administered OVA dose. However, CD86 expression by CD1a+ DDCs, but not by LCs or 
CD14+ DDCs, was significantly increased in a dose-dependent manner after intradermal 
administration of OVA (Fig. 2D). Vitamin D3 treatment resulted in a significant increase 
in CD86 expression by CD1a+ DDCs in comparison to negative controls. No differences 
between PBS injection and biopsy alone were observed for HLA-DR or CD86 expression.
OVA uptake
The effect of the OVA dose on OVA uptake by LCs, CD1a+ and CD14+ DDCs was 
determined by intradermal administration of increasing (fluorescently labeled) OVA 
doses. Representative histograms of OVA fluorescence after intradermal administration 
of 50 μg OVA or PBS are shown in Fig. 3A.
A dose-dependent OVA uptake by LCs and CD1a+ DDCs was observed, illustrated by an 
increasing MFI for OVA with increasing OVA doses (presented in Fig. 3B). Contrarily, the 
OVA uptake by CD14+ DDCs was independent of OVA dose, indicating that CD14+ DDCs 
are very efficient in uptake of OVA. In fact, when examining the 50 μg OVA dose, OVA 
uptake was highest in CD14+ DDCs, followed by that of CD1a+ DDCs (3.5-fold lower) and 
LCs (15.7-fold lower). As expected, no OVA fluorescence was detected after intradermal 
administration of control formulations.
Next, the percentage of cells within the LC, CD1a+ and CD14+ DDC subpopulations that 
took up OVA was determined, as detailed in Fig. 3A. Nearly each CD14+ DDC had taken up 
OVA, even at the lowest OVA dose (99%), as presented in Fig. 3C. Similarly, the percentage 
of CD1a+ DDCs which had taken up OVA was high (91-99%). However, an OVA dose-
dependent increase in OVA uptake was observed, as administration of 50 or 25 μg OVA 
doses resulted in a statistically significant higher percentage of CD1a+ DDCs which had 
taken up OVA (99% and 97%, respectively), as compared to intradermal administration 
of 5 and 1 μg OVA (95 and 91%, respectively). Furthermore, the percentage of LCs which 
had taken up OVA strongly depended on the OVA dose, as an equal percentage of LCs 
and CD1a+ or CD14+ DDCs that had taken up OVA was only reached using the highest OVA 
doses. Moreover, nearly each LC had taken up OVA after intradermal administration of 
50 and 25 μg OVA (99%), whereas only approximately 60% or 12% of LCs had taken up 
OVA after intradermal administration of 5 and 1 μg OVA, respectively.




















Fig. 2 Maturation of LCs, CD1a+ and CD14+ DDCs is affected by the administered OVA dose.
The maturation of LCs, CD1a+ and CD14+ DDCs was analyzed by measuring the MFI of HLA-DR and 
co-stimulatory molecule CD86. Representative histograms are shown for LCs, CD1a+ and CD14+ 
DDCs, for 50 μg of OVA (red) and PBS (blue), for HLA-DR (A) and CD86 (B). The MFI was analyzed as 
function of OVA dose, vitamin D3 or PBS after intradermal administration by using a conventional 
hypodermic needle-and-syringe or biopsy alone. The MFI is represented for HLA-DR in (C) and for 
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CD86 in (D). The data represents mean ± SEM (n = 3). Statistical significant differences (p < 0.05) 
are indicated with an asterisk (*). The statistical significant differences for vitamin D3 treatment are 
omitted and are as follows: Fig. 2D CD1a+ DDCs (vitamin D3 against 1 μg OVA, PBS and biopt).
 
Fig. 3 OVA uptake differs between LCs, CD1a+ and CD14+ DDCs and is affected by the administered 
OVA dose.
OVA uptake by LCs, CD1a+ and CD14+ DDCs was investigated by flow cytometry as function of the 
OVA dose, vitamin D3 or PBS after intradermal administration by using a conventional hypodermic 
needle-and-syringe or biopsy alone. OVA fluorescence was measured within migrated LCs, CD1a+ 
and CD14+ DDCs. This is demonstrated in representative histograms (A), where OVA fluorescence 
from migrated LCs, CD1a+ and CD14+ DDCs after administration of 50 μg of (fluorescently labeled) 
OVA (red) or PBS (blue) is depicted. The amount of OVA uptake by LCs, CD1a+ and CD14+ DDCs 
was quantified by measuring the MFI of (fluorescently labeled) OVA, represented in (B). The 
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a threshold for OVA fluorescence (A). Following this discrimination, the percentage of cells within 
each LC, CD1a+ or CD14+ DDC subpopulation which had taken up OVA is represented in (C). The 
data represents mean ± SEM (n = 3). Statistical significant differences (p < 0.05) are indicated with 
an asterisk (*).
Single hollow microneedle-mediated depth-controlled intradermal microinjections 
of OVA
Because LCs, CD1a+ and CD14+ DDCs reside at different depths in the skin, we 
hypothesized that OVA uptake may be influenced by administration of OVA at different 
depths in skin. Therefore, 0.1 μg OVA was administered intradermally in 0.2 μL at shallow 
(50 μm), medium (500 μm) and deep (1000 μm) depths in skin, by using single hollow 
microneedle-mediated depth-controlled microinjections. Subsequent percentages of 
specific subsets of total migrated HLA-DR+ DCs, maturation and OVA uptake of migrated 
LCs, CD1a+ and CD14+ DDCs were analyzed and compared to intradermal administration 
of 0.1 μg OVA in 10 μL by using a conventional hypodermic needle-and-syringe.
Migration of skin DC subsets
No differences were found in absolute cell counts (Fig. 4A), percentage of specific 
subsets of total migrated HLA-DR+ DCs (Fig. 4B) or in relative changes in comparison 
to PBS treatment (Fig. 4C) of LCs, CD1a+ and CD14+ DDCs upon administration of OVA 
at different depths into the skin (50, 500 and 1000 μm). Similarly, no differences were 
found between intradermal administration of OVA by using a single hollow microneedle 
at different depths or a conventional hypodermic needle-and-syringe. However, 
intradermal administration of OVA by using a single hollow microneedle (at 500 or 1000 
μm depths) resulted in an increased percentage of CD14+ DDCs of total migrated HLA-
DR+ DCs in comparison to biopsy alone (Fig. 4B). Likewise, intradermal administration 
of OVA by using a single hollow microneedle (at 500 or 1000 μm depths) or by using a 
conventional hypodermic needle-and-syringe resulted in an increase of CD14+ DDCs in 
relative changes in comparison to PBS treatment (Fig. 4C).
The percentage of CD14+ DDCs of total migrated HLA-DR+ DCs and relative changes in 
comparison to PBS treatment increased upon intradermal administration of vitamin D3. 
Neither PBS or biopsy treatment resulted in any effect.
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Fig. 4 Migration of LCs, CD1a+ and CD14+ DDCs is independent of the injection depth in skin and 
by injection method.
For LCs, CD1a+ and CD14+ DDCs, the absolute cell count (A), the percentage of total migrated HLA-
DR+ DCs (B) and the relative changes in comparison to PBS treatment (C) was investigated as function 
of the injection depth in skin by using a single hollow microneedle and as function of intradermal 
administration by using a conventional hypodermic needle-and-syringe (ID) of OVA, vitamin D3 or 
PBS or as function of biopsy alone. The data represents mean ± SEM (n = 5). Statistical significant 
differences (p < 0.05) are indicated with an asterisk (*). The statistical significant differences for 
the vitamin D3 group are omitted and are as follows: Fig. 4B CD14+ DDCs and Fig. 4C CD14+ DDCs 
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Maturation
As demonstrated in Fig. 5, the expression of HLA-DR and co-stimulatory molecule CD86 
was independent of intradermal administration of OVA at different depths or upon 
comparing intradermal administration of OVA either by using a single hollow microneedle 
or by using a conventional hypodermic needle-and-syringe. Nor was the expression of 
HLA-DR or CD86 affected by treatment with OVA, vitamin D3, PBS or biopsy alone.
 
Fig. 5 Maturation of LCs, CD1a+ and CD14+ DDCs is independent of the depth in skin at which OVA 
is administered and intradermal administration method.
The maturation of LCs, CD1a+ and CD14+ DDCs was analyzed by measuring the MFI of HLA-DR (A) 
and co-stimulatory molecule CD86 (B). Maturation was investigated as function of the depth in skin 
at which OVA was administered by using a single hollow microneedle or as function of intradermal 
administration by using a conventional hypodermic needle-and-syringe (ID) of OVA, vitamin D3 or 
PBS or as function of biopsy alone. The data represents mean ± SEM (n = 5).
OVA uptake
Upon analyzing the effect of depth-controlled intradermal administration of OVA 
on antigen uptake by skin DCs (Fig. 6A and -B), no differences were found, with one 
exception. Intradermal administration of OVA at 50 μm depth resulted in a decreased 
percentage of LCs that had taken up OVA compared to intradermal administration of 
OVA at 500 and 1000 μm depths by using a single hollow microneedle and by using a 
A
B
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conventional hypodermic needle-and-syringe. However, the amount of OVA which had 
been taken up on average by an individual LC was independent of injection depth, as 
indicated by the MFI in Fig. 6A. Furthermore, the amount of OVA uptake by CD14+ DDCs 
was highest, followed by that of CD1a+ DDCs and LCs (Fig. 6A). As expected, controls did 
not result in the detection of OVA uptake by LCs, CD1a+ or CD14+DDCs.
Fig. 6 OVA uptake differs between LCs, CD1a+ and CD14+ DDCs and is independent of the depth 
in skin at which OVA is administered and intradermal administration method.
OVA uptake by LCs, CD1a+ and CD14+ DDCs was investigated by flow cytometry as function of the 
depth in skin at which OVA was administered by using a single hollow microneedle, as function of 
intradermal administration by using a conventional hypodermic needle-and-syringe (ID) of OVA, 
vitamin D3 or PBS or as function of biopsy alone. The amount of OVA uptake by LCs, CD1a+ and 
CD14+ DDCs was quantified by measuring the MFI of OVA, represented in (A). The percentage of cells 
which had taken up OVA is represented in (B). The data represents mean ± SEM (n = 5). Statistical 
significant differences (p < 0.05) are indicated with an asterisk (*).
Determination of the diffusion coefficient of OVA in skin
No differences in OVA uptake by skin DCs were observed upon OVA administration at 
different depths into the skin. For this reason, it was decided to measure the diffusion 
coefficient of OVA at different depths in skin, which was done using FRAP.
A
B
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From the fluorescence recovery monitored with confocal microscopy combined with 
finite element analysis, the OVA diffusion coefficient was determined on 3 locations in 
the skin within 10 samples. Based on the criteria for the quality of experiments and 
quality of the fit, 17 of the 30 measurements were selected for further analysis. As 
demonstrated in Fig. 7, the mean diffusion coefficient of OVA was 17 μm2/s at a depth 
of about 90 μm in the epidermis and was approximately two-fold higher in the dermis, 
namely 35 μm2/s at a depth of about 300 μm and 27 μm2/s at a depth of about 1000 μm.
Fig. 7 The diffusion coefficient of OVA in the epidermis and dermis.
The diffusion coefficient of OVA at 50% of the depth of the epidermis, at 50% of the depth of the 
papillary dermis and at 10% of the depth of the reticular dermis was determined by a combination 
of FRAP experiments and finite elements analysis. The data represents mean ± SEM (n = 6, 9, 2 for 
50% epidermis, 50% papillary dermis and 10% reticular dermis, respectively).
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DISCUSSION
In this study, OVA was administered into ex vivo human skin at various doses and depths 
in skin to examine the resulting migration of, maturation of and OVA uptake by LCs, 
CD1a+ and CD14+ DDCs. Upon intradermal administration of increasing OVA doses, an 
(non-significant) increased percentage of LCs was detected amongst the migrated DCs, 
while significantly decreased percentages of CD1a+ and CD14+ DDCs were observed. 
Moreover, an increase in the expression of costimulatory molecule CD86 was found 
on CD1a+ DDCs, whereas no differential expression was detected on LCs and CD14+ 
DDCs. Intradermal administration of increasing OVA doses correlated with increased 
OVA uptake by LCs and CD1a+ DDCs, whereas CD14+ DDCs were seemingly saturated 
even at the lowest dose investigated, demonstrating a very high level of OVA uptake. In 
addition, nearly each individual CD14+ DDC took up OVA at the examined doses, closely 
followed by CD1a+ DDCs, whereas LCs only reached similar levels as CD1a+ and CD14+ 
DDC at the highest OVA doses tested. Taken together, CD1a+ and CD14+ DDCs were more 
efficient in OVA uptake compared to LCs. Furthermore, no difference in OVA uptake was 
observed between intradermal administration of OVA, either by using a conventional 
hypodermic needle-and-syringe or by using a single hollow microneedle for depth-
controlled microinjections at a 50x reduced injection volume. These results indicate 
however, that the volume of vaccine formulations for intradermal administration can 
be significantly reduced, lowering discomfort associated with intradermal injections [17], 
while maintaining high antigen uptake by skin DCs.
Using single cell suspensions consisting of DCs extracted from human skin, it was 
demonstrated that CD14+ DDCs were superior in OVA uptake compared to CD1a+ DDCs, 
which were superior compared to LCs [32]. Our findings are similar to those, but resulting 
from in situ intradermal administration of OVA. Although the CD14+ DDCs subpopulation 
was not distinctively determined, similar results were presented in another study in 
which OVA uptake was examined upon in situ intradermal administration of OVA by using 
a conventional needle-and-syringe [52]. In addition, by using cryo-sectioned and stained 
samples of skin analyzed by using confocal microscopy, it was shown that DDCs had 
superior OVA uptake compared to LCs [52]. Uptake of antigen by LCs in the epidermis 
upon intradermal administration was demonstrated in other studies, both in human [53] 
and mice skin [54-59], but were limited in distinguishing between LCs and the two subsets 
of DDCs or did not quantify antigen uptake.
DDCs are also superior in uptake of bacteria in comparison to LCs, as DDCs more 
efficiently internalized Gram-negative [35, 60, 61] and Gram-positive bacteria [35, 61] than 
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LCs. In this case, the reduced expression of TLR 2, 4 and 5 [35], important to bacterial 
recognition, may play an important role. In fact, it has been proposed that LCs provide 
an immune regulating role in the epidermis, maintaining tolerance to commensal skin 
bacteria [61-63].
A comparison of the diffusion coefficient of macromolecules at various depths in human 
skin has previously only been performed for fluorescein dextran of 40 and 500 kDa [51]. 
Although dextran (at 40 kDa MW) and OVA (at 42.7 kDa MW [64]) share a similar molecular 
weight, a direct comparison of dextran and OVA cannot be made as the molecular 
structure is dissimilar: dextran is a complex branched glucan and OVA is a protein. For 
this reason, we decided to determine the diffusion coefficient of OVA in the epidermis 
as well as in the dermis. In comparison, the diffusion coefficient of OVA is somewhat 
higher than that of 40 kDa dextran [51]. The diffusion coefficient of both OVA and 40 kDa 
dextran was two-fold higher in the dermis compared to the epidermis [51]. Owing to this 
relatively high diffusion coefficient, within the 3-day culturing period used in the human 
skin explant model, the administered OVA might diffuse in all compartments of the skin 
and subsequently be taken up by the LCs or DDCs independent of the injection depth. 
Therefore, the relatively high diffusion rate might be partly responsible for the absence 
of differences as function of the injection depth. Interestingly, a study tracking motility 
of the DCs in skin demonstrated that DDCs actually take up antigen from the highest 
skin regions [59], which may further clarify why a high OVA loading was observed in DDCs 
as compared to LCs.
Historically, performance of vaccines is evaluated on the ability to induce antibody 
responses. In some studies, elevated antibody responses at reduced doses have been 
reported for intradermal immunization in comparison to intramuscular and subcutaneous 
routes [17], while other studies report no difference in response [65]. It is suggested that 
intradermal immunization route may provide a dose-sparing strategy, as the skin is 
rich in a variety of DCs [66]. Our study showed that CD14+ DDCs easily internalized large 
amounts of OVA, even at low dose. This suggests efficient processing and presentation 
and subsequent initiation of adaptive immune responses [29, 32, 41].
Recently, however, attention has shifted to the role of cellular responses in vaccination, 
especially in the scope of therapeutic vaccines (e.g., against cancer) and intercellular 
pathogens. LCs are more efficient than CD1a+ or CD14+ DDCs in initiating CTL responses 
[29, 32, 35-38]. For cellular responses, a higher abundance of antigen seems to lead towards 
a stronger CTL response [67]. Our results and those by others [32] indicate that LC uptake 
of OVA at low dose is inefficient and a high dose must be utilized to achieve high antigen 
72 | CHAPTER 3
3
loading in LCs. If this can be translated to other antigens, vaccination strategies aiming 
for high CTL responses may require a high dose to load LCs. However, increasing 
antigen doses may affect specificity, affinity and stability of a peptide binding to MHCI 
molecules, the internal processing by DCs for presentation on MHCI molecules and gene 
and protein expression levels, which may influence CTL responses [68, 69]. Therefore, it 
remains to be elucidated whether there is a correlation between high antigen loading 
in LCs and high CTL responses. Moreover, glycosylation of antigens may enhance their 
uptake and therefore alter the efficiency of T cell priming [70-73].
CONCLUSION
In this study, the role of antigen uptake by individual DC subsets in skin was further 
investigated. We demonstrated that the uptake of antigen is most efficient by CD14+ 
DDCs followed by CD1a+ DDCs. Furthermore, LCs require high antigen doses to internalize 
large quantities of protein antigen (OVA). There was no influence of the injection depth 
in skin on antigen uptake by skin DCs. Importantly, intradermal microinjection by a single 
hollow microneedle using a 50x reduced injection volume results in similar antigen 
uptake as compared to intradermal administration with a conventional hypodermic 
needle-and-syringe, which opens possibilities for improved vaccination strategies using 
hollow microneedles.
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Supplementary Fig. 1 The absolute cell counts of migrated skin DCs was independent of 
administered OVA dose.
Leukocytes were selected on their forward-scatter and sideward-scatter characteristics (A), 
doublet-cells were excluded by selection on forward-scatter area and -height characteristics 
(B) and finally skin DCs were selected on the expression of CD11c and HLA-DR (C). The skin DCs 
were discriminated in three skin DC subsets, based on the expression of CD14 and CD1a (D). LCs 
were discriminated as CD1ahigh/CD14-, while DDCs were distinguished as CD1a+ DDCs (discriminated 
as CD1amid/CD14-) and CD14+ DDCs (discriminated as CD1a-/ CD14+). The absolute cell counts of 
migrated skin DCs selected from (C) are expressed in (E) and are independent of the OVA dose. The 
dot plots are representative for the flow cytometry experiments. The data in (E) represents mean 
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Supplementary Fig. 2 Migration of skin DCs is independent of the depth in skin at which OVA is 
administered and intradermal administration method.
The absolute cell counts of migrated skin DCs was investigated as function of the depth in skin 
at which OVA was administered by using a single hollow microneedle, as function of intradermal 
administration by using a conventional hypodermic needle-and-syringe (ID) of OVA, vitamin D3 or 
PBS or as function of biopsy alone. The data represents mean ± SEM (n = 5).
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by a single hollow microneedle  
leads to superior immune responses
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ABSTRACT
The purpose of this study was to investigate the effect of various repeated fractional 
intradermal dosing schedules of inactivated polio vaccine serotype 1 (IPV1) on IPV1-
specific IgG responses in rats. By utilizing an applicator that allowed for precisely 
controlled intradermal microinjections by using a single hollow microneedle, rats were 
immunized intradermally with 5 D-antigen units (DU) of IPV1 at 150 μm skin depth. 
This dose was administered as a bolus, or in a repeated fractional dosing schedule: 4 
doses of 1.25 DU (1/4th of total dose) were administered on four consecutive days or 
every other day; 8 doses of 0.625 DU (1/8th of total dose) were administered on eight 
consecutive days; or 4 exponentially increasing doses (0.04, 0.16, 0.8 and 4 DU), either 
with or without an exponentially increasing CpG oligodeoxynucleotide 1826 (CpG) dose, 
were administered on four consecutive days. All of these fractional dosing schedules 
resulted in up to ca. 10-fold higher IPV1-specific IgG responses than intradermal and 
intramuscular bolus dosing. IPV1 combined with adjuvant CpG in exponential dosing did 
not significantly increase the IPV1-specific IgG responses further, which demonstrated 
that maximal responses were achieved by fractional dosing. In conclusion, repeated 
fractional intradermal IPV1 dosing leads to superior IPV1-specific IgG responses without 
the use of adjuvants. These results indicate that a controlled release delivery system for 
intradermal IPV1 delivery can potentiate IPV1-specific IgG responses. 
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INTRODUCTION
The World Health Organization has initiated a plan to eradicate poliomyelitis completely. 
Extensive vaccination programs play a major role in this plan [1]. Currently, inactivated 
polio vaccine (IPV) and oral polio vaccine (OPV) are both used to prevent poliomyelitis. 
IPV is expensive, because of high production costs and the requirement of a relatively 
large dose for protection [2]. However, because OPV is based on attenuated live polio 
virus strains, it carries the risk that it may revert to wildtype poliovirus and cause 
outbreaks of vaccine-derived polioviruses. Sometimes this results in vaccine-associated 
paralytic poliomyelitis in vaccinated individuals or their contacts [3, 4]. For that reason, 
the strategy of the World Health Organization is to replace OPV by IPV [1]. Simultaneously, 
several strategies to reduce costs for IPV immunization are investigated, including dose 
sparing strategies, such as adjuvanting IPV [2]. Studies have been conducted focusing on 
the IPV-specific immune response-enhancing effects of adjuvants, such as aluminum 
salts, calcium phosphate, oil emulsions, chitosan, vitamin D, CpG oligodeoxynucleotides, 
stearyl tyrosine, liposomes and others [5-13]. Although adjuvants may increase (antigen-
specific) immune responses and may result in antigen dose sparing, they can also 
cause side-effects, may be expensive and may introduce vaccine formulation stability 
problems [14]. Therefore, avoidance of adjuvants in vaccine formulations can increase 
vaccine safety and stability and reduce costs.
As an alternative strategy for dose sparing, other delivery routes than the intramuscular 
route have gained much interest in recent years [2]. The intradermal delivery route has 
been regarded as very attractive, as it has been reported that intradermal immunization 
may result in increased immune responses, owing to the unique immunological 
properties of the densely packed skin dendritic cells [15]. Indeed, IPV dose sparing has 
been reported for intradermal IPV immunization of infants by intradermal injections with 
conventional needles [16]. However, intradermal injections with conventional needles are 
difficult to perform and painful. Therefore, there is a need for alternative intradermal 
immunization methods. Microneedle-mediated vaccine delivery is a relatively new 
strategy to intradermally deliver vaccines in a minimally invasive and potentially pain-
free manner [17]. For this reason, microneedle-mediated intradermal IPV immunization 
was examined in rats, rhesus macaques and humans [6, 13, 18-23]. Previously, we developed 
hollow microneedles and an applicator for hollow microneedles, [18] that allows 
precisely controlled intradermal microinjections [13], taking full advantage of the unique 
immunological properties of the skin. Furthermore, prolonged delivery of a peptide 
antigen has led to increased immune responses [24]. However, it is unknown whether 
prolonged delivery of a vaccine antigen that is used in vaccine programs will lead to 
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increased immune responses as well and whether precise dosing in time is affecting 
antigen-specific IgG responses. 
In the present study, the IPV dose was divided over multiple days using various multi-
day dosing schedules and injected into the skin by hollow microneedle-mediated 
microinjections. In this way, the IPV dose was delivered into the skin in repeated fractional 
doses. We present that superior IPV-specific immune responses by immunization 
with repeated fractional doses are induced, without the use of adjuvants and taking 
advantage of the potentially pain-free IPV delivery into skin by hollow microneedles. This 
demonstrates that a controlled release delivery system which delivers IPV1 intradermally 
over multiple days may substantially increase IPV1-specific IgG responses.
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MATERIALS
Concentrated sulfuric acid 95-98% and hydrofluoric acid 49% w/w were purchased 
from Sigma-Aldrich, Zwijndrecht, the Netherlands. Silicone oil AK350 was ordered at 
Boom, Meppel, the Netherlands and 20 μm inner diameter polyimide coated fused silica 
capillary at Polymicro, Phoenix, USA. Female Wistar Han IGS rats (Crl:WI(Han), strain code 
273, 175-225 g) were obtained from Charles River, Saint-Germain-sur-l’Arbresle, France. 
Isoflurane 100% w/w was purchased from Abbott, Maidenhead, UK. Phosphate buffered 
saline (PBS: 163.9 mM Na+, 140.3 mM Cl-, 8.7 mM HPO4
2- and 1.8 mM H2PO4
-, pH 7.4) was 
ordered at B. Braun Melsungen, Melsungen, Germany and CpG oligodeoxynucleotide 
1826 (CpG) at Invivogen, Toulouse, France. 2.5 mL Vacuette® Z-serum-separator clot-
activator premium-tubes were obtained from Greiner Bio-One, Alphen a/d Rijn, the 
Netherlands. Monovalent IPV type-1 (IPV1) was kindly provided by Intravacc, Bilthoven, 
the Netherlands.
METHODS
Applicator and fabrication of hollow microneedles 
Hollow microneedles were produced in-house as previously described [13, 18]. In short, 
the inner lumen of 20 μm inner diameter polyimide-coated fused-silica capillaries was 
filled with silicone oil overnight in vacuo at 100 °C. These capillaries were wet-etched 
into hollow microneedles, by immersing one side (± 10 mm) of the capillaries in 49% 
hydrofluoric acid for 4 h. Next, the polyimide coating was removed by immersing the 
etched capillaries in concentrated sulfuric acid at 250 °C for 5 min, which resulted 
in hollow microneedles. An in-house designed hollow microneedle applicator [18], 
allowing for controllable injection rate, volume and depth [13], was used for intradermal 
microinjections by these hollow microneedles.
Immunization studies
Animal studies were performed obeying the guidelines and regulations enforced 
by Dutch law and the animal ethic committee. These studies were approved by the 
“Dierexperimentencommissie Universiteit Leiden (UDEC)” under number 12084. 
Female Wistar Han rats (weight on arrival 175-225 g) were housed in groups of five in 
a controlled environment subjected to guidelines of the animal facilities of the Leiden 
Academic Centre for Drug Research, Leiden University. The animals were randomly 
assigned to immunization groups (10 animals per group). Animals were anesthetized 
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with isoflurane prior to shaving, blood withdrawal and immunization. Animals that were 
assigned to intradermal immunization groups were shaved (an area of 4 cm2 on the left 
posterior flank) prior to the intradermal microinjection. For intradermal immunization, 
a single hollow microneedle was applied by using an applicator for hollow microneedles 
to perform microinjections into the skin at a pre-defined skin injection depth, rate 
and volume of 150 μm, 20 μL/min and 10 μL, respectively. Control groups received 
intramuscular injections of 100 μL per hind leg (200 μL in total). 
Two immunization studies were performed to investigate effects of repeated fractional 
IPV1 dosing. The dosing schedule of the first study is presented in Table 1. In detail, 
all groups (except the PBS treated group) received a total IPV1 dose of 5 D-antigen 
units (5 DU, 1/8th human dose) per immunization course, injected either by intradermal 
microinjections or by intramuscular injections by a hypodermic 26G needle. The total IPV1 
dose was either given at once (bolus), was divided into four 1/4th doses and delivered over 
four consecutive days (4 x 1/4th (4 d)) or was divided into four exponentially increasing 
doses and delivered over four consecutive days (Exp). The latter dosing schedule was 
also performed for IPV1 doses combined with adjuvant CpG (Exp-CpG). The total CpG 
dose was 10 μg and this dose was also divided into four exponentially increasing doses 
over four consecutive days, similar to the IPV1 dose. A bolus dose was delivered either 
by a single hollow microneedle-mediated intradermal microinjection (ID-bolus) or by a 
single conventional intramuscular injection by a hypodermic needle (IM-bolus). These 
dosing schedules were performed on day 0 as prime immunization course and these 
same dosing schedules were repeated, starting on day 21, for a booster immunization 
course. Blood samples of each individual animal were collected on 7-day intervals, 
which started on day 0 and ended on day 42. Blood samples were collected in 2.5 mL 
Vacuette® tubes and stored on ice before centrifugation at 2000g for 10 min to isolate 
serum, which was stored at -80 °C prior to analysis.
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Table 1 Dosing schedule of the first immunization study.
The IPV1 dose delivered during each immunization course (prime and boost) was 5 DU. This dose 
was delivered as single injection (bolus) or was delivered over 4 days (4 d). The total IPV1 dose 















Intradermal ID-Bolus 5 - - - 5 10
4x1/4th (4d) 1.25 1.25 1.25 1.25 5 10
Exp 0.04 0.2 0.8 3.96 5 10
Exp-CpG* 0.04 0.2 0.8 3.96 5 10
Intramuscular IM-Bolus 5 - - - 5 10
PBS 0 - - - 0 0
* The IPV1 dose was combined with an exponentially increasing CpG dose of 0.08, 0.32, 1.6 and 8 μg, respectively 
(total CpG dose 10 μg)
A second immunization study was performed to further examine the effect of repeated 
fractional IPV1 dosing. The dosing schedule of the second study is presented in Table 2. 
All groups (except the PBS treated group) received a total IPV1 dose of 5 DU in this study. 
During this study, the total IPV1 dose was either given in bolus, in four 1/4th doses over 
four consecutive days (4 x 1/4th (4 d)), in four 1/4th doses on every other day over 7 days 
(4 x 1/4th (7 d)), or in eight 1/8th doses over eight consecutive days (8 x 1/8th (8 d)). No 
boost immunization course was performed. Blood sampling, collection and storage was 
performed as described above.
Table 2 Dosing schedule of the second immunization study.
The total IPV1 dose delivered in this study after the single (prime) immunization course was 5 DU. 
This dose was delivered as single injection (bolus) or was delivered over 4 days (4 d), 7 days (7 d) or 





IPV1 dose (DU) on day Total IPV1  
dose (DU)0 1 2 3 4 5 6 7
Intradermal ID-Bolus 5 - - - - - - - 5
4 x 1/4th 
(4 d)
1.25 1.25 1.25 1.25 - - - - 5
4 x 1/4th 
(7 d)
1.25 - 1.25 - 1.25 - 1.25 - 5
8 x 1/8th 
(8 d)
0.625 0.625 0.625 0.625 0.625 0.625 0.625 0.625 5
Intramuscular IM-Bolus 5 - - - - - - - 5
PBS 0 - - - - - - - 0
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IPV1-specific serum IgG titers and virus-neutralization (VN) titers
A capture ELISA was performed to measure IPV1-specific serum IgG titers of the collected 
serum samples, as previously described [12, 13]. Endpoint titers were determined, which 
were defined as the reciprocal of the serum dilution that resulted in an absorbance (at 
450 nm) equal to the mean plus three times the standard deviation of the absorbance 
(at 450 nm) of IPV1-specific-antibody negative serum samples. The titer determination 
of antibodies that neutralize wildtype poliovirus serotype-1 was outsourced to Bilthoven 
Biologicals (Bilthoven, the Netherlands) and was performed as previously described [12, 
25]. VN antibody titers were analyzed on two-fold serially diluted (211-222) pooled serum 
samples of each immunization group of the first immunization study.
Statistical analysis
Statistics were performed by using GraphPad Prism (v.6.00, GraphPad Software, 
LaJolla, CA, USA). Kruskall-Wallis tests with Dunn’s post-hoc tests were performed, as 
IPV1-specific IgG titers were non-normally distributed. Differences were considered 
significant at p < 0.05.




In the first immunization study, a prime-boost immunization was performed as presented 
in Table 1. IPV1-specific immune responses resulting from repeated fractional doses 
delivered by hollow microneedle-mediated intradermal microinjections, were compared 
to the responses resulting from ID-bolus and IM-bolus dosing. CpG was selected as 
adjuvant, as in a previous study CpG acted as a potent adjuvant for intradermal IPV1 
immunization [13].
As presented in Fig. 1A, at day 21, IPV1-specific IgG responses resulting from any 
repeated fractional intradermal dosing schedule were significantly increased, compared 
to conventional IM-bolus dosing. 4 x 1/4th (4 d), Exp and Exp-CpG dosing led to 8.1, 
10.2 and 13.2-fold increased IPV1-specific IgG responses, respectively, compared to IM-
bolus dosing. Compared to ID-bolus dosing, 4 x 1/4th (4 d), Exp and Exp-CpG dosing 
resulted in 3.5, 4.5 and 5.8-fold increased IPV1-specific IgG responses, respectively. The 
IPV1-specific IgG response resulting from Exp-CpG dosing was significantly increased 
compared to ID-bolus dosing. Although not significantly different, IPV1-specific IgG 
responses resulting from ID-bolus dosing were 2.3-fold increased versus those resulting 
from IM-bolus dosing. Additionally, a higher number of low responding individuals 
(log10 titer < 2) was observed after IM-bolus dosing than ID-bolus dosing. Interestingly, 
adjuvanted Exp-CpG dosing did not result in significantly increased IPV1-specific IgG 
responses, compared to unadjuvanted Exp dosing.
After the booster immunization course, the potent IPV1-specific IgG response-enhancing 
effects by repeated fractional dosing were maintained at day 42 (presented in Fig. 1B). 
4 x 1/4th (4 d), Exp and Exp-CpG dosing resulted in 2.9, 4.3 and 7.8-fold increased 
IPV1-specific IgG responses, respectively, compared to conventional IM-bolus dosing. 
Compared to ID-bolus dosing, 4 x 1/4th (4 d), Exp and Exp-CpG dosing led to 3.6, 5.4 
and 9.6-fold increased IPV1-specific IgG responses, respectively. The latter two dosing 
schedules resulted in significantly increased IPV1-specific IgG responses compared to 
IM-bolus and ID-bolus dosing. In contrast to day 21, at this time IM-bolus resulted in a 
non-significant 1.2-fold higher IPV1-specific IgG responses than those resulting from 
ID-bolus dosing.
Kinetics of IPV1-specific IgG responses were also determined at 7-day intervals, to 
examine whether an accelerated response occurs, resulting from repeated fractional 
intradermal dosing (presented in Fig. 1C and in supplementary Fig. 1 (S1)). At day 7, IPV1-
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specific IgG responses in IPV1 immunized groups were significantly increased compared 
to IPV1-specific IgG responses of these same groups at day 0. From day 14 onwards, 
Exp and Exp-CpG dosing resulted in significantly increased IPV1-specific IgG responses 
compared to IM-bolus dosing and Exp-CpG also compared to ID-bolus dosing. At day 28, 
7 days after the boost immunization course, IPV1-specific IgG responses had increased 
sharply, whereafter they leveled off. At day 28 and day 35, significantly higher IPV1-
specific IgG responses were observed for any group treated with repeated fractional 
intradermal dosing (4 x 1/4th (4 d), Exp and Exp-CpG), compared to ID-bolus dosing. 












































































































Fig. 1 IPV1-specific serum IgG antibody responses of study 1, at 21 days past the prime immunization 
course (A, day 21), 21 days past the boost immunization course (B, day 42) or from day 0 to 42 (C). 
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Dosing schedules are presented in Table 1. Formulations were delivered intradermally by hollow 
microneedle-mediated microinjections (ID) or intramuscularly by conventional 26G hypodermic 
needles (IM). In part A and B, bars represent the mean IPV1-specific IgG titer, the error bars the 
95% confidence interval and an asterisk (*) designates a statistical significant difference (p < 0.05).
Besides measurements of IPV1-specific IgG antibody responses in serum as determined 
by ELISA, functionality of these serum antibodies was assessed in a VN assay. The serum 
antibodies resulting from any IPV1-treated group were able to neutralize virus, except 
the serum antibodies resulting from the PBS treated group (Table 3). VN titers resulting 
from Exp and Exp-CpG dosing was 2-fold and 4-fold increased, respectively, compared 
to the VN titer resulting from IM-bolus dosing. Compared to the VN titer resulting from 
ID-bolus dosing, VN titers resulting from Exp and Exp-CpG dosing were 4-fold and 8-fold 
increased, respectively.
Table 3 Virus-neutralization (VN) titers for study 1.
Study 1 VN antibody titers measured in serum obtained at day 42, after prime and booster 
immunization courses. The presented data was measured on a pool of serum samples of all 
individuals per immunization group. Dosing schedules are presented in Table 1. Formulations were 
delivered intradermally by hollow microneedle-mediated microinjections or intramuscularly by 
conventional 26G hypodermic needles.
Immunization route Dosing schedule VN titer (log2)
Intradermal ID-Bolus 11
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Second immunization study
In the second immunization study, the effect of different repeated fractional intradermal 
dosing schedules (see Table 2) was examined. In contrast to the first study, a single 
immunization course was performed. The IPV1-specific IgG responses resulting from 4 
x 1/4th (4 d), 4 x 1/4th (7 d) and 8 x 1/8th (8 d) dosing schedules were compared to 
responses resulting from IM-bolus and ID-bolus dosing over an extended period of time. 
The non-responders (one in the 4 x 1/4th (7 d) dosing group and one in the IM-bolus 
dosing group) were excluded from analyses.
Similar to study 1, all repeated fractional intradermal dosing schedules examined in study 
2 led to significantly increased IPV1-specific IgG responses after 21 days, compared to 
conventional IM-bolus dosing (Fig. 2A). Compared to IM-bolus dosing, 4 x 1/4th (4 d), 
4 x 1/4th (7 d) and 8 x 1/8th (8 d) dosing resulted in 15.1, 9.5 and 17.9-fold significantly 
increased IPV1-specific IgG responses, respectively. Compared to ID-bolus dosing, 4 
x 1/4th (4 d), 4 x 1/4th (7 d) and 8 x 1/8th (8 d) dosing resulted in 9.3 (significantly), 
5.9 (not significantly) and 11.1-fold (significantly) increased IPV1-specific IgG responses, 
respectively.
At day 42, only 8 x 1/8th (8 d) dosing resulted in significantly increased IPV1-specific IgG 
responses, compared to both IM-bolus and ID-bolus dosing (Fig. 2B). Groups treated 
with 4 x 1/4th (4 d), 4 x 1/4th (7 d) and 8 x 1/8th (8 d) dosing led to 3.8, 3.8 and 9.4-fold 
increased IPV1-specific IgG responses, respectively, compared to IM-bolus dosing and 
led to 1.8, 1.8 and 4.5-fold increased responses, respectively, compared to ID-bolus 
dosing.
Similar to study 1, IPV1-specific IgG responses were examined at 7-day intervals. As 
presented in Fig. 2C, IPV1-specific IgG responses were already maximal at day 21 for 
the repeated fractional intradermal dosing groups. The differences in IPV1-specific IgG 
responses between the repeated fractional intradermal dosing groups and the bolus 
dosing groups was most evident at day 21 as well, as presented in Fig. 2A and C and in 
supplementary Fig. 2 (S2). IM-bolus and ID-bolus dosing reached maximal IPV1-specific 
IgG responses at day 28. From day 28 onwards, IPV1-specific IgG responses resulting 
from IM-bolus and ID-bolus dosing were comparable and those resulting from 4 x 1/4th 
(4 d) and 4 x 1/4th (7 d) dosing were comparable. Interestingly, 8 x 1/8th (8 d) dosing 
already led to a significantly increased IPV1-specific IgG response at day 14 and retained 
this significant difference, until the end of the study. No IPV1-specific IgG responses 
were observed in the PBS treated group. Alike the first study, although not significantly 
different, IPV1-specific IgG responses resulting from ID-bolus dosing were 1.6-fold and 
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2.1-fold increased at day 21 and at day 42 of the study, respectively, versus the IPV1-





















































































































Fig. 2 IPV1-specific serum IgG antibody responses of study 2, at 21 days past the prime immunization 
course (A, day 21), 42 days past the prime immunization course (B, day 42) or from day 0 to 42 (C). 
Dosing schedules are presented in Table 2. Formulations were delivered intradermally by hollow 
microneedle-mediated microinjections (ID) or intramuscularly by conventional 26G hypodermic 
needles (IM). In part A and B, bars represent the mean IPV1-specific IgG titer, the error bars the 
95% confidence interval and an asterisk (*) designates a statistical significant difference (p < 0.05).
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DISCUSSION
In this study, we investigated whether repeated fractional intradermal dosing would 
enhance IPV1-specific IgG responses compared to the responses after conventional 
bolus dosing. To this end, four (4 x 1/4th (4 d), 4 x 1/4th (7 d), Exp or Exp-CpG) or eight 
(8 x 1/8th (8 d)) fractional IPV1 doses were delivered into skin over an extended time 
period, or a conventional bolus dose was administered. Repeated fractional intradermal 
IPV1 dosing led to a significant increase in IPV1-specific IgG responses compared to 
bolus dosing. Moreover, this effect was robust, as similar IPV1-specific IgG responses 
resulting from prime immunization by repeated fractional intradermal IPV1 dosing (4 x 
1/4th (4 d)) were observed in two individual immunization studies. Therefore, repeated 
fractional intradermal dosing has a potential for dose sparing, but additional studies 
need to be performed to further substantiate this.
The use of adjuvants is an important strategy to achieve antigen dose sparing [2]. Although 
aluminum hydroxide and aluminum phosphate are normally used as adjuvants, they are 
not allowed for intradermal immunization, due to granuloma formation [26]. However, 
alternative adjuvants for intradermal IPV bolus dosing have been studied in mouse 
models: double mutant heat-labile enterotoxin from E. coli LT (R192G/L211A), CpG ODN 
2006, CpG ODN 1826, cholera toxin and the CAF01 liposomal formulation resulted in 
a 2.5-, 4-, 6.9-, 7.3- and 10-fold increase in IPV-specific IgG responses after prime 
immunization, respectively, compared to unadjuvanted intradermal IPV bolus dosing 
[7, 10, 13, 27]. In our study, similarly potent increases in IPV1-specific IgG responses were 
observed upon intradermal delivery of fractional IPV1 doses, even without co-delivery 
of an adjuvant. In fact, IPV1-specific IgG responses of the Exp-CpG dosing group were 
similar to those of the (unadjuvanted) Exp dosing group. This demonstrates that by using 
alternative dosing strategies, antigen-specific immune responses can be increased and 
the use of an adjuvant can be avoided. 
A fast induction of polio immunity is important for disease control during a polio outbreak. 
Therefore, the kinetics of IPV1-specific IgG responses were examined to determine 
whether different repeated fractional dosing schedules alter the kinetics of IPV1-
specific IgG responses after prime immunization. In both studies, it was observed that 
repeated fractional dosing resulted in a faster increase in IPV1-specific IgG responses 
compared to bolus dosing. As presented in the second study, repeated fractional dosing 
reached maximal IPV1-specific IgG responses at day 21, whereas bolus dosing reached 
maximal IPV1-specific IgG responses 7 days later. Moreover, it is also important for 
disease control to boost immunity to stop pathogen replication in previously immunized 
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individuals. Therefore, booster responses are also important. In the first study, at 7 
days after boost immunization, a similarly fast increase in IPV1-specific IgG responses 
was observed. Although responses were already maximal at that time, fractional dosing 
retained its significantly increased IPV1-specific IgG titers compared to ID-bolus and 
IM-bolus dosing. So, repeated fractional dosing resulted in both faster and higher IPV1-
specific IgG responses. 
For the delivery of IPV, this study was focused on the potential of minimally-invasive 
intradermal immunization by hollow microneedle-mediated microinjections. In this study, 
ID-bolus and IM-bolus dosing resulted in two individual immunization studies in slightly 
(but not-significantly) higher IPV1-specific IgG responses. In the literature, similar results 
on the comparison of ID-bolus and IM-bolus dosing have been reported in rats, mice 
and rhesus macaque animal models [6, 7, 13, 18-21]. In humans, the IPV seroconversion rates 
after intradermal and intramuscular immunization have been compared. Intradermal 
immunization of IPV naïve newborn infants resulted in either similar [16, 28] or inferior 
[23, 29, 30] seroconversion rates, compared to intramuscular immunization. Additionally, 
intradermal booster immunization of previously IPV vaccinated adults resulted in 
either similar [22, 31] or inferior [32, 33] seroconversion rates, compared to intramuscular 
immunization. However, intradermal immunization in these studies was performed 
with 1/5th of a full IPV dose and the resulting seroconversion was compared to the 
seroconversion which resulted from intramuscular immunization with a full IPV dose. To 
fully elucidate whether intradermal immunization results in dose-sparing in humans, a 
dose-response study should be performed comparing intradermal and intramuscular 
immunization.
Interestingly, there was no significant difference observed between the different 
repeated fractional dosing schedules. Therefore, fractional dose delivery over 4 or 8 days 
did not influence the observed effects on IPV1-specific IgG responses. Moreover, in the 
4 x 1/4th (4 d) and 4 x 1/4th (7 d) dosing schedules, an equal dose and concentration was 
delivered at a differentiating time period, but this still resulted in similarly increased IPV1-
specific IgG responses. Therefore, it seems that the observed increased IPV1-specific 
IgG responses are not sensitive to the time period in which the dose is delivered. This 
demonstrates that flexibility in the fractional dosing schedules is allowed. Therefore, 
our studies demonstrate that enhanced IgG responses are expected to be achieved, by 
making use of a controlled release delivery system that is administered by using a single 
injection and which releases IPV1 over a certain time period, but that the exact release 
profile does not affect the IPV1-specific IgG levels. The latter observation makes it more 
easy and attractive to design a controlled release delivery system. This will be subject of 
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future studies in our group. 
The increased immune responses resulting from repeated fractional dosing might stem 
from prolonged exposure of the antigen to relevant immune cells. It was previously 
described that antigen depots are formed in germinal centers and that this depot is 
needed for B-cells to proliferate into plasma B-cells and memory B-cells [34, 35]. Moreover, 
it has been presented that the exposure time of T-cells to antigens determines the type 
of responses and level of responses by T-cells, including induction of T-cell memory [24, 
36-39]. Therefore, it is likely that by repeated fractional dosing, an immune modulation 
is triggered by prolonged exposure of the antigen to relevant immune cells. Another 
potential influencing factor is that antigen delivery over a prolonged time period targets 
more dendritic cells, as opposed to bolus dosing, as migrated dendritic cells will be 
replaced by new skin dendritic cells within 16 h [40, 41]. Therefore, whether pulsatile or 
continuous dosing or alternatively dosing at multiple injection sites is better remains to 
be elucidated. Furthermore, repeated fractional dosing should be examined in a dose-
response study, to precisely quantify dose-sparing effects.
CONCLUSION
In this study, the IPV1 dose was fractionated in 4, 8 or exponential increasing doses 
and was delivered intradermally over multiple days by minimally-invasive hollow 
microneedle-mediated microinjections. These repeated fractional intradermal dosing 
schedules resulted in superior immune responses, compared to ID-bolus and IM-
bolus dosing, without the use of adjuvants. Moreover, there were no increased immune 
responses when fractionated IPV1 doses were adjuvanted with CpG. Furthermore, our 
data suggests that a controlled release delivery system for the intradermal delivery of 
IPV1 can lead to increased IPV1-specific IgG responses.
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SUPPLEMENTARY MATERIALS
Supplementary Fig. 1 (S1) IPV1-specific serum IgG antibody responses of study 1, at 7 days (A, 
day 7) and 14 days (B, day 14) past the prime immunization course or 7 days (C, day 28) and 14 
days (D, day 35) past the booster immunization course. Dosing schedules are presented in Table 
1. Formulations were delivered intradermally by hollow microneedle-mediated microinjections 
(ID) or intramuscularly by conventional 26G hypodermic needles (IM). Bars represent the mean 
IPV1-specific IgG titer, the error bars the 95% confidence interval and an asterisk (*) designates a 
statistical significant difference (p < 0.05).
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Supplementary Fig. 2 (S2) IPV1-specific serum IgG responses of study 2, at 7 days (A, day 7), 14 
days (B, day 14), 28 days (C, day 28) and 35 days (D, day 35) past the prime immunization course. 
Dosing schedules are presented in Table 2. Formulations were delivered intradermally by hollow 
microneedle-mediated microinjections (ID) or intramuscularly by conventional 26G hypodermic 
needles (IM). Bars represent the mean IPV1-specific IgG titer, the error bars the 95% confidence 
interval and an asterisk (*) designates a statistical significant difference (p < 0.05).
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Diphtheria toxoid and N-trimethyl chitosan 
layer-by-layer coated pH-sensitive microneedles 
induce potent immune responses upon 
dermal vaccination in mice
5
ABSTRACT
Dermal immunization using antigen-coated microneedle arrays is a promising vaccination 
strategy. However, reduction of microneedle sharpness and the available surface 
area for antigen coating is a limiting factor. To overcome these obstacles, a layer-by-
layer coating approach can be applied onto pH-sensitive microneedles. Following this 
approach, pH-sensitive microneedle arrays (positively charged at coating pH 5.8 and 
nearly uncharged at pH 7.4) were alternatingly coated with negatively charged diphtheria 
toxoid (DT) and N-trimethyl chitosan (TMC), a cationic adjuvant. First, the optimal DT 
dose for intradermal immunization was determined in a dose-response study, which 
revealed that low-dose intradermal immunization was more efficient than subcutaneous 
immunization and that the EC50 dose of DT upon intradermal immunization is 3-fold 
lower, as compared to subcutaneous immunization. In a subsequent immunization study, 
microneedle arrays coated with an increasing number (2, 5, and 10) of DT/TMC bilayers 
resulted in step-wise increasing DT-specific immune responses. Dermal immunization 
with microneedle arrays coated with 10 bilayers of DT/TMC (corresponding with ±0.6 
μg DT delivered intradermally) resulted in similar DT-specific immune responses as 
subcutaneous immunization with 5 μg of DT adjuvanted with aluminum phosphate 
(8-fold dose reduction). Summarizing, the layer-by-layer coating approach onto pH-
sensitive microneedles is a versatile method to precisely control the amount of coated 
and dermally-delivered antigen that is highly suitable for dermal immunization.
GRAPHICAL ABSTRACT
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INTRODUCTION
Intradermal immunization has several benefits over conventional immunization 
by intramuscular bolus injection, as the skin is easily accessible and intradermal 
immunization is potentially pain-free. Moreover, superior immunization responses 
resulting from intradermal immunization as compared to conventional intramuscular 
immunization were reported for hepatitis B [1, 2], influenza [3-8] and polio [9-11]. This may be 
caused by the specialized dendritic cell subsets that are present in high numbers in the 
skin [12]. To deliver a sufficient amount of antigen to these cells, the physical barrier of 
the skin, the stratum corneum, must be overcome [13]. For this purpose microneedles 
can be used, which are needle-like structures used to pierce the stratum corneum in a 
minimally-invasive way. Several technologies for microneedle-mediated vaccine delivery 
are under development [14], such as coated microneedle arrays.
The amount of antigen delivery by coated microneedle arrays may be limited, because of 
the limited surface area available for coating. Therefore, different approaches have been 
developed to increase the amount of coated antigen. For example, dipping low-density 
microneedle arrays in an antigen-containing viscous solution leads to thick coatings 
containing a high amount of antigen (2 μg) [15, 16]. However, applying the dip-coating 
technique to high-density microneedle arrays results in blunting of the microneedles, 
which may impair the skin penetration ability of the microneedles [15, 17-19].
An alternative coating approach resulting in a thin coating is to modify the microneedle 
surface to control the antigen coating onto microneedle arrays and subsequent release 
into the skin by pH-dependent electrostatic interactions. In this approach, a negatively 
charged antigen adheres to a microneedle surface that is positively charged at a coating 
pH of 5.8. Upon piercing these antigen-coated pH-sensitive microneedles into skin, 
the electrostatic interactions between the antigen and the microneedles surface cease. 
This is caused by shifting the pH from a slightly acidic one (of the coating solution) 
towards a slightly alkaline one (physiological pH (7.4) of the skin). This pH-change induces 
a change in microneedle surface charge from positive to neutral, respectively [20]. Such 
pH-sensitive microneedle surface modifications allow to efficiently coat thin layers 
of antigens onto high-density microneedle arrays and for a controllable and effective 
antigen delivery.
However, the limitation of this manner of antigen-coating is that only low amounts of 
antigens can be coated onto microneedle arrays. This limitation can be overcome by 
using a layer-by-layer coating approach [21-23]. To effectively increase the amount of 
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antigen coated onto microneedle arrays, multiple layers of antigen and polymer are 
stacked onto one another, utilizing electrostatic interactions between antigen and 
polymer. Using this approach, high-density microneedle arrays were successfully coated 
with inactivated polio vaccine (IPV) particles and the adjuvant N-trimethyl chitosan 
(TMC) [24]. However, this approach was not yet examined for subunit vaccines such as 
diphtheria toxoid (DT), which is used in all pediatric vaccination programs worldwide.
In this study, a layer-by-layer coating approach of DT (a negatively charged antigen 
above a pH of 5) and the adjuvant TMC (a positively charged polymeric adjuvant) on 
high-density microneedle arrays modified with a pH-sensitive microneedle-surface was 
developed. It was demonstrated that the amount of DT coated onto the microneedle 
array was reproducible and the dermally-delivered amount of antigen was tuned by 
selecting the number of coated DT/TMC bilayers. Furthermore, the DT/TMC-coated 
microneedle arrays were capable of inducing potent and functional DT-specific immune 
responses upon dermal application in mice.
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MATERIALS
The materials are provided in Supplementary data S1.
METHODS
Preparation of fluorescently labeled DT, aluminum phosphate-adsorbed DT and 
(fluorescently labeled) TMC
To visualize DT and/or TMC adhesion to microneedle arrays and release into skin, DT 
and TMC were fluorescently labeled. DT was fluorescently labeled with Alexa Fluor® 488 
(DT-AF488) according to the manufacturer’s protocol. TMC with a 15% quaternization 
degree was synthesized as described elsewhere [25], and was fluorescently labeled with 
rhodamine B isothiocyanate (TMC-RHO) as previously reported [26]. To quantify the 
delivery of DT into skin, DT was fluorescently labeled with a near-infrared fluorescent 
label IRDye® 800CW (DT-IRDYE800) according to the manufacturer’s protocol. Aluminum 
phosphate-adsorbed DT (DT-ALUM) was prepared in a DT:alum ratio of 1:30 (w/w) and 
the adsorption was between 70 and 80% as determined by a DT-specific ELISA, as 
described elsewhere [27].
DT/TMC layer-by-layer coating approach for high-density microneedle arrays
To coat DT and TMC onto high-density microneedle arrays via a layer-by-layer coating 
approach, the following procedures were used. High-density silicon microneedle 
arrays with 576 microneedles on a 5x5 mm backplate (microneedle density of 2304 
microneedles/cm2) and a microneedle length of 220 μm were kindly provided by Robert 
Bosch GmbH (Stuttgart, Germany). In order to produce pH-sensitive microneedle 
surfaces with a surface pKa of 6.9, the surfaces of microneedle arrays were chemically 
modified with a pyridine functional group, as explained in detail elsewhere [20, 24]. 
Consequently, at a coating pH of 5.8, the microneedle surfaces are positively charged, 
while (unlabeled and fluorescently labeled) DT is negatively charged and (unlabeled 
and fluorescently labeled) TMC is positively charged. Subsequently, a layer-by-layer 
coating approach was used to coat multiple layers of negatively charged DT and 
positively charged TMC by electrostatic interactions onto the microneedle arrays, as 
schematically represented in Fig. 1. Optimization of the coating procedure is described 
in Supplementary data S2. Some studies required the microneedle arrays to be coated 
with fluorescently labeled DT and fluorescently labeled TMC. For these studies, plain 
DT was replaced by either fluorescently labeled DT-AF488 or DT-IRDYE800 and plain 
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TMC was replaced by fluorescently labeled TMC-RHO. The fluorescence of (unlabeled 
and fluorescently labeled) DT and fluorescently labeled TMC was measured on a 
Tecan Infinite M1000 plate reader (Männedorf, Switzerland) at excitation and emission 
wavelengths shown in Table 1.
Table 1 Excitation and emission wavelengths of DT and TMC used for fluorimetric assays (for 
details, see methods section).
Compound Fluorescence Excitation wavelength (nm) Emission wavelength (nm)
DT Intrinsic 280 320
DT-AF488 Extrinsic 490 525
DT-IRDYE800 Extrinsic 774 789
TMC-RHO Extrinsic 550 580
Fig. 1 Schematic illustration of the layer-by-layer coating approach of pH-sensitive microneedle 
surfaces.
To make use of the electrostatic interactions in the layer-by-layer coating approach, a 1 mM EDTA 
buffer at pH 5.8 was used as coating buffer, with DT or TMC in a concentration of 40 μg/mL. The 
first layer of DT was coated by applying a 50 μL droplet of the DT solution onto the pH-sensitive 
surface of the microneedle array for 30 min at room temperature. Then, the microneedle arrays 
were washed with 450 μL coating buffer. Subsequently, the microneedle arrays were dried under 
a flow of nitrogen gas. After drying, a layer of TMC was applied onto the DT-coated surface of the 
microneedle array, followed by washing and drying, as described above. Then a subsequent DT/
TMC bilayer was coated onto the surface of the microneedle arrays, as described above, until the 
preselected number of DT/TMC bilayers was coated onto the microneedle arrays. The amount of 
coated DT or TMC, was determined by measuring the fluorescence of DT or fluorescently labeled 
DT-AF488, DT-IRDYE800 or TMC-RHO in the non-adhered fraction in each of the wash samples.
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Scanning electron microscopy (SEM) and confocal laser scanning microscopy (CLSM) 
imaging of DT/TMC coated microneedle arrays
SEM imaging of DT/TMC coated microneedle arrays was performed to inspect the 
microneedle tip sharpness, geometry and surface morphology of the microneedles on a 
FEI NOVA nanoSEM 200 in high-voltage mode (10.0 kV). To this end, 4 microneedle arrays 
coated with 5 bilayers of DT/TMC and as control, 4 microneedle arrays with only a pH-
sensitive surface (plain microneedle arrays) were imaged.
To visualize the distribution of DT and TMC on the surface of DT/TMC coated microneedles, 
CLSM imaging of microneedle arrays coated with 5 bilayers of fluorescently labeled DT-
AF488/TMC-RHO was performed. CLSM was performed by utilizing a Nikon TE2000-E 
inverted microscope and a Nikon C1 confocal unit (Amsterdam, The Netherlands), in 
conjunction with a Nikon CFI Plan-Apochromat λ DM 20x (numerical aperture 0.75) 
objective. An argon laser (488 nm, laser intensity 75 and gain 106) and a 515/30 nm 
emission filter were used to visualize fluorescently labeled DT-AF488, while a diode-
pumped solid-state laser (561 nm, laser intensity 75 and gain 95) and a 590/50 nm 
emission filter were used to visualize fluorescently labeled TMC-RHO. Nikon NIS Elements 
software version 4.20.00 was utilized for scan acquisition and analysis. The xy resolution 
was 1.10 μm/pixel and xyz scans were taken in steps of 2 μm.
Antigenicity and structural integrity of coated DT
To assess whether coated DT remained antigenic, DT or fluorescently labeled DT-AF488 
released in vitro from 4 microneedle arrays coated with 5 bilayers of DT/TMC or DT-
AF488/TMC-RHO, was examined by DT-specific ELISA or fluorescence measurements, 
respectively. To assess the structural integrity of coated DT, the integrity of in vitro 
released DT-AF488 was determined by measuring the molecular weight by non-reducing 
SDS-PAGE. In vitro release was triggered by submerging DT/TMC coated microneedles 
in release buffer (5 mM EDTA with 0.9% (w/v) sodium chloride) at pH 7.4, which induces 
a change to a (nearly) neutral surface charge on the pH-sensitive microneedle surfaces, 
loss of electrostatic interactions of the DT/TMC bilayers with the microneedle surface 
and subsequently release of DT and TMC, as explained in detail elsewhere [20]. More 
detailed procedures for this experiment are provided in Supplementary data S3.
Delivery of DT/TMC into the skin by DT/TMC coated microneedle arrays
Visualization of fluorescently labeled DT-AF488/TMC-RHO delivery into human skin
Human skin was obtained from a local hospital and prepared as described in 
Supplementary data S4. To examine whether fluorescently labeled DT-AF488 and TMC-
RHO can be delivered into human skin by coated microneedle arrays, microneedle arrays 
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coated with 5 bilayers of fluorescently labeled DT-AF488/TMC-RHO were applied onto 
ex vivo human skin fixed on Styrofoam, by impact insertion using an in-house designed 
microneedle applicator. An average insertion speed of 0.5 m/s by the microneedle 
applicator was set on a uPRAX Microsolutions microneedle applicator controller (The 
Hague, The Netherlands). After insertion, the microneedle arrays were fixed onto 
the skin by applying a force of 5 N on top of the microneedle array. After 90 min, the 
microneedle arrays were withdrawn from the skin and immediately prepared for CLSM 
imaging by fixing the skin in a sample holder. The skin was imaged by CLSM using the 
same equipment as described above, except that a Nikon CFI Plan-Apochromat λ 4x 
(numerical aperture 0.2) objective was used. A laser intensity of 75 and gain 95 for 
the 488 nm laser were used to visualize fluorescently labeled DT-AF488, while a laser 
intensity of 75 and gain 86 for the 561 nm laser were used to visualize fluorescently 
labeled TMC-RHO. The xy resolution was 5.18 μm/pixel and xyz scans were taken in steps 
of 5 μm. The focal plane of the scans was parallel to the surface of the skin.
Quantification of dermally-delivered DT
To study the effect of the number of DT/TMC bilayers on the dermally-delivered DT 
dose, microneedle arrays coated with an increasing number of fluorescently labeled DT-
IRDYE800/TMC bilayers were applied onto ex vivo human or mouse skin. The delivered 
DT dose was quantified by using an intradermally injected calibration curve.
For this purpose, an in-house developed system consisting of a single hollow microneedle 
and a hollow microneedle applicator was used in conjunction with a uPRAX microneedle 
applicator controller and a syringe pump (NE-300, Prosense, Oosterhout, The 
Netherlands). This system allowed for intradermal microinjections at a pre-determined 
skin depth and an accurate volume [10]. The near-infrared fluorescence of the delivered 
DT-IRDYE800 was measured in a Perkin-Elmer IVIS Lumina Series III in vivo imaging system 
(Waltham, MA, USA), by using a 745 nm excitation wavelength and an ICG emission filter, 
acquisition time 4 s, F-stop 2, binning 4 and field of view of 12.5 cm. Perkin-Elmer Living 
Image software version 4.3.1.0 was used for image acquisition and analysis. Background 
measurements were taken from control regions of the skin.
Quantification of DT delivered into ex vivo human skin by DT/TMC coated microneedle 
arrays was performed as follows. Microneedle arrays coated with 5 bilayers of 
fluorescently labeled DT-IRDYE800/TMC were applied onto ex vivo human skin for a 
period of either 30 or 90 min. A calibration curve in ex vivo human skin was obtained by 
intradermal microinjections with an injection volume varying between 0.5 and 20 μL at a 
DT-IRDYE800 concentration of 150 μg/mL and at an injection depth of 150 μm.
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As all immunization studies were performed in mice, quantification of DT delivered by DT/
TMC coated microneedle arrays into ex vivo mouse skin was also examined. Microneedle 
arrays coated with either 1, 2, 5, 10 or 20 bilayers of fluorescently labeled DT-IRDYE800/
TMC were applied onto ex vivo mouse skin for a period of 90 min. A calibration curve in 
ex vivo mouse skin was obtained by intradermal microinjections with injection volumes 
varying between 0.1 and 10 μL at a DT-IRDYE800 concentration of 300 μg/mL and at an 
injection depth of 150 μm.
Immunization studies
Animal studies were performed in compliance with the guidelines and regulations 
enforced by Dutch laws and the Dutch animal ethic committee. These studies were 
approved by the “Dierexperimentencommissie Universiteit Leiden” under number 
14166. Female BALB/c (BALB/cAnNCrl, strain code 028, 6 weeks of age on arrival) were 
obtained from Charles River, Saint-Germain-sur-l’Arbresle, France. The mice were 
housed in groups of 4 in a controlled environment subjected to the guidelines of the 
animal facilities of the Leiden Academic Centre for Drug Research, Leiden University. 
The mice were randomly assigned to the immunization groups (8 animals per group) and 
were first acclimatized for 2 weeks after arrival before a study started.
Dose-response study of intradermally- and subcutaneously-delivered DT 
To determine the required amount of DT to be delivered by the DT/TMC coated 
microneedle arrays for sufficient DT-specific immune responses, a DT dose-response 
study was performed. DT-specific immune responses were determined after intradermal 
or subcutaneous immunization. DT doses ranging between 0.02 and 5 μg were examined. 
Detailed experimental descriptions are provided in Supplementary data S5.
Immunization study with DT/TMC coated microneedle arrays
The potential for a dermally applied DT/TMC coated microneedle array to induce DT-
specific immune responses was investigated and compared to immunization by an 
intradermal injection with a single hollow microneedle or a subcutaneous injection. All 
immunization groups are provided in Table 2. 
Immunization was performed at day 1 (prime immunization), day 22 (boost immunization) 
and day 43 (2nd boost immunization). One day prior to immunization by a DT/TMC 
coated microneedle array or a single hollow microneedle, the mice were shaved (an 
area of 4 cm2 on the left posterior flank). Serum was collected from each mouse one 
day prior to immunization. Venous blood (200 μL) was drawn by tail vein incision and was 
collected in a 0.8 mL MiniCollect® tube, which was stored on ice before centrifugation 
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at 3000g at room temperature for 10 min to isolate serum. At day 63, all mice were 
sacrificed and bled by incision of the hind leg main artery. This blood was collected 
in 2.5 mL Vacuette® tubes and stored on ice before centrifugation at 2000g at room 
temperature for 10 min to isolate serum. Sera were stored at -80 °C until analysis. All 
mice were immobilized for 90 min by anesthesia with 1% isoflurane (with 100% oxygen 
as carrier gas) prior to and during immunization. During anesthesia, the eyes of the mice 
were protected by oculentum simplex.
The following immunization procedures were included in the study:
1. Dermal immunization was performed by applying a microneedle array coated with 
2, 5 or 10 bilayers of DT/TMC to the skin. The selected number of coated DT/TMC 
bilayers was based on two factors: i) the DT-specific immune responses resulting 
from DT delivered into the skin by a single hollow microneedle as observed in the 
DT dose-response study and ii) the amount of fluorescently labeled DT-IRDYE800 
delivered by microneedle arrays coated with 2, 5 and 10 bilayers into ex vivo mouse 
skin. The DT/TMC coated microneedle arrays were applied onto shaved mouse 
skin at a speed of 0.5 m/s by the in-house designed impact insertion microneedle 
applicator in conjunction with a uPRAX microneedle applicator controller and were 
held in the skin with dermal tape and a specially designed clothespin for 90 min.
2. As control to the dermal immunization with a DT/TMC coated microneedle array, 
intradermal immunization by microinjection with a single hollow microneedle 
was performed with i) 0.31 μg DT and ii) 0.31 μg DT mixed with 0.31 μg TMC, using 
an injection volume of 10 μL at injection depth of 150 μm. The injected DT dose 
was based on the amount of fluorescently labeled DT-IRDYE800 delivered by a 
microneedle array coated with 5 bilayers into ex vivo mouse skin. The TMC dose was 
based on the nearly 1:1 coating ratio of DT and TMC. The intradermal microinjections 
were performed as described above.
3. As controls to the (intra-)dermal immunization, a group of mice received 
subcutaneous injections of 100 μL via a conventional 26G hypodermic needle of i) 
0.31 μg DT ii) 5 μg DT and 150 μg AlPO4 (DT-ALUM) as positive control or iii) phosphate 
buffered saline (PBS) pH 7.4 as mock treatment.
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Table 2 Immunization study with DT/TMC coated microneedle arrays.
The study parameters of the various immunization groups are summarized below. The following 
abbreviations are used. D: dermal, ID: intradermal, MN: microneedle, SC: subcutaneous.
Immunization route Application method Group name DT dose (µg)
D Coated MN array 2 bilayers DT/TMC 0.05*
5 bilayers DT/TMC 0.3*
10 bilayers DT/TMC 0.6*
ID Single hollow MN ID DT control 0.31
ID DT/TMC control 0.31 (+0.31  μg TMC)
SC Conventional 26G 
hypodermic needle
SC DT control 0.31
DT-ALUM** 5 (+ 150 μg AlPO4)
PBS pH 7.4*** 0
* As determined by the amount of DT delivered from microneedle arrays coated with fluorescently labeled DT-
IRDYE800/TMC into ex vivo mouse skin.
** DT adjuvanted with aluminum phosphate (as positive control).
*** PBS pH 7.4 mock treated group (as negative control).
Determination of DT-specific serum IgG titers and diphtheria toxin-neutralizing 
antibody titers
To measure DT-specific total IgG, IgG1 and IgG2a titers in serum, an ELISA was performed, 
of which a detailed description of the procedures is provided in Supplementary data S6. 
Determination of the antibody titer capable of neutralizing active diphtheria toxin (DTx) 
was performed as described elsewhere [27].
Statistical analysis
Graphs were plotted as mean (±SEM or ±95% confidence interval for the immunization 
studies) and statistics were performed by using GraphPad Prism (v.7.00, GraphPad 
Software, LaJolla, CA, USA). To statistically compare groups amongst each other, 
Kruskall-Wallis tests with Dunn’s post-hoc tests were performed because DT-specific 
IgG midpoint titers and DTx neutralizing antibody titers were non-normally distributed. 
Differences were considered significant at p < 0.05.
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RESULTS
DT/TMC layer-by-layer coating approach for high-density microneedle arrays
Variations in the coating procedure were examined in order to maximize the amount 
of coated DT for each individual bilayer (see Supplementary data S2 for details). The 
optimal DT and TMC coating concentrations were 40 μg/mL, which were used for 
further experiments.
To determine whether an increased number of coated DT/TMC layers resulted in an 
increased amount of coated DT and TMC, microneedle arrays were coated with up to 30 
bilayers of fluorescently labeled DT-AF488 and TMC-RHO. As shown in Fig. 2, 30 bilayers 
of DT-AF488/TMC-RHO were successfully coated onto the microneedle arrays and the 
amount of coated DT-AF488 and TMC-RHO increased linearly for up to 30 bilayers. 
The slopes in Fig. 2 represent the mean amount of coated DT-AF488 and TMC-RHO 
per bilayer, being 334.1 ng/bilayer (R2 = 0.9963) for DT-AF488 and 251.5 ng/bilayer (R2 
= 0.9983) for TMC-RHO. The coating was not linear in the first layers, as demonstrated 
by the intersect with the y-axis, which is -543.8 ng and -89.0 ng for DT-AF488 and 
TMC-RHO, respectively. After 30 bilayers of DT-AF488/TMC-RHO were coated, 9.67 
(±0.51) μg DT-AF488 and 7.58 (±0.38) μg TMC-RHO were cumulatively coated onto the 
microneedle arrays. Therefore, the ratio of coated DT to TMC was 1.3:1. Furthermore, a 
coating of 5 bilayers of fluorescently labeled DT-AF488/TMC-RHO resulted in a coated 
amount of 1.20 (±0.09) μg DT-AF488, while a coating of 5 bilayers of DT/TMC resulted 
in a coated amount of 2.08 (±0.14) μg DT. These results indicate that DT is coated more 
efficiently onto the microneedle arrays than fluorescently labeled DT-AF488.
SEM and CLSM imaging of DT/TMC coated microneedle arrays
SEM imaging was performed to determine whether the microneedle tip sharpness, 
geometry, and surface morphology of microneedles coated with 5 bilayers of DT/
TMC were maintained. As demonstrated in Fig. 3A and B, a similar geometry with a tip 
diameter of < 1 μm and surface morphology were obtained for both plain and coated 
microneedles. 
To visualize the distribution of DT and TMC over the surface of DT/TMC coated 
microneedles, CLSM imaging was performed on microneedles coated with 5 bilayers of 
fluorescently labeled DT-AF488/TMC-RHO. As demonstrated in Fig. 3C, DT-AF488 and 
TMC-RHO were indeed both coated onto the microneedles.
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Fig. 2 Coating 30 bilayers of fluorescently labeled DT-AF488 and TMC-RHO.
Cumulative amounts of coated fluorescently labeled DT-AF488 and TMC-RHO by applying 30 DT-
AF488/TMC-RHO bilayers onto microneedle arrays via a layer-by-layer coating approach. The 
mean cumulative amounts ± SEM of DT-AF488 (green dots) and TMC-RHO (red squares) coated 
onto the microneedle array are presented as a function of the number of coated DT-AF488/TMC-
RHO bilayers (n = 14).
Antigenicity and structural integrity of coated DT
To assess whether coated DT remained antigenic, DT or fluorescently labeled DT-AF488 
released in vitro from 4 microneedle arrays coated with 5 bilayers of DT/TMC or DT-AF488/
TMC-RHO, was examined by DT-specific ELISA or fluorescence measurements, respectively. 
The release of DT and DT-AF488 (amount released/amount coated*100%) from the coated 
microneedle arrays was similar at 28.5% (±0.5) and 29.0% (±2.0) (mean ± SEM), respectively, 
suggesting that the antigenicity of coated and released DT was preserved.
Non-reducing SDS-PAGE was performed to determine the structural integrity of the 
coated DT. Fluorescently labeled DT-AF488 released in vitro from microneedle arrays 
coated with 30 bilayers of DT-AF488 and TMC-RHO was analyzed together with control 
samples of DT-AF488 diluted from stock solution and a mixture of DT-AF488 and TMC-
RHO taken from stock solutions. The molecular weight of the coated and released DT-
AF488 was comparable to that of the DT-AF488 control samples. Moreover, no bands 
indicative of fragments or covalent aggregates were observed (data not shown).
Altogether, these results indicate that DT retained its structural integrity and antigenicity 
after it was released from the microneedle surfaces.
DT/TMC LAYER-BY-LAYER COATED MICRONEEDLES | 117
5
Fig. 3 SEM and CLSM imaging of DT/TMC coated microneedle arrays.
Representative SEM images of plain microneedles (A) and microneedles coated with 5 bilayers of 
DT/TMC (B) at 600x magnification, size bars represent 100 μm. Representative CLSM images of (C) 
microneedles coated with 5 bilayers of fluorescently labeled DT-AF488 and TMC-RHO (10x objective) 
and (D) DT-AF488 and TMC-RHO that are released into ex vivo human skin, after microneedles 
coated with 5 bilayers of fluorescently labeled DT-AF488 and TMC-RHO were applied and held in 
the skin for 90 min and subsequently removed before imaging (4x objective). The images are overlays 
of DT-AF488 fluorescence represented in green and TMC-RHO fluorescence represented in red.
Visualization of fluorescently labeled DT-AF488/TMC-RHO delivery into human skin
To examine whether fluorescently labeled DT-AF488 and TMC-RHO can be delivered 
into skin from coated microneedle arrays, microneedle arrays coated with 5 bilayers of 
DT-AF488/TMC-RHO were applied by impact-insertion and held in ex vivo human skin 
for 90 min. Immediately after withdrawal of the coated microneedles, CLSM imaging 
of the skin at the injection site was performed. From the image in Fig. 3D, showing 
fluorescence in the conduits in the skin from both DT-AF488 (green) and TMC-RHO 
(red), it is clear that DT-AF488 and TMC-RHO were successfully delivered into the skin 
after application and withdrawal of the DT-AF488/TMC-RHO coated microneedle array.
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Quantification of dermally-delivered DT
To quantitatively determine the amount of DT delivered by DT/TMC coated microneedle 
arrays into the skin, microneedle arrays coated with 5 bilayers of fluorescently labeled 
DT-IRDYE800/TMC were used. Initially, ex vivo human skin studies were conducted to 
determine the effect of the application period of DT/TMC coated microneedle arrays 
on the amount of dermally-delivered DT. After application periods of 30 and 90 min, 184 
(±16) ng and 293 (±46) ng DT were delivered, respectively. Because a 90 min application 
period was superior in comparison to a 30 min application period, a 90 min application 
period was used in subsequent studies.
As the immunization studies with DT/TMC coated microneedle arrays were carried 
out in mice, subsequent studies were performed on ex vivo mouse skin. To determine 
how the amount of dermally-delivered DT depends on the number of coated DT/TMC 
bilayers, the amount of dermally-delivered DT by microneedle arrays coated with either 
1, 2, 5, 10 or 20 bilayers of fluorescently labeled DT-IRDYE800/TMC was quantified. The 
amount of dermally-delivered DT-IRDYE800 was linearly dependent on the number of 
bilayers coated onto the microneedle arrays, as shown in Fig. 4. The slope coefficient 
for DT-IRDYE800 delivery into ex vivo mouse skin was 67.5 ng/layer with a R2 of 0.9967.
Fig. 4 Quantification of DT delivered into ex vivo mouse skin.
Quantification of the amount of fluorescently labeled DT-IRDYE800 (mean ± SEM, n 
= 3) dermally delivered into ex vivo mouse skin by microneedle arrays coated with an 
increasing number of bilayers of fluorescently labeled DT-IRDYE800/TMC.
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Dose-response study of intradermally- and subcutaneously-delivered DT
To determine the required amount of dermally-delivered DT for the induction of DT-
specific immune responses, a dose-response study was performed. DT was delivered 
intradermally by using a single hollow microneedle or subcutaneously by a conventional 
26G hypodermic needle. The DT-specific IgG responses after the 2nd booster 
immunization are presented in Fig. 5A (for responses after prime and 1st booster 
immunization and IgG1:IgG2a ratios see Supplementary data S5). As shown in Fig. 5A, 
after the 2nd booster immunization, the midpoint (EC50) of the intradermal curve (37 ng) 
was significantly lower (± 3-fold) than the subcutaneous curve (116 ng). This indicated that 
higher DT-specific IgG titers using lower DT doses are to be expected from intradermal 
immunization as compared to subcutaneous immunization. With regard to dose 
selection, although a DT dose of 0.02 μg already resulted in DT-specific IgG responses, 
a 0.3 μg dose resulted in similar responses as a 5 μg dose (16.6-fold lower). Moreover, 
as shown in Fig. 5B, a minimum DT dose of 0.3 μg was required for DTx neutralization 
titers, whilst a 0.78 μg dose resulted in similar DTx neutralization titers in comparison to 
a 5 μg dose (6.4-fold lower). Therefore, a minimum dose of 0.3 μg DT is required to be 
delivered by DT/TMC coated microneedle arrays to induce potent DT-specific IgG titers 
and DTx neutralization responses.
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Fig. 5 A dose-response study of DT delivered into the skin.
DT-specific immune responses as a result of intradermal (ID) and subcutaneous (SC) delivery of 
doses ranging from 0.02 to 5 μg after the 2nd boost immunization. The DT-specific IgG midpoint 
titers (A) and DTx neutralization titers (B) are represented by blue circles (ID) and purple squares 
(SC), respectively. The DT-specific IgG responses were used to plot a 4-parameter fit (solid line) 
and a 95% confidence interval of that fit (dotted line) in (A) (n = 8). The blue and purple lines 
represent the fit for intradermal and subcutaneous delivery, respectively. Black lines represent the 
mean ± 95% confidence interval and stars represent a significant decrease (p < 0.05) in (B) (n = 8).
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Immunization study with DT/TMC coated microneedle arrays
To study the potential to induce immunization of dermally-delivered DT by DT/TMC 
bilayer coated microneedle arrays, the DT-specific immune responses as a function of 
the number of DT/TMC bilayers (2, 5 and 10) coated onto the microneedle arrays was 
investigated in an immunization study. As 0.3 μg DT is required to induce DT-specific 
immune responses upon intradermal immunization (based on results of the dose-
response study), microneedle arrays should be coated with at least 5 DT/TMC bilayers 
(see delivery studies in ex vivo skin).
The DT-specific IgG titers increased with an increasing number of coated DT/TMC bilayers 
after every subsequent immunization (prime, boost and 2nd boost), as shown in Fig. 
6A-C. The higher response owing to immunization with an increased number of coated 
DT/TMC bilayers was also reflected in the DTx neutralization titers after the 2nd boost 
immunization, as shown in Fig. 6D. After every subsequent immunization, DT-specific IgG 
titers and DTx neutralization titers resulting from dermal immunization with microneedle 
arrays coated with 10 bilayers of DT/TMC (corresponding with approximately 0.6 μg 
delivered DT) and subcutaneous immunization with 5 μg DT-ALUM were not significantly 
different. The addition of TMC to the DT formulation for intradermal immunization 
with a single hollow microneedle did not result in increased DT-specific responses. 
As demonstrated in Fig. 6E, a stepwise decrease in IgG1:IgG2a ratio was observed 
for immunization by microneedle arrays coated with 2, 5 and 10 bilayers of DT/TMC. 
DT-specific responses resulting from subcutaneous immunization with or without 
anesthesia were similar (data not shown), demonstrating that anesthesia had no effect 
on the DT-specific immune responses. PBS pH 7.4 mock treatment did not result in any 
DT-specific IgG titers.
Upon comparing immunization routes, dermal immunization with microneedle arrays 
coated with 5 or 10 DT/TMC bilayers or intradermal immunization with a single hollow 
microneedle resulted in higher DT-specific IgG titers in comparison to subcutaneous 
immunization after the prime and boost immunization. The DT-specific IgG titers of 
dermal or intradermal and subcutaneous immunization were only comparable after the 
2nd boost immunization. These results indicate that dermal or intradermal immunization 
resulted in a faster development of IgG responses than subcutaneous immunization. A 
similar trend was observed for the DTx neutralization titers.
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Fig. 6 Immunization study with DT/TMC coated microneedle arrays.
Assessment whether DT/TMC coated microneedle arrays induce DT-specific immune responses, 
in which a microneedle array coated with an increasing number of DT/TMC bilayers is applied onto 
the skin and compared to intradermal and subcutaneous control groups (see Table 2). Presented 
are the DT-specific IgG midpoint titers 21 days past prime immunization (A), boost immunization (B) 
and 2nd boost immunization (C) resulting from DT immunization via the dermal route by a DT/TMC 
coated microneedle array (coated MN, green triangles or bars), intradermal route by a single hollow 
microneedle (ID, blue circles or bars) or subcutaneous route by a conventional 26G hypodermic needle 
(SC, purple squares or bars). DTx neutralization titers (D) and IgG1:IgG2a ratios (E) were determined in 
serum at 21 days past the 2nd boost immunization as well. Black lines and bars represent mean ± 95% 
confidence interval (n = 8) and stars represent a significant increase (p < 0.05).
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DISCUSSION
In this study, it was demonstrated that the DT/TMC layer-by-layer coating approach on 
pH-sensitive high-density microneedle arrays offers a tunable vaccine delivery system. 
The amount of DT that was coated and delivered into the skin was reproducible and 
could be tuned by selecting the number of coated DT/TMC bilayers. Moreover, dermal 
immunization of mice by using the DT/TMC coated microneedle arrays resulted in strong 
functional DT-specific immune responses.
DT/TMC layer-by-layer coating approach for high-density microneedle arrays
The amount of coated DT or TMC incremented linearly with each increasing bilayer of 
DT/TMC coated onto the microneedle arrays. This was also observed for coating IPV 
and TMC onto high-density microneedle arrays utilizing a similar layer-by-layer coating 
approach [24]. This demonstrates that a layer-by-layer coating procedure onto pH-
sensitive microneedles is a versatile method to precisely control the amount of coated 
antigen by selecting the number of coated bilayers. Furthermore, this coating procedure 
may be applicable, not only to proteins, but also to nanoparticles.
Moreover, the microneedle tips of microneedles coated with 5 bilayers of DT/TMC had 
a tip diameter < 5 μm, which is required for effortless skin penetration [28]. Coating high-
density microneedle arrays while preserving sharp microneedle tips is possible, by using 
this layer-by-layer coating approach or a nitrogen jet drying coating approach [17, 29], while 
dip-coating approaches resulted in blunt microneedle tips [15, 17-19]. Furthermore, viscosity 
enhancers, lyoprotectants or surfactants are not required for this layer-by-layer coating 
approach, which simplifies the formulation, while coating a high amount of antigen in a 
thin layer onto the microneedle arrays.
Delivery of DT/TMC into the skin by DT/TMC coated microneedle arrays
Using CLSM, we demonstrated that the DT and TMC delivered by DT/TMC coated 
microneedle arrays were co-localized in the conduits in the skin, but this method is not 
suitable to quantify the amount of DT within the skin. For this reason, we measured the 
near-infrared fluorescence intensity in the skin of DT-IRDYE800 delivered by the coated 
microneedle arrays.
Although precise dosing has been considered critical in dermal immunization [13, 14], it 
only has been convincingly addressed in a limited number of studies [30-32]. In the current 
study, we demonstrate that a linear increase in coated DT with an increasing numbers 
of DT/TMC bilayers also resulted in a linearly increased amount of DT delivered into 
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skin, allowing to select a precise dose that is reproducibly delivered into the skin. The 
delivery efficiency (amount released/amount coated onto the microneedle array*100%) 
of 16.7% in ex vivo mouse skin was comparable to that reported (between 7.6 and 37.5%) 
for other dry coating approaches for high-density microneedle arrays [29, 32-35].
Immunization studies
Coated microneedle arrays
Dermal immunization by microneedle arrays coated with 10 DT/TMC bilayers led to 
similar DT-specific immune responses compared with subcutaneous immunization 
by 5 μg DT-ALUM. The dose delivered in the skin by these coated microneedle arrays 
was determined at about 0.6 μg, i.e., about 8-fold lower than the subcutaneous dose. 
Moreover, coated microneedle arrays are easier to use for (intra-) dermal immunization 
compared to hollow microneedles, which require a sophisticated applicator [14]. 
Additionally, dry vaccine formulations generally are more stable than liquid ones [14, 15, 18, 
33]. Altogether, this demonstrates the potential of antigen-coated microneedle arrays as 
an alternative for subcutaneous immunization.
The accuracy at which the DT dose was delivered in the skin by selecting an increasing 
number of DT/TMC bilayers coated onto the microneedle arrays was reflected in the 
corresponding increasing levels of DT-specific immune responses. For example, dermal 
immunization with microneedle arrays coated with 5 bilayers of DT/TMC, corresponding 
with a DT dose of 0.3 μg delivered into the skin, resulted in similar DT-specific immune 
responses as intradermal immunization with 0.3 μg DT delivered by a single hollow 
microneedle.
Application mode of the DT/TMC coated microneedle arrays
A supposed drawback of coated microneedle arrays is the lengthy application period 
of 90 min in the skin to deliver a sufficient amount of antigen. For this reason, in a 
pilot study a short-lasting repetitive application mode was investigated to strongly 
reduce the required application time. By using the impact insertion applicator system, 
microneedle arrays coated with 5 bilayers of DT/TMC were repeatedly applied onto 
the skin for 10 applications at a frequency of 1 Hz (1 application per second, 10 s total, 
with an application time of 0.5 s per application). Intriguingly, 10 repeated applications 
in 10 s resulted in similar DT-specific immune responses as a single 90 min application 
(Supplementary data S7). Therefore, this application mode permits very short application 
times, which may increase the attractiveness of the use of coated microneedle arrays 
even more, from a patient compliance perspective.
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Influence of TMC
TMC was used as a poly-cation to enable layer-by-layer coating (as DT is negatively 
charged at coating pH) and because it has been reported to enhance DT-specific 
immune responses upon intradermal immunization [26]. However, in the current study 
only a mild increase in DT-specific immune responses (not significant) was observed, 
likely because much lower DT and TMC doses were used.
Intradermal versus subcutaneous immunization
It became evident in both immunization studies that (intra-)dermal immunization is 
more efficient at inducing DT-specific immune responses at low doses as compared 
to subcutaneous immunization. This high immunization efficiency at low antigen doses 
could lead to dose-sparing and thereby cost reduction of vaccination programs, which 
is especially of interest to low-income countries [36].
For both intradermal and subcutaneous immunization, humoral immune responses were 
dominant over cellular immune responses. This is represented by a high IgG1:IgG2a ratio, 
as humoral immune responses are characterized by the production of IgG1 antibodies, and 
cellular immune responses are characterized by the production of IgG2a antibodies [37, 38]. 
Surprisingly, in contrast to subcutaneous immunization (less dominant humoral immune 
responses at low antigen doses), upon intradermal immunization the humoral immune 
responses became predominant at low antigen doses in a dose-dependent manner.
CONCLUSION
In this study, we examined a layer-by-layer coating approach to coat high-density 
microneedle arrays with DT as anionic antigen and TMC as counter poly-cation and 
adjuvant. This coating approach allowed to control the amount of DT coated onto 
the microneedle arrays and delivered into the skin, whilst maintaining tip sharpness 
and integrity of the coated DT. After studying dose-response of DT immunization 
via the intradermal and subcutaneous route, it was demonstrated that intradermal 
immunization at low DT doses resulted in superior immune responses compared to 
subcutaneous immunization. Furthermore, we have demonstrated that immunization 
by DT/TMC coated microneedle arrays induced strong DT-specific immune responses. 
Summarizing, the layer-by-layer coating approach onto pH-sensitive microneedles is a 
versatile method to precisely control the amount of microneedle-coated and dermally-
delivered antigen, which is highly-suitable for dermal immunization.
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Ultrapure water (type 1, resistivity 18.2 MΩ•cm at 25 °C) was produced by an Elga Purelab Ultra 
and was used to prepare aqueous solutions. DT (12.25 mg/mL in Phosphate buffered saline 
(PBS) pH 7.4) was kindly provided by Intravacc (Bilthoven, The Netherlands). Alexa Fluor® 488 
protein labeling kit and 1-Step™ Ultra TMB-ELISA substrate solution were purchased from 
Thermo Fisher Scientific (Waltham, MA, USA). IRDye® 800CW protein labeling kit was obtained 
from Li-cor (Lincoln, NE, USA). Adju-Phos® (aluminum phosphate) was purchased from 
Brenntag (Ballerup, Denmark). Rhodamine B isothiocyanate, ethylenediaminetetraacetic 
acid (EDTA), sodium chloride, glycine, sodium carbonate, sodium bicarbonate, bovine serum 
albumin (BSA), glycerol, acetic acid ≥99.7% (v/v), methanol ≥99.9% (v/v), ethanol 96% (v/v), 
polysorbate 20 and sulfuric acid (95-98%) were ordered at Sigma-Aldrich (Zwijndrecht, 
The Netherlands). Nitrogen and oxygen gas were purchased from Linde Gas (Schiedam, 
The Netherlands). Tris(hydroxymethyl)aminomethane-hydrochloride (TRIS-HCL), sodium 
dodecyl sulfate (SDS), 7.5% polyacrylamide (pre-cast) gels, reference molecular weight 
ladders and fixative enhancer were ordered at Bio-Rad (Hercules, CA, USA). Parafilm M® 
was obtained from Bemis (Monceau-sur-Sambre, Belgium). Styrofoam (5 cm thick) was 
purchased from a local hardware store. Polystyrene 48-well and 96-well microtiter plates, 
0.8 and 2.5 mL Vacuette® Z serum separator clot activator premium tubes were ordered at 
Greiner Bio-One (Alphen aan den Rijn, The Netherlands). PBS pH 7.4 (163.9 mM Na+, 140.3 
mM Cl-, 8.7 mM HPO4
2- and 1.8 mM H2PO4
-, pH 7.4) was purchased from B. Braun Melsungen, 
Melsungen, Germany. PBS pH 7.2 (160.6 mM Na+, 155.2 mM Cl-, 2.7 mM HPO4
2-, 1.5 mM 
H2PO4
- and 1.5 mM K+, pH 7.2) was ordered at Gibco (Thermo Fisher Scientific (Waltham, MA, 
USA)). Rompun® (20 mg/mL xylazine, Bayer B.V., Mijdrecht, The Netherlands), Nimatek® 
(100 mg/mL ketamine, Eurovet Animal Health B.V., Bladel, The Netherlands) and oculentum 
simplex were obtained from a local pharmacy. IsoFlo® (isoflurane 100% w/w) was ordered 
at Abbott Laboratories, Maidenhead, UK. Horseradish peroxidase-conjugated goat-anti-rat 
IgG, IgG1 and IgG2a were obtained from Southern Biotech, Birmingham, AL, USA.
S2 OPTIMIZATION OF THE DT/TMC LAYER-BY-LAYER COATING 
APPROACH FOR HIGH-DENSITY MICRONEEDLE ARRAYS
METHODS
Variations in the coating procedure were examined in order to maximize the amount of 
coated DT for each individual bilayer. Firstly, the influence of the DT concentration in the 
coating formulation on the cumulative amount of coated DT over 5 bilayers of DT/TMC 
was determined. The DT concentration was varied from 10 to 40 μg/mL in the coating 
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buffer (1 mM EDTA buffer at pH 5.8), while the TMC concentration was kept constant 
at 10 μg/mL in the coating buffer. Secondly, the influence of TMC on the cumulative 
amount of coated DT over 5 bilayers of DT/TMC was examined. The TMC concentration 
was varied from 10 to 40 μg/mL in the coating buffer, while the DT concentration was 
kept constant at 40 μg/mL in the coating buffer.
RESULTS
As shown in Supplementary Fig. S2A, the cumulative amount of DT coated over 5 bilayers 
of DT/TMC was highest, when a DT concentration of 40 μg/mL was used. As shown in 
Supplementary Fig. S2B, the cumulative amount of DT coated over 5 bilayers of DT/TMC 
was highest when a TMC concentration of 40 μg/mL was used.
Supplementary Fig. S2 Optimization of the DT/TMC layer-by-layer coating approach.
Effects of variations in the DT/TMC layer-by-layer coating approach on the cumulative amount of coated 
antigen. The mean cumulative amount ± SEM of coated DT after each incrementally coated DT/TMC bilayer 
is presented in (A) for different DT coating concentrations and a constant TMC coating concentration and 
in (B) for different TMC coating concentrations and a constant DT coating concentration (n = 8).
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S3 ANTIGENICITY AND STRUCTURAL INTEGRITY OF COATED DT
METHODS
To assess whether coated DT remained antigenic, DT or fluorescently labeled DT-AF488 
released in vitro from 4 microneedle arrays coated with 5 bilayers of DT/TMC or DT-
AF488/TMC-RHO, was examined by DT-specific ELISA or fluorescence measurements, 
respectively. To initiate the DT release in vitro, each DT/TMC or DT-AF488/TMC-RHO 
coated microneedle array was placed in a well of a 48-well plate and 500 μL of release 
buffer (5 mM EDTA at pH 7.4 with 0.9% (w/v) sodium chloride) was added, followed by 
a 30 min incubation period at room temperature. The release of DT/TMC in vitro was 
triggered by changing the pH-sensitive microneedle surfaces from cationic to neutral 
by a pH-shift from slightly acidic towards physiological pH (7.4), as explained in detail 
elsewhere [S3-1]. Subsequently, DT or fluorescently labeled DT-AF488 was quantified in 
the supernatant: DT by a DT-specific sandwich ELISA (performed as described elsewhere 
[S3-2]) and fluorescently labeled DT-AF488 by fluorescence.
To assess the structural integrity of coated DT, 4 microneedle arrays were coated with 30 
bilayers of fluorescently labeled DT-AF488/TMC-RHO. After in vitro release of the coated 
DT-AF488 as described above, the integrity of DT-AF488 was determined by measuring 
the molecular weight of released DT-AF488 by non-reducing SDS-PAGE as follows. The 
in vitro released fluorescently labeled DT-AF488, reference DT-AF488, fluorescently 
labeled TMC-RHO and a mixture of DT-AF488 and TMC-RHO (weight ratio 1:1), were mixed 
1:1 with sample buffer (60 mM TRIS-HCL pH 6.8, 25% (v/v) glycerol and 2% (w/v) SDS), 
of which 50 μL was loaded onto a 7.5% polyacrylamide gel. Reference molecular weight 
ladders were added as well, after which samples were electrophoretically separated at 
80 Volts for 10 min followed by 120 Volts for 45 min in running buffer (25 mM TRIS-
HCL pH 8.3, 192 mM glycine, 0.1% (w/v) SDS). Subsequently, gels were fixated in fixation 
buffer (50% (v/v) methanol, 10% (v/v) acetic acid and 10% (v/v) fixative enhancer) in 
the dark on an orbital shaker for 20 min before analysis by fluorescence detection by a 
Bio-Rad ChemiDoc MP gel imaging system (Hercules, CA, USA). Fluorescently labeled DT-
AF488 and TMC-RHO and the molecular weight ladder were detected by fluorescence 
by using settings to detect AF488, rhodamine and Cy5, respectively. Bio-Rad Image Lab™ 
software version 4.1 was used for image acquisition and analysis.
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S4 PREPARATION OF EX VIVO SKIN
To examine the DT/TMC delivery into skin, ex vivo human and ex vivo mouse skin were 
used. Abdominal ex vivo human skin was obtained from local hospitals after cosmetic 
surgery. The subcutaneous fat was removed and the skin was cleaned as described 
below. Cleaning was performed by using PBS pH 7.4, 70% (v/v) ethanol and PBS pH 7.4 
again. The skin was then dermatomed to 600 μm thickness by using a Padgett Electro 
Dermatome Model B dermatome (Kansas City, MO, USA) and it was frozen at -80 °C in 
a Petri dish containing a wetted tissue, to prevent excess drying during thawing. Ex vivo 
mouse skin was isolated from BALB/c mice, immediately after being sacrificed, and was 
frozen at -80 °C in a Petri dish containing a wetted tissue. Prior to use, ex vivo human or 
mouse skin was thawed at 37 °C, the mouse skin was shaved and the skin was cleaned. 
Subsequently, the skin was slightly pre-stretched by pinning the skin on a flat piece of 
Parafilm-covered Styrofoam.
S5 DOSE-RESPONSE STUDY OF INTRADERMALLY- AND 
SUBCUTANEOUSLY-DELIVERED DT
METHODS
DT-specific immune responses resulting from intradermal DT immunization were 
compared to those resulting from subcutaneous DT immunization. For the intradermal 
immunization, a single hollow microneedle was used in combination with the single 
hollow microneedle applicator system, to perform intradermal microinjections at a 
pre-defined skin injection volume and -depth of 10 μL and 150 μm, respectively [S5]. 
Subcutaneous immunization groups received an injection of 100 μL with a conventional 
26G hypodermic needle in the skin-fold of the neck. For both immunization routes, mice 
were immunized with a DT dose of 5, 1.25, 0.78, 0.31, 0.08 or 0.02 μg. As positive control, 
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one group received subcutaneous injections of 5 μg DT and 150 μg AlPO4 (DT-ALUM). 
A mock treated group received subcutaneous injections of PBS pH 7.4. Immunization 
was performed at day 1 (prime immunization), day 22 (boost immunization) and day 43 
(2nd boost immunization). Mice that were assigned to intradermal immunization, were 
shaved (an area of 4 cm2 on the left posterior flank) one day prior to immunization, 
at day 0, 21 and 42, and were immobilized during immunization by anesthesia with a 
mixture of ketamine (150 mg/kg) and xylazine (10 mg/kg). During anesthesia, the eyes 
of the mice were covered by oculentum simplex for protection of the eyes. Serum was 
collected from all mice one day prior to immunization. Venous blood (200 μL) was drawn 
by tail vein incision and was collected in a 0.8 mL MiniCollect® tube, which was stored 
on ice before centrifugation at 3000g at room temperature for 10 min to isolate serum, 
which was stored at -80 °C until analysis. At day 63, all mice were sacrificed and bled by 
incision of the hind leg main artery. This blood was collected in 2.5 mL Vacuette® tubes 
and stored on ice before centrifugation at 2000g at room temperature for 10 min to 
isolate serum, which was stored at -80 °C until analysis. Dose-response titration curves 
were calculated by a 4-parameter fit on the log10 values of the DT dose (in ng) versus the 
DT-specific total IgG midpoint titers.
RESULTS
After the prime immunization at day 21, DT-specific IgG titers resulting from intradermal 
and subcutaneous delivery were equal at low doses, as shown in Supplementary Fig. S5A. 
Although DT-specific IgG titers resulting from subcutaneous delivery at the highest dose 
of 5 μg appeared higher compared to intradermal delivery, this was not significant (p = 
0.16). The bottom, top, hillslope and the midpoint (EC50) of the dose-response curves 
resulting from intradermal or subcutaneous delivery were similar.
Three weeks after the first boost immunization, DT-specific IgG titers resulting from 
intradermal delivery were increased in comparison to subcutaneous delivery when lower 
DT doses were injected, as shown in Supplementary Fig. S5B. The bottom and hillslope 
of the dose-response curves resulting from intradermal or subcutaneous delivery were 
similar. However, the midpoint (EC50) of the intradermal curve (89 ng) was significantly 
lower than the subcutaneous curve (194 ng). This indicated that higher DT-specific 
IgG titers using lower doses are to be expected from intradermal delivery compared 
to subcutaneous delivery. Contrarily, the top of the subcutaneous curve (4.655) was 
significantly increased compared to the intradermal curve (4.177). This indicated that 
higher DT-specific IgG titers are to be expected from subcutaneous delivery compared 
to intradermal delivery, when a high DT dose is injected. However, direct comparisons 
of equal doses injected intradermally or subcutaneously did not result in statistically 
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significant differences.
Three weeks after the second booster immunization, DT-specific IgG titers resulting 
from intradermal delivery were again increased compared to subcutaneous delivery 
when lower DT doses were injected, as shown in Supplementary Fig. S5C (which is a 
copy of Fig. 5A). However, at this time point, intradermal and subcutaneous delivery 
resulted in similar DT-specific IgG titers when higher DT doses were injected. In detail, 
the bottom, top and hillslope of the dose-response curves resulting from intradermal 
or subcutaneous delivery were similar. However, the midpoint (EC50) of the intradermal 
curve (37 ng) was again significantly lower (± 3-fold) than the subcutaneous curve (116 ng). 
This indicated that higher DT-specific IgG titers using lower doses are to be expected 
from intradermal delivery as compared to subcutaneous delivery.
As shown in Supplementary Fig. S5D, the IgG1:IgG2a ratio was determined at day 63 and 
similar ratios for all tested doses were observed, with the exception of the 0.02 μg DT 
dose injected subcutaneously. A trend towards a higher IgG1:IgG2a ratio was observed 
for intradermal immunization with lower DT doses. PBS pH 7.4 mock treatment did not 
result in any DT-specific IgG titers.
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Supplementary Fig. S5 Dose-response study of intradermally- and subcutaneously-delivered 
DT.
Dose-response study, in which DT-specific immunization responses were investigated as a result 
of intradermal (ID) and subcutaneous (SC) delivery at doses ranging from 0.02 to 5 μg. The DT-
specific IgG midpoint titers 21 days past prime immunization (A), boost immunization (B) and 2nd 
boost immunization (C) as a result of intradermal or subcutaneous delivery of different DT doses 
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are represented by blue circles and purple squares, respectively, which represent the mean ± 95% 
confidence interval (n = 8). These DT-specific IgG responses were used to plot a 4-parameter 
fit (solid line) and a 95% confidence interval of that fit (dotted line). The blue and purple lines 
represent the fit for intradermal and subcutaneous delivery, respectively. 
IgG1:IgG2a ratios (D) were determined in serum at 21 days past the 2nd boost immunization 
as function of delivery route and DT dose as well. Blue and purple bars represent mean ± 95% 
confidence interval (n = 8) for intradermal and subcutaneous delivery, respectively, and stars 
represent a significant increase (p < 0.05).
S6 DETERMINATION OF DT-SPECIFIC SERUM IgG TITERS BY ELISA
METHODS
To measure DT-specific total IgG, IgG1 and IgG2a titers in serum, an indirect ELISA was 
performed. To coat the wells of a polystyrene 96-well microtiter plate, 100 μL of 1.4 μg/
mL DT in 0.05 M bicarbonate buffer pH 9.6 was added per well and incubated overnight 
at 4 °C. Next, a washing step was performed utilizing a Tecan 96PW plate washer and wash 
buffer (PBS pH 7.2 and 0.05% (v/v) polysorbate 20). A blocking step was then performed 
by adding 150 μL/well of 1% (w/v) BSA dissolved in PBS pH 7.2 and incubation for 1 hour 
at 37 °C. Afterwards, a washing step was performed and threefold serial dilutions of 
serum samples were made in assay buffer (PBS pH 7.2, 0.5% (w/v) BSA and 0.05% (v/v) 
polysorbate 20) in the 96-well plate at 100 μL/well. Afterwards, plates were incubated 
at 37 °C for 2 h, followed by a washing step. Subsequently, 100 μL/well of horseradish 
peroxidase-conjugated goat-anti-mouse IgG, IgG1 or IgG2a was added to the wells in 
a 5000-fold dilution in assay buffer. Afterwards, plates were incubated at 37 °C for 1.5 
hour, followed by a double washing step. Next, 100 μL/well of TMB substrate solution 
was added and incubated for 10 min at room temperature. The reaction was stopped 
by adding 100 μL/well of 2 M sulfuric acid. Finally, sample absorbance was measured at 
450 nm on a Tecan Infinite M1000 plate reader. Midpoint titers were determined as the 
logIC50 of the 4-parameter fit on the log10 values of the dilution factor versus the 450 
nm absorbance.
S7 COMPARISON BETWEEN A SINGLE INSERTION AND REPEATED 
INSERTIONS OF DT/TMC COATED MICRONEEDLE ARRAYS ON 
DT-SPECIFIC IMMUNE RESPONSES
Microneedle arrays coated with 5 bilayers of DT/TMC were applied onto shaved mouse 
skin by impact insertion at a speed of 0.5 m/s by the in-house designed impact insertion 
microneedle applicator, which was controlled by a uPRAX microneedle applicator 
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controller. To investigate the possibility to reduce the application time, microneedle 
arrays coated with 5 bilayers of DT/TMC were applied by (see Fig. S7):
i. A single application of 90 min
ii. 10 applications at a frequency of 1 Hz (1 application per second, 10 s total, with an 
application time of 0.5 s per application)
Supplementary Fig. S7 Comparison between a single insertion and repeated insertions of DT/
TMC coated microneedle arrays on DT-specific immune responses.
Comparison of DT/TMC coated microneedle arrays to induce DT-specific responses, in which 
microneedle arrays coated with 5 bilayers of DT/TMC were pierced into the skin and kept for 90 
min onto the skin (single insertion) or were repeatedly inserted in the skin for 10 applications at a 
frequency of 1 Hz (1 application per second, 10 s total, with an application time of 0.5 s per application). 
Presented are the DT-specific IgG midpoint titers (A) 21 days past prime immunization (light gray bars), 
past 1st boost immunization (gray bars) and past 2nd boost (black bars). DTx neutralization titers were 
determined in serum at 21 days past the 2nd boost immunization as well (B). Bars represent mean ± 
95% confidence interval (n = 8).
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Chemical modifications of gold surfaces  
with basic groups and a fluorescent nanoparticle 
adhesion assay to determine their surface pKa
ABSTRACT
PURPOSE
For pharmaceutical, biological and biomedical applications the functionalization of 
gold surfaces with pH-sensitive groups has great potential. The aim of this work was to 
modify gold surfaces with pH-sensitive groups and to determine the pKa of the modified 
gold surfaces using a fluorescent nanoparticle adhesion assay. 
METHODS
To introduce pH-sensitive groups onto gold surfaces, we modified gold-coated silicon 
slides with four different bases: 4-mercaptopyridine (4-MP), 4-pyridylethylmercaptan 
(4-PEM), 4-aminothiophenol (4-ATP), and 2-mercaptoethylamine (2-MEA). To screen 
whether the modifications were successful, the binding of negatively charged 
fluorescently labeled nanoparticles to the positively charged surfaces was visualized 
by fluorescence microscopy. Next, the pKa of the modified surfaces was determined by 
quantifying the pH-dependent adhesion of the fluorescently labeled nanoparticles with 
fluorescence spectroscopy. 
RESULTS
Fluorescence microscopy showed that the gold surfaces were successfully modified with 
the four different basic molecules. Moreover, fluorescence spectroscopy revealed that 
fluorescently labeled negatively charged nanoparticles bound onto gold surfaces that 
were modified with one of the four bases in a pH-dependent manner. By quantifying 
the adsorption of negatively charged fluorescently labeled nanoparticles onto the 
functionalized gold surfaces and using the Henderson-Hasselbalch equation, the pKa of 
these surfaces was determined to be 3.7±0.1 (4-MP), 5.0±0.1 (4-PEM), 5.4±0.1 (4-ATP), 
and 7.4±0.3 (2-MEA).
CONCLUSION
We successfully functionalized gold surfaces with four different basic molecules, 
yielding modified surfaces with different pKa values as determined with a fluorescent 
nanoparticle adhesion assay. 
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INTRODUCTION
Gold microstructures and nanoparticles are often researched for pharmaceutical, 
biological and biomedical applications, because of their biocompatible nature [1]. 
Microneedles, for example, which are needle-like structures with micrometer dimensions 
that are used for minimally-invasive and pain free dermal drug delivery or sampling of 
biological fluids [2] that are made of silicon have been coated with a layer of gold [3-
5]. Such gold-coated silicon microneedles have been functionalized in order to detect 
vancomycin [3]. Furthermore, gold nanoparticles are used for the delivery of genes [6] and 
anticancer drugs [7, 8]. To further extend the applicability of gold microstructures and 
nanoparticles for pharmaceutical purposes, their surfaces can be functionalized with 
pH-sensitive groups. This will enable the immobilization/desorption of DNA, proteins, 
antigens and nanoparticles via electrostatic interactions onto/from gold microstructures 
and nanoparticles as a function of the pH. Importantly, the success of pH-dependent 
drug delivery will depend on the pKa of functionalized gold surfaces, which in turn 
depends on the choice of the functional group and has to be experimentally confirmed.
Fluorescent nanoparticles can be used to investigate the surface properties of 
chemically-modified surfaces. Recently, we developed a fluorescent nanoparticle 
adhesion assay (FNAA) to determine the pKa of silicon surfaces that are modified with 
acidic and basic molecules [9]. This method is based upon pH-dependent adsorption 
of cationic or anionic fluorescent nanoparticles onto surfaces with an opposite charge 
via electrostatic interactions. So far, the FNAA has been used to determine the pKa 
of silicon surfaces modified with amine groups (APTES) [9], carboxylic groups [9], and 
pyridine groups [10, 11]. Besides, this method was used to analyze more complex surfaces 
(i.e., determination and design of the isoelectric point of chemically-modified silicon 
surfaces) [11]. Furthermore, since most methods are not suitable to detect more than 
one pKa value
 [12], the FNAA could be an attractive method to analyze surfaces that have 
more than one pKa value
 [9]. So far, the FNAA has not been used to determine the pKa of 
surfaces other than silicon.
In this work we modify gold-coated silicon surfaces with a panel of basic molecules. 
Such modified surfaces are potentially suitable for pharmaceutical applications. Besides, 
we used negatively charged fluorescently labeled nanoparticles and fluorescence 
microscopy to study the success of the modifications. Moreover, we show that by 
determining the pH-dependent fluorescent nanoparticle adhesion onto gold-coated 
silicon slides, the pKa of gold surfaces modified with a variety of basic molecules can be 
determined. 
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MATERIALS
Acetone (puriss.), methanol (HPLC grade), hydrogen peroxide (30% w/w, puriss. 
p.a.), hydrochloric acid (HCl, 37%, ACS reagent grade), 4-mercaptopyridine (4-MP), 
4-pyridylethylmercaptan (4-PEM), 4-aminothiophenol (4-ATP), 2-mercaptoethylamine 
(2-MEA), ethylenediaminetetraacetic acid (EDTA, ACS reagent grade), and 100-nm 
fluorescent orange sulfate-modified polystyrene latex beads were purchased from 
Sigma-Aldrich, Zwijndrecht, the Netherlands. Absolute ethanol (dehydrated, HPLC 
grade) was purchased from Biosolve, Valkenswaard, the Netherlands. Concentrated 
sulfuric acid (95-98%, ACS reagent grade) and sodium hydroxide (NaOH, ACS reagent 
grade) were ordered from Boom, Meppel, the Netherlands. Ultrapure deionized Milli-Q 
(MQ) water with a resistivity of 18 MΩ•cm at 25 °C was produced by an ELGA Purelab 
Ultra water purification system. BrandTech Scientific 1.5 mL cuvettes were purchased 
at VWR, Ede, the Netherlands. Parafilm M® was obtained from Bemis (Monceau-sur-
Sambre, Belgium). Black flat-bottom polystyrene 96-wells plates were obtained from 
Greiner Bio-One, Alphen a/d Rijn, the Netherlands.
METHODS
Preparation of silicon slides and gold-coated silicon slides
Silicon wafers with <100> orientation and a thickness of 500 μm, one side of which was 
coated with a 1000 Å gold layer (Sigma-Aldrich), were diced into slides of 1x1 cm by 
using a General Signal Micro Automation Model 602M dicing saw in conjunction with 
Disco ZH05 series dicing saws, (further referred to as gold-coated silicon slides, having 
a gold-coated surface area of 1 cm2 on one side and a non-coated (plain) silicon surface 
area of 1 cm2 on the other side). To study non-specific nanoparticle binding onto the 
(non-coated) silicon side of the gold-coated silicon slides, plain 2-side polished silicon 
wafers with <100> orientation and a thickness of 300 μm, which were cut into slides of 
1x1 cm (further referred to as silicon control slides, having a total silicon surface area of 
2 cm2, obtained from Tyndall National Institute, Cork, Ireland), were used as a control.
Surface modification
To obtain chemically-modified gold surfaces with pH-sensitive groups, gold-coated 
silicon slides were modified with four different gold-reactive molecules from which it was 
expected that they result in different surface pKa values, as schematically represented 
in Fig. 1. To simultaneously modify up to 45 silicon slides, polychlorotrifluoroethylene 
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coating containers were developed by the fine mechanical department of Leiden 
University. Prior to the introduction of pH-sensitive surface groups, the slides were 
cleaned with acetone and methanol, and were subsequently dried in a vacuum oven at 
50 °C for 30 min. To remove residual organic contaminants, the slides were incubated 
in a piranha solution (7:3 (v/v) mixture of sulfuric acid and hydrogen peroxide) for 60 
min at 120 °C. Caution: piranha solution is an extremely corrosive mixture that should 
be treated with utmost carefulness. After removal of the piranha solution, the slides 
were washed with MQ water until the pH was above 5. Next, the slides were sequentially 
washed with methanol and dried.
To obtain pH-sensitive groups onto the gold-coated silicon slides, the slides were 
incubated overnight in a 10 mM solution of a gold-specific reactant (4-MP, 4-PEM, 
4-ATP, or 2-MEA) in absolute ethanol at room temperature whilst gently rocking. Finally, 
non-reacted chemicals were removed by extensively washing the slides sequentially 
with absolute ethanol and methanol, after which the slides were dried. Slides were 
stored under vacuum until use. Silicon control slides, which were used to correct for 
non-specific binding onto the silicon side of the gold-coated slides, were treated with 
the same procedure as gold-coated silicon slides.
Colloidal stability of nanoparticles as function of pH
The pH-dependent colloidal stability of the 100-nm fluorescently labeled sulfate-
modified negatively charged nanoparticles was assessed to investigate whether these 
nanoparticles are suitable to be used to determine the surface pKa of the gold-coated 
silicon slides in the selected pH-range (2 to 10). To this end, the pH-dependent 
hydrodynamic diameter and polydispersity index (PDI) of these nanoparticles were 
determined by using dynamic light scattering and the ζ-potential by using Laser Doppler 
electrophoresis on a Zetasizer Nano (Malvern Instruments).
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Fig. 1 Introduction of pH-sensitive groups onto gold-coated silicon surfaces. Abbreviations: 2-MEA 
(2-mercaptoethylamine); 4-MP (4-mercaptopyridine); 4-PEM (4-pyridylethylmercaptan); 4-ATP 
(4-aminothiophenol).
Fluorescence microscopy for qualitative assessment of surface modification
To qualitatively assess the success of the modification of the gold-coated silicon slides, 
the adhesion of negatively charged fluorescently labeled nanoparticles at three pH 
values was imaged by using fluorescence microscopy. To this end, chemically-modified 
gold-coated silicon slides were incubated with 1 μL/mL nanoparticle dispersions in 1 mM 
EDTA buffers with pH values of 2.0, 2.5 and 7.5. After 2 h the slides were washed with a 
1 mM EDTA buffer having the same pH as the nanoparticle dispersion, and dried by using 
a gentle air stream. The slides were imaged by using a Nikon Eclipse E600 with a GFP 
filter set in conjunction with a Photometrics Coolsnap-pro CF monochrome camera and 
Media Cybernetics imaging software. 
Fluorescent nanoparticle adhesion assay
To investigate the applicability of the FNAA to determine the pKa of functionalized 
gold surfaces, the surface pKa of the chemically-modified gold-coated silicon slides 
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was determined by using the general principles of the FNAA [9]. This assay is based on 
electrostatic interactions between electrochemically-charged surfaces and oppositely 
charged nanoparticles as a function of the pH. Because only one side of the gold-
coated silicon slides was modified with pH-sensitive groups, the FNAA was adapted to 
determine the surface pKa of the chemically-modified gold-coated side (i.e., for each 
pH determination nanoparticle adhesion was determined for gold-coated silicon slides 
and silicon control slides).
For each titration, 1 μL/mL nanoparticle dispersions in 1 mM EDTA with pH values from 
10.5 to 2 (in steps of approximately 0.5 pH values per dispersion) were prepared by 
using 0.1 or 0.01 M HCl to adjust the pH. At each pH value 750 μL of the nanoparticle 
dispersion was transferred to a 1.5 mL cuvette in triplicate. Next, to each of these 
cuvettes 1) a gold-coated silicon slide, 2) a silicon control slide, or 3) no silicon slide 
(control) was added, which were subsequently sealed with Parafilm® and covered in 
aluminum foil to protect the fluorescent nanoparticles from light. For each chemically-
modified gold-coated silicon slide a titration was performed at least twice. After 4 h of 
shaking at 500 rpm (IKA VXR Basic Vibrax orbital shaker), from each sample two aliquots 
of 200 μL were transferred to a flat-bottom black 96-wells plate. The fluorescence was 
measured on a Tecan Infinite® M1000 plate reader at an excitation wavelength of 520 nm 
and an emission wavelength of 540 nm. 
Surface-specific nanoparticle binding
To determine the surface-specific binding of nanoparticles onto chemically-modified 
gold surfaces, first the pH-dependent binding percentage of nanoparticles per cm2 
onto the silicon control slides (BSi) was calculated according to equation 1:
BSi = (1 – [FluoSi / Fluocontr] ) / 2 * 100%    (Eqn. 1)
Where FluoSi is the fluorescence of the nanoparticle dispersion that was incubated with 
a silicon control slide; and Fluocontr is the fluorescence of the nanoparticle dispersion 
that was not incubated with a silicon slide, which served as a control for non-specific 
adhesion of nanoparticles to the cuvette.
Next, the total binding of nanoparticles onto the gold-coated silicon slides (BAu) as a 
function of the pH was calculated according to equation 2:
BAu = (1 – [FluoAu / Fluocontr] ) * 100%    (Eqn. 2)
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Where FluoAu is the fluorescence of the nanoparticle dispersion that was incubated 
with a gold-coated silicon slide. Binding data was smoothed by averaging the binding 
percentage at five successive pH values.
Because the gold-coated silicon slides expose 1 cm2 silicon surface (non-coated side), 
the percentage of specific binding of nanoparticles onto the chemically-modified gold 
side (BAu-specific) was calculated by subtracting the percentage of the nanoparticles that 
bound onto 1 cm2 silicon surface (BSi) from BAu, see equation 3:
BAu-specific = BAu – BSi      (Eqn. 3)
Calculation of surface pKa
To compare the binding of nanoparticles onto the different functionalized gold surfaces, 
first the minimum (Bmin) and maximum (Bmax) percentage of nanoparticle binding onto 
each chemically-modified gold-coated surface was calculated (horizontal bottom and 
top asymptote, respectively), according to equation 4:
BAu-specific = Bmin + ( [Bmax – Bmin] / [1 + 10
(pKa – pH)] )   (Eqn. 4)
Next, for each functionalized gold surface, at each pH value nanoparticle binding was 
normalized between the minimum and maximum binding according to equation 5:
Norm. surface charge = ( [BAu-specific – Bmin] / [Bmax – Bmin] ) * 100% (Eqn. 5)
Finally, the normalized surface charge was plotted as a function of the pH and an 
S-shaped curve with its 95% confidence interval was calculated according to the 
Henderson-Hasselbalch equation. The pKa was defined and calculated as the mid-point 
of the S-shaped curve. All calculations were performed by using GraphPad Prism (v.7.00, 
GraphPad Software, LaJolla, CA, USA).
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RESULTS
pH-dependent stability of nanoparticles
To determine the pKa of gold surfaces that have been modified with basic molecules 
by using oppositely charged (sulfate-modified) nanoparticles, the nanoparticles should 
be physicochemically stable in the investigated pH-range. As shown in Fig. 2, the 
hydrodynamic diameter (94±1 nm), PDI (0.16±0.01), and ζ-potential (-58±6 mV) of the 
negatively charged nanoparticles did not noticeably change in the investigated pH range 
(pH 2 – 10). Besides, no significant difference in fluorescence was observed in a pH range 
between 3-12. So, these nanoparticles are suitable to be used to analyze gold surfaces 
that have been modified with basic groups having surface pKas ranging from 3-9.
Fig. 2 pH-dependent hydrodynamic diameter (A), polydispersity index (PDI, B), ζ-potential (C), 
and fluorescence (D) of fluorescently labeled sulfate modified negatively charged polystyrene 
nanoparticles.
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Assessment of surface modification
The success of the chemical modification of the gold surfaces was assessed by imaging 
the adhesion of the negatively charged fluorescently labeled nanoparticles at three 
different pH values onto the gold-coated silicon slides using fluorescence microscopy. 
As shown in Fig. 3, the nanoparticles bound onto plain (uncoated) silicon surfaces at a 
pH value of 2, but hardly bound at pH values of 2.5 and 7.5. Furthermore, they did not 
bind onto non-modified gold surfaces. In contrast, the fluorescently labeled negatively 
charged fluorescent nanoparticles bound onto the chemically-modified gold surfaces in 
a pH dependent manner. Therefore, this data qualitatively shows that the modification 
of the gold surfaces with the four basic molecules was successful.
pKa determination of chemically-modified gold surfaces
After it was shown that the gold surfaces were successfully modified with a panel of 
basic groups, the FNAA (see materials and methods) was performed. As shown in Fig. 4 
(left side), the binding of negatively charged nanoparticles onto the chemically-modified 
gold-coated silicon slides and the silicon control slides was determined as a function of 
the pH. Because the fluorescently labeled negatively charged nanoparticles also bound 
onto uncoated silicon surfaces at low pH values, the binding of these nanoparticles onto 
the gold-coated silicon slides was corrected for nanoparticle adhesion onto the silicon 
side according to equation 3. As shown in Fig. 4 (right side), the maximum binding of 
negatively charged nanoparticles onto gold surfaces (pH ~2.5) modified with 2-MEA, 
4-MP, or with 4-PEM was comparable (21±4%, 26±14% and 25±3%, respectively), but 
higher for 4-ATP-coated gold surfaces (41±15%).
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Fig. 3 Representative fluorescence microscopy images (200x magnification) of silicon and 
chemically-modified gold-coated silicon surfaces that had been incubated with negatively 
charged fluorescently labeled nanoparticles at different pH values. Abbreviations: 2-MEA 
(2-mercaptoethylamine); 4-MP (4-mercaptopyridine); 4-PEM (4-pyridylethylmercaptan); 4-ATP 
(4-aminothiophenol).
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Fig. 4 Results of FNAA of negatively charged fluorescently labeled nanoparticles onto silicon slides 
(BSi) and gold coated silicon slides modified with pH-sensitive groups (BAu ,left), and gold coated silicon 
slides corrected for nanoparticle adhesion onto the silicon side (BAu-specific ,right). Abbreviations: 
2-MEA (2-mercaptoethylamine); 4-MP (4-mercaptopyridine); 4-PEM (4-pyridylethylmercaptan); 
4-ATP (4-aminothiophenol). Values are represented as mean ± SEM.
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To calculate the pKa value of gold surfaces that were modified with basic groups, the pH-
dependent binding of the negatively charged fluorescently labeled nanoparticles onto 
the gold-coated silicon slides was normalized to the minimum and maximum binding 
(normalized surface charge) according to equation 5. As shown in Fig. 5, the normalized 
surface charge of the gold-coated silicon surfaces modified with the four different 
gold-specific modifiers were significantly distinguishable from each other (as the 95% 
confidence intervals did not overlap between normalized surface charges of 10% to 
90%). The calculated pKa values were 7.4±0.3 (2-MEA), 3.7±0.1 (4-MP), 5.0±0.1 (4-PEM), 
and 5.4±0.1 (4-ATP). These data show that the FNAA is a powerful tool to distinguish 
between pH-sensitive surface groups having different pKa values on gold surfaces that 
are modified with basic molecules.
Fig. 5 Normalized surface charge of chemically-modified gold-coated silicon surfaces as 
a function of the pH, as determined by FNAA. The black dashed line indicates the surface 
pKa where the normalized surface charge is 50% of its maximal value. Abbreviations: 2-MEA 
(2-mercaptoethylamine); 4-MP (4-mercaptopyridine); 4-PEM (4-pyridylethylmercaptan); 4-ATP 
(4-aminothiophenol). Values are represented as mean ± 95% confidence intervals (dotted lines).
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DISCUSSION
Well-characterized functionalized gold surfaces have great potential for pharmaceutical, 
biological and biomedical applications, such as DNA delivery [6], pH-dependent drug 
delivery to cancer cells [13], and biosensors [3]. In this work, gold surfaces were successfully 
modified with a panel of different basic molecules, which was confirmed by using 
negatively charged fluorescently labeled nanoparticles and fluorescence microscopy. 
Such a method using nanoparticles and fluorescence microscopy is a fast, easy and 
cheap approach to check whether the surface modification is successful.
The modification of gold-coated silicon slides with 4-MP, 4-PEM, and 4-ATP resulted in 
pH-sensitive surfaces that are highly positively charged in a (slightly) acidic environment 
and that are (almost) uncharged at physiological pH (7.4). Therefore, these surface 
modifiers have potential for, e.g., pH-dependent drug delivery whereby anionic drugs 
may be adhered to the gold surface at (slightly) acidic pH (positively charged surface) and 
can be released at physiological pH (non-charged surface) [10, 14]. However, the binding of 
negatively charged nanoparticles onto 2-MEA-modified gold surfaces decreased from 
20% to 10%, but did not reach 0%, indicating that 2-MEA surfaces have two surface pKa 
values, one of which is above 10 (2-MEA in solution has a pKa of 10). Similarly to 2-MEA 
on gold (ethylamine surface groups), APTES-modified silicon (propylamine surface 
groups) resulted in surfaces having two pKas, one of 7 and the second of 10
 [9]. However, 
the potential second surface pKa was not further investigated, because the binding of 
negatively charged nanoparticles at higher pH values is not relevant under physiological 
conditions and therefore was outside the scope of this research.
To determine the pKa of functionalized surfaces, a variety of methods have been 
developed, such as an indirect laser-induced temperature jump method [15], interfacial 
impedance [16, 17], differential capacitance measurements [18], reductive desorption [19], 
electrochemical titration [20, 21], piezoelectric quartz crystal microbalance [22], surface 
potential measurements [23, 24], optical absorption spectroscopy [25], surface enhanced 
Raman scattering [26-29], chemical force microscopy [30], faradaic impedance titration 
[31], and contact angle titration [29]. However, most of these methods require expensive 
equipment, are complicated, or lack accuracy because of their invasive character [9, 
32]. As fluorescence spectroscopy is widely available in pharmaceutical and biological 
laboratories, a FNAA may be a good alternative to the methods described above. However, 
a FNAA as previously reported [9] is not directly applicable to determine the surface pKa 
of gold-coated silicon surfaces that have been modified with basic molecules, which 
was therefore adapted in this study.
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In this research it was shown that negatively charged fluorescently labeled nanoparticles 
bound onto plain silicon surfaces at low pH values. This was expected because the 
isoelectic point of silicon surfaces containing silanol groups is between 0.5-3.5 [33]. 
Below the isoelectric point the surface is positively charged and capable of binding 
negatively charged nanoparticles. Therefore, the adhesion of nanoparticles onto gold-
coated silicon slides was corrected for the adhesion of nanoparticles onto the silicon 
side.
The surface pKas obtained by using a FNAA was compared to surface pKa values reported 
in the literature (shown in Table 1). This shows that different surface pKa values have 
been found for the same chemically-modified gold surfaces when using different 
methods (e.g., (Fourier transform)- surface enhanced Raman scattering, chemical force 
microscopy, faradaic impedance titration [12, 18, 19, 26, 28-31]). The surface pKa values obtained 
by using the FNAA (at least for 2-MEA and 4-MP) are in the same range as the values 
reported in the literature. To our knowledge, in the literature there is only one report 
where two of the same gold reactive molecules have been used as in this study. In that 
study by Bryant and Crooks the surface pKa of gold surfaces modified with 4-MP and 
4-ATP were determined by using differential interfacial capacitance [18]. Although the 
surface pKa values obtained in our study using the FNAA were about 1 pKa unit lower, the 
relative difference between the two chemically-modified gold surfaces was similar to 
the difference found by them (~2 pKa units difference). Therefore, these results show 
that the FNAA is a powerful tool to study nanoparticle-surface interaction and is a fairly 
easy and cheap alternative to conventional methods to determine the surface pKa of 
chemically-modified gold surfaces.
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Table 1 Surface pKa (with 95% confidence interval (CI)) of chemically-modified gold surfaces 
obtained by our fluorescent nanoparticle adhesion assay (FNAA) or via various methods reported in 
















































3.3 FT-SERS (Note: authors refer to unpublished 





6.9 Differential interfacial capacitance [18]
CONCLUSION
In this work we have successfully modified gold surfaces with a panel of basic groups with 
different pKa values that are potentially useful for pharmaceutical applications. We have 
shown that the success of the modification of gold surfaces with basic molecules can be 
assessed easily and fast by using negatively charged fluorescently labeled nanoparticles 
and fluoresce microscopy. Finally, by determining the pH-dependent nanoparticle 
adhesion onto gold-coated silicon slides corrected for nanoparticle adhesion onto the 
silicon side, the pKa of gold surfaces modified with a variety of basic molecules can be 
determined.
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Summary, prospects and conclusion
7
SUMMARY
Classically, the intramuscular and subcutaneous routes are used to administer vaccines 
using hypodermic needles. In recent decades, the interest in methods to administer 
vaccines intradermally has increased, as it has become evident that the skin contains a 
much higher number of immune cells in comparison to muscle or subcutis tissue [1-6]. The 
skin may therefore provide a more efficient route for immunization, perhaps even with a 
lower vaccine dose, while retaining safety and efficacy [1-6]. For example, a 60-80% dose 
reduction for intradermal rabies vaccination compared to intramuscular vaccination has 
been reported [7-9]. Dose sparing has also been reported for vaccination against hepatitis 
B [10, 11], influenza [12-17] and polio [18, 19] via the intradermal administration route as compared 
to intramuscular administration.
To administer vaccines into the skin, the physical obstruction provided by the stratum 
corneum must be bypassed in order to deliver the vaccine to the immune cells in the 
skin. The stratum corneum is the outermost layer of the skin and has a thickness of ca. 
15-20 μm [20]. The stratum corneum can be bypassed by using microneedles that are 
long enough to cross the stratum corneum. In addition, the microneedles should be 
short enough to avoid reaching nerve endings and thereby avoiding any pain sensation. 
As such, the advent of microneedles has paved the way for potentially pain-free and 
minimally invasive intradermal immunization [21]. Microneedle-mediated intradermal 
vaccination offers additional advantages over classical intramuscular and subcutaneous 
vaccination, which use hypodermic needles. The use of hypodermic needles results in 
painful injections, carries a risk for needle re-use and needle-stick injuries and has the 
downside of requiring trained personnel to perform the injections. As microneedles are 
short, can be designed for single use and are easy to administer, they may alleviate the 
problems associated with hypodermic needles.
Of the several types of microneedles available [21], the focus in this thesis is on the use 
of hollow microneedles and coated microneedles. Hollow microneedles are hollow-bore 
needles of micrometer scale. The hollow microneedle is inserted into the skin, after 
which a liquid formulation flows through the bore of the needle, effectively injecting 
the formulation into the skin. In the research described in this thesis, a single hollow 
microneedle was used in conjunction with an injection system. Coated microneedles 
are prepared from solid microneedles, which are usually produced in arrays of needles 
protruding from a backplate. The surfaces of these arrays of solid microneedles are 
coated with a vaccine and after insertion into the skin, the coating is released. The 
design and usage of microneedles and microneedle arrays may affect the immune 
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responses, especially as the density and type of immune cells depend on the depth in 
skin at which the antigen is administered.
Dendritic cells (DCs) are immune cells, specialized in the initiation of antigen-specific 
immune responses. Various subsets of DCs are located at different depths in the skin. 
The Langerhans cell (LC) is a type of DC which resides exclusively in the epidermis (upper 
layer of the skin), while the dermal DCs (DDCs) reside exclusively in the dermis (skin layer 
located underneath the epidermis) [1]. As explained in more detail in the introduction of 
this thesis in chapter 1, three subsets of DCs are known to reside in human skin, which 
have seemingly distinct immunological roles. LCs seem to specialize in cytotoxic T cell 
responses, whereas CD14+ DDCs seem more likely to induce humoral responses and 
CD1a+ DDCs are somewhat in between. How these subsets of DCs are most efficiently 
triggered to enhance or shift the immune response to the benefit of intradermal 
vaccination is not fully understood. Therefore, the aim of the research described in 
chapters 2 and 3 was to unravel the dependency of immune responses on the depth at 
which the antigen is administered into skin.
In chapter 2 it is described how the performance of a single hollow microneedle 
injection system was improved to achieve accurate injections at various depths in skin 
using hollow microneedles. These improvements allowed for accurate microinjections 
into rat skin at predetermined injection depths (varying between 50-900 μm), injection 
volumes (1-100 μL) and injection rates (up to 60 μL/min). After establishing the accuracy 
of depth-controlled microinjections, the dependency of monovalent inactivated polio 
vaccine serotype 1 (IPV1)-specific immune responses on the intradermal injection depth 
of IPV1 was investigated. The use of a classic adjuvant, i.e. aluminum salts, is prohibited 
in intradermal immunization due to toxicity. Therefore, IPV1-specific immune response-
enhancing effects of adjuvants CpG oligodeoxynucleotide 1826 (CpG) or cholera 
toxin (CT) in intradermal immunization were also investigated. IPV1-specific immune 
responses resulting from microinjections of IPV1 at skin depths ranging between 50-550 
μm resulted in similar IgG and virus-neutralizing antibody titers against IPV1 and did not 
differ from conventional intramuscular immunization. Furthermore, IPV1 adjuvanted with 
either CpG or CT was administered by intradermal microinjections at a depth in skin 
of 400 μm and by intramuscular administration. Regardless of administration method, 
CpG or CT adjuvanted IPV1 immunization resulted in significantly (7-fold) increased 
IPV1-specific IgG titers. Although IPV1-specific immune responses were unaffected by 
intradermal injection depth, they were enhanced by CpG and CT, which indicates that 
both adjuvants are promising candidates to enhance intradermal IPV1 immunization, as 
an alternative to aluminum salts.
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In chapter 3, the aim was to determine whether migration of, maturation of and antigen 
uptake by LCs, CD1a+ and CD14+ DDCs differ as a result of administration of antigen at 
various doses (1-50 μg) or injection depths (50-1000 μm) in ex vivo human skin. Ovalbumin 
(OVA) was selected as model antigen. By using a skin explant model, after injection of 
antigen into skin, migrated skin cells were collected. Next, the migration, maturation 
and OVA uptake were determined per skin DC subset by using flow cytometric analysis. 
Increasing OVA doses resulted in a trend of enhanced migration of LCs, whilst it resulted 
in statistically significant decreased migration of CD1a+ and CD14+ DDCs. Moreover, 
increasing OVA doses only resulted in increased maturation of CD1a+ DDCs, determined 
as increased expression of costimulatory molecule CD86. Furthermore, the amount of 
OVA uptake and percentage of OVA-containing cells was enhanced for Langerhans cells 
(12-99%) and CD1a+ DDCs (91-99%) with increasing OVA dose. Antigen uptake by CD14+ 
DDCs was most efficient, as demonstrated by a seemingly saturated amount of OVA 
uptake and very high percentage of OVA-containing cells (±99%), even at the lowest 
dose tested. The amount of OVA uptake by CD14+ DDCs was followed by that of CD1a+ 
DDCs and LCs, which demonstrated a 3.5-fold lower and 15.7-fold lower amount of OVA 
uptake, respectively, at the highest tested dose. The migration of, maturation of and 
OVA uptake by LCs, CD1a+ and CD14+ DDCs were independent of the injection depth. 
After determination of the diffusion coefficient of OVA in human skin, it was found that 
the diffusion coefficient of OVA was high enough to obscure any effect of the injection 
depth. Nonetheless, intradermal microinjection by using a single hollow microneedle 
with a 50-fold reduced injection volume resulted in similar antigen uptake as compared 
to an intradermal injection using a conventional hypodermic needle-and-syringe. Thus, 
by using hollow microneedles, the injection volume for intradermal injections may be 
strongly reduced, avoiding discomfort associated with intradermal injections with larger 
injection volumes (100-200 μL) [19].
Upon invading the skin, a pathogen will increase in numbers exponentially during 
infection, simultaneously growing the immune response. Therefore, it was hypothesized 
that mimicking a natural infection during intradermal immunization will enhance vaccine-
specific immune responses. In chapter 4, the aim was to determine whether IPV1-specific 
responses could be enhanced by repeated intradermal injections of fractional IPV1 
doses, compared to a single intradermal or intramuscular bolus injection. Intradermal 
microinjections through a single hollow microneedle were compared to intramuscular 
injections through a hypodermic needle. Rats were immunized intradermally with 5 
D-antigen units (DU) of IPV1 at 150 μm skin depth. This dose was administered as a bolus, 
or in a repeated fractional dosing schedule: 4 doses of 1.25 DU (1/4th of total dose) were 
administered on four consecutive days or every other day; 8 doses of 0.625 DU (1/8th of 
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total dose) were administered on eight consecutive days; or 4 exponentially increasing 
doses (0.04, 0.16, 0.8 and 4 DU), either with or without an exponentially increasing CpG 
oligodeoxynucleotide 1826 (CpG) dose, were administered on four consecutive days. All 
of these repeated fractional dosing schedules resulted in up to ca. 10-fold higher IPV1-
specific IgG responses in comparison to intradermal and intramuscular bolus dosing. 
IPV1 combined with adjuvant CpG in exponential dosing did not significantly increase 
the IPV1-specific IgG responses further. In conclusion, repeated fractional intradermal 
IPV1 dosing leads to superior IPV1-specific IgG responses without the use of adjuvants. 
Based on results in this study, it is expected that a controlled release delivery system 
simulating repeated fractional dosing will result in enhanced antigen-specific immune 
responses, while only using a single administration.
A benefit of using coated microneedle arrays is that the vaccine is in a solid state. 
Therefore, vaccine coated to microneedle arrays is expected to be more stable at 
room temperature as compared to liquid vaccine formulations. In addition, coated 
microneedles are easier to apply than hollow microneedles, which rely on a pumping 
mechanism to flow liquids through the bore of the needle. In order to prepare coated 
microneedle arrays, pH-sensitive microneedle surfaces provide a method to adhere 
antigen to the microneedle surface during coating and to release antigen upon piercing 
the skin, depending amongst others on the environmental pH and surface pKa. However, 
the surface area of the microneedles piercing the skin is a limiting factor for the amount 
of vaccine that can be coated onto the microneedle array. To increase the surface area 
available for coating on the microneedle array, two approaches were investigated in 
chapters 5 and 6. 
A layer-by-layer coating approach effectively stacks alternating positively and negatively 
charged layers of coating onto the microneedle surfaces, thereby increasing the amount 
of vaccine coated onto the microneedle array. The aim of the work described in chapter 
5 was to examine whether a layer-by-layer antigen-coating approach on pH-sensitive 
modified silicon surfaces of microneedles can be used for intradermal immunization. 
Following this approach, pH-sensitive silicon surfaces of high-density microneedle arrays 
(positively charged at coating pH 5.8 and nearly uncharged at pH 7.4) were alternatingly 
coated with negatively charged diphtheria toxoid (DT, an anionic antigen) and positively 
charged N-trimethyl chitosan (TMC, a cationic polymer with adjuvant function). In a dose-
response study, the required DT dose for sufficient DT-specific immune responses was 
first determined. In this dose-response study, intradermal immunization using a single 
hollow microneedle was compared to subcutaneous immunization using a hypodermic 
needle. This study revealed that low-dose intradermal immunization is more efficient 
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than subcutaneous immunization and that the EC50 dose of DT (dose resulting in half 
of maximum effect) upon intradermal immunization is 3-fold lower, as compared to 
subcutaneous immunization. After selecting the DT doses that were required to be 
administered intradermally for sufficient DT-specific immune responses, the DT/TMC 
layer-by-layer coating approach was optimized. It was demonstrated that the amount 
of DT coated onto the microneedle array is reproducible and the intradermally-
administered amount of antigen can be tuned by selecting the number of coated DT/
TMC bilayers. In a subsequent immunization study, microneedle arrays were coated with 
an incrementally increasing number (2, 5, and 10) of DT/TMC bilayers and intradermal 
immunization using these microneedle arrays resulted in incrementally increasing DT-
specific immune responses. Intradermal immunization using microneedle arrays coated 
with 10 bilayers of DT/TMC (corresponding with about 0.6 μg DT delivered intradermally) 
resulted in similar DT-specific immune responses as subcutaneous immunization with 5 
μg of DT adjuvanted with aluminum phosphate, which is an 8-fold dose reduction of DT. 
In chapter 5, it was demonstrated that the layer-by-layer coating approach onto pH-
sensitive microneedles is a versatile method to precisely control the amount of coated 
and intradermally-administered vaccine and that this approach is highly suitable for 
intradermal immunization for DT.
Another approach to increase the surface area available for coating on microneedle 
arrays, is to create a sponge-like gold surface on top of a silicon surface [22]. To this 
end, gold ions were sputtered onto silicon surfaces, creating a sponge-like surface, 
greatly increasing the surface available for coating. In chapter 6, the aim was to evaluate 
the possibilities to create pH-sensitive surface-functionalization on gold surfaces, 
to eventually enable antigen coating for use on coated microneedles. To this aim, 
gold surfaces were functionalized with pH-sensitive basic groups and the pKa of the 
functionalized gold surfaces were determined by using a fluorescent nanoparticle 
adhesion assay. As demonstrated by the binding of negatively charged fluorescently 
labeled nanoparticles to the positively charged functionalized gold surfaces, as visualized 
by fluorescence microscopy, gold-coated silicon slides were successfully modified with 
four different bases: 4-mercaptopyridine (4-MP), 4-pyridylethylmercaptan (4-PEM), 
4-aminothiophenol (4-ATP), and 2-mercaptoethylamine (2-MEA). By quantifying the 
pH-dependent adsorption of negatively charged fluorescently labeled nanoparticles 
onto the functionalized gold surfaces with fluorescence spectroscopy and by using 
the Henderson-Hasselbalch equation, the pKa of these surfaces was determined to be 
3.7±0.1 (4-MP), 5.0±0.1 (4-PEM), 5.4±0.1 (4-ATP), and 7.4±0.3 (2-MEA). In conclusion, gold 
surfaces were successfully functionalized with four different basic molecules, yielding 
modified surfaces with different pKa values.
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PROSPECTS
The single hollow microneedle injection system: the next step in development
After improvements were made to the single hollow microneedle injection system as 
described in chapter 2, this system was used extensively in several studies described in 
this thesis. Major advantages of the system are its accuracy in injection volume, -depth 
and -rate. This accuracy in injection parameters allowed to study several hypotheses 
regarding depth-controlled intradermal vaccine administration. In addition, this system 
was used to perform intradermal microinjections in mice, rat and (ex vivo) human skin. 
Although this injection system is impressive in its accuracy and flexibility in injection 
parameters, it is rather large and too complicated to be used by untrained personnel. 
So, the single hollow microneedle injection system should be miniaturized and made 
user-friendly. Miniaturization could be achieved using a small pump and reservoir for the 
solution for injection, as it was proven in chapter 3 that a very small injection volume still 
resulted in adequate antigen uptake by skin immune cells. User-friendly operation could 
be achieved by opting for fixed injection parameters, removing the need for flexibility 
and extensive configuration before injection, whilst simplifying and miniaturizing the 
design. Results from chapters 2 and 3 indicate that the requirement for depth-controlled 
administration in skin is not strict, which allows for a fixed injection depth.
Ideally a single device is designed, consisting of a single hollow microneedle or an array 
of hollow microneedles, in combination with a reservoir for the solution for injection 
and a method to flow the solution through the bore of the needle (e.g., by using a pump 
or pressure) into the skin. In addition, the device should be safe to use, by preventing 
premature actuation (i.e., before the injection site is targeted) and by preventing needle-
stick injuries by retracting the needle(s) after use. In a most optimistic view, the device is 
ready to be deployed for administration by non-medically trained personnel, to enlarge 
access to vaccines in more difficult to reach areas in the world, where vaccination 
coverage is low due to lack of medically trained personnel.
Depth-controlled intradermal immunization
One of the aims of this thesis was to investigate the effect of administering a vaccine 
at various depths in skin on vaccine-specific immune responses. The rationale stems 
from the distinct immune functions of the various skin DC subsets residing at different 
depths in skin: by administering a vaccine at a specific depth in skin, different skin DC 
subsets may be targeted, exploiting these distinct immune functions. However, the 
results described in chapters 2 and 3 indicate no great influence of depth-controlled 
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intradermal vaccine administration on vaccine-specific immune responses. These 
results suggest that there is no strict requirement with respect to the injection depth 
when using hollow microneedles or the length of the microneedle when using solid 
(dissolvable or coated) microneedles (or microneedle arrays). However, as outlined in 
chapter 3, the diffusion coefficient in skin of the model antigen, OVA (±42 kDa [23]), might 
be high enough to possibly obscure a depth-dependent effect on antigen uptake by 
DCs in skin. Nevertheless, also for IPV1, which is a particulate antigen of about 30 nm 
in diameter [24, 25], no dependency on the injection depth was observed in chapter 2. 
Since most vaccines consist of particulate antigens larger than IPV1, such as (partially) 
inactivated viruses, bacteria, and alum-adsorbed antigens, it will be interesting to 
investigate whether the conclusions for depth-controlled administration of OVA and 
IPV1 can be extrapolated to such larger particulate antigens, which are expected to 
diffuse slower through the different layers of the skin.
As studies described in this thesis investigating depth-controlled intradermal immunization 
were performed solely using a liquid formulation, it will be interesting to evaluate vaccine-
specific immune responses resulting from intradermal immunization with solid (dissolvable 
or coated) microneedles of different length, as it is expected that the intradermal 
diffusion profile of an antigen being released from solid microneedles differs from that of 
an antigen that is formulated in a liquid and delivered via a hollow microneedle.
Dosing schedule
In chapter 4, alternative IPV1 dosing schedules to conventional bolus dosing were 
examined. The dosing schedule was demonstrated to influence the IPV1-specific immune 
responses. Specifically, injection of 1/4 of the total dose on four consecutive days or 
every other day; 1/8 of the total dose on eight consecutive days; or 4 exponentially 
increasing doses, either with or without an exponentially increasing CpG dose, all 
resulted in increased IPV1-specific immune responses. A prolonged dosing schedule 
most probably leads to an antigen depot being formed in germinal centers and it has 
been shown that such a depot is needed for B-cells to proliferate into plasma B-cells 
and memory B-cells [26, 27]. These results indicate that a prolonged-release formulation 
(releasing antigen over several days) may enhance the immune response. Therefore, it 
will be of interest to design a (micro- or nanoparticulate) formulation that is capable of 
delivering the vaccine in multiple doses (perhaps using multiple layers of degradation 
and antigen release), exploiting the prolonged dosing schedule effect as demonstrated 
in chapter 4. In a study investigating different particulate formulations, it was elegantly 
shown that OVA was released in burst at first, but then was released linearly with time for 
lipid bilayer coated OVA encapsulated mesoporous silica nanoparticles [28]. This type of 
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antigen release is continuous, instead of the immediate fractional dosing per day studied 
in chapter 4. Investigating these types of antigen release profiles head-to-head will be 
interesting, in order to determine which release profile is needed for optimal vaccine-
specific immune responses. This information may then be used to develop particulate 
or microneedle designs further, possibly by using solid microneedle (arrays) combining 
antigen burst-release with prolonged antigen release [29-32], ideally with particulate 
systems with different release rates, simulating fractionated dosing.
The future of intradermal immunization
The intradermal immunization route has been quoted as being more efficient than 
other immunization routes. Intradermal rabies immunization resulted in a 60-80% dose 
reduction compared to intramuscular immunization [7-9]. Moreover, dose sparing has 
been reported for intradermal immunization (compared to conventional intramuscular 
immunization) for hepatitis B [10, 11] and influenza [12-17]. The results described in chapter 5 
clearly indicate that a lower DT dose is required when immunizing via the intradermal 
route compared to the conventional subcutaneous route in mice. To consolidate 
whether the intradermal route is truly more efficient in comparison to the conventional 
intramuscular route, more of such preclinical dose-response studies comparing both 
routes are required. Such studies will lay a foundation for multi-armed clinical trials in 
humans studying intradermal versus conventional routes at different doses, to provide 
evidence whether dose-sparing is a possibility by using intradermal immunization. 
Comparative studies in humans are limited, but are needed to validate whether the 
intradermal route is also more efficient in humans.
The best evidence in humans of increased immune responses after intradermal 
immunization in comparison to conventional intramuscular immunization has been 
demonstrated by using IPV. Intradermal immunization of IPV in naïve newborn infants 
resulted in either similar [18, 33] or inferior [34-36] seroconversion rates, compared to 
intramuscular immunization. In addition, intradermal booster immunization of previously 
IPV vaccinated adults resulted in either similar [19, 37] or inferior [38, 39] seroconversion rates, 
compared to intramuscular immunization. However, intradermal immunization in these 
studies was performed with 1/5th of a full IPV dose and was compared to intramuscular 
immunization with a full IPV dose. It is not known why this 1/5 dose was chosen and 
whether it was based on an explorative dose-response study, which is required to 
properly design such studies.
Besides efficacy, the safety of a vaccine is an important aspect as well. Regulatory 
authorities will balance an application for marketing authorization of the vaccine based 
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on safety and efficacy data. Moreover, at the time of writing, the vaccination coverage is 
decreasing [40-42]. This is due to numerous reasons, including religious and philosophical 
reasons [43], but also false claims of adverse effects of vaccines [44-46]. For these reasons, 
the regulatory and public attention to vaccine safety is high. It is therefore imperative to 
maintain a high level of (public) confidence for new intradermal vaccine administration 
devices. As such, in the design of human clinical trials, a risk-based assessment on 
expected adverse events is to be included.
However, to move into clinical trials, the concepts described in this thesis for hollow 
and coated microneedles need to be developed into a (drug) product. Major hurdles to 
take are, for example, the production of the antigen(s), the (removal of) impurities from 
the bulk product, the excipients and perhaps adjuvant(s) to be used in the formulation 
of the vaccine, the stability, shelf-life and storage conditions. Another concern is the 
sterility of the product. Perhaps it is easier to achieve sterility for liquid formulations via 
conventional procedures, than for layer-by-layer coated microneedles, for which new 
procedures will have to be developed.
Intradermal immunization by using the hollow microneedle approach in comparison 
to the coated microneedle approach
In this thesis, vaccines administered by using either a single hollow microneedle injection 
system or a coated microneedle array have been studied. As summarized in Table 1, 
both of the two approaches to deliver vaccines intradermally have distinct advantages 
and disadvantages.
Development of a production process for liquid formulations combined with hollow 
microneedle(s) and applicators will be easier in comparison to development of a 
production process for coated microneedle arrays. Although technical difficulties 
producing the microneedles themselves will be similar, especially the solution 
for injection is easier to develop than a dry formulation of a vaccine coated onto a 
microneedle array. A solution for injection to be administered by hollow microneedle(s) 
is either already available or knowledge and experience in producing one is more readily 
available. Marketing authorization of a hollow microneedle-based vaccine may be easier 
as well, as regulatory experience is available for the solution for injection formulation 
and the medical device will be subjected to regulations for an injection device, for which 
regulatory experience exists as well. Thus, the hollow microneedle approach has a large 
potential to generate a marketable product within a reasonable amount of time.
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Table 1 Comparison of intradermal immunization by using coated microneedle arrays vs. hollow 
microneedles.
Hollow microneedles Coated microneedle arrays







•	 Formulations readily 
available
•	 Shorter development 
times for the  
formulation
•	 Development of a 
multivalent formulation 
is relatively easy
•	 No vaccine is wasted 
during production of 
the product
•	 No limits on dose
•	 A concentrated 
antigen formula-









•	 Extensive reformulation 
needed
•	 More extensive devel-




•	 Coating procedure 
may lead to substantial 
wastage of vaccine
•	 Limited dose requires 












•	 Risk of  
microneedle 
clogging
•	 No increased 
risk of leakage 
for arrays
•	 No risk of  
microneedle 
clogging
•	 Dosing accuracy 
difficult to control, 











•	 No pump 
required
•	 Injection parameters 
not controllable
Although the coated microneedle approach may have a longer route and higher hurdles 
to overcome before being developed into a product ready for marketing authorization, 
it has unique advantages over the hollow microneedle approach. As the coated 
microneedle approach is based on a dry-coated vaccine, it is expected that the vaccine 
is more stable than a liquid vaccine formulation [47, 48], potentially avoiding the need for a 
cold-chain supply. This makes the coated microneedle approach an ideal candidate for 
a vaccine that can be used in extreme environments with high or low temperatures, or 
where a cold-chain supply is not supported. In addition, coated microneedles do not 
require a complicated device to apply them into the skin. This would help spread vaccine 
coverage in remote locations in the world, as untrained personnel should be able to 
administer the vaccine to the population. Or, in case of a pandemic, self-administration 
could help spread vaccine coverage quickly.
In summary, although both approaches have unique advantages over one another, 
hollow microneedle-based vaccines are a more realistic approach and may be expected 
sooner on the market than coated microneedles-based vaccines.
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CONCLUSION
In this thesis, several aspects of microneedle-mediated intradermal vaccination 
were explored. It was demonstrated that vaccine-specific immune responses are 
not dependent on the intradermal administration depth of the vaccine. In contrast, 
by providing a prolonged exposure to the vaccine through repeated fractional doses 
that were intradermally delivered via a hollow microneedle, vaccine-specific immune 
responses were significantly increased. Furthermore, it was demonstrated that a layer-
by-layer coating approach on solid microneedles allows for a dose-tunable and simple 
administration of vaccine. These layer-by-layer coated microneedles were utilized for 
effective immunization and might provide an escape from cold-chain supply.
174 | CHAPTER 7
7
REFERENCES
1. C. Levin, H. Perrin, B. Combadiere, Tailored 
immunity by skin antigen-presenting cells, Hum 
Vaccin Immunother, 11 (2015) 27-36.
2. J.F. Nicolas, B. Guy, Intradermal, epidermal and 
transcutaneous vaccination: from immunology 
to clinical practice, Expert Rev Vaccines, 7 
(2008) 1201-1214.
3. R.B. Belshe, F.K. Newman, J. Cannon, C. Duane, 
J. Treanor, C. Van Hoecke, B.J. Howe, G. Dubin, 
Serum antibody responses after intradermal 
vaccination against influenza, N Engl J Med, 351 
(2004) 2286-2294.
4. B. Bonnotte, M. Gough, V. Phan, A. Ahmed, 
H. Chong, F. Martin, R.G. Vile, Intradermal 
injection, as opposed to subcutaneous 
injection, enhances immunogenicity and 
suppresses tumorigenicity of tumor cells, 
Cancer Res, 63 (2003) 2145-2149.
5. S. Kaushik, A.H. Hord, D.D. Denson, D.V. 
McAllister, S. Smitra, M.G. Allen, M.R. Prausnitz, 
Lack of pain associated with microfabricated 
microneedles, Anesth Analg, 92 (2001) 502-
504.
6. S.M. Bal, Z. Ding, E. van Riet, W. Jiskoot, J.A. 
Bouwstra, Advances in transcutaneous vaccine 
delivery: do all ways lead to Rome?, J Control 
Release, 148 (2010) 266-282.
7. M.J. Warrell, K.G. Nicholson, D.A. Warrell, P. 
Suntharasamai, P. Chanthavanich, C. Viravan, 
A. Sinhaseni, M.K. Chiewbambroongkiat, X. 
Pouradier-Duteil, C. Xueref, et al., Economical 
multiple-site intradermal immunisation with 
human diploid-cell-strain vaccine is effective 
for post-exposure rabies prophylaxis, Lancet, 1 
(1985) 1059-1062.
8. B.P. Quiambao, E.M. Dimaano, C. Ambas, R. 
 
 
Davis, A. Banzhoff, C. Malerczyk, Reducing 
the cost of post-exposure rabies prophylaxis: 
efficacy of 0.1 ml PCEC rabies vaccine 
administered intradermally using the Thai 
Red Cross post-exposure regimen in patients 
severely exposed to laboratory-confirmed 
rabid animals, Vaccine, 23 (2005) 1709-1714.
9. A. Ambrozaitis, A. Laiskonis, L. Balciuniene, A. 
Banzhoff, C. Malerczyk, Rabies post-exposure 
prophylaxis vaccination with purified chick 
embryo cell vaccine (PCECV) and purified 
Vero cell rabies vaccine (PVRV) in a four-
site intradermal schedule (4-0-2-0-1-1): an 
immunogenic, cost-effective and practical 
regimen, Vaccine, 24 (2006) 4116-4121.
10. T. Propst, A. Propst, K. Lhotta, W. Vogel, P. 
Konig, Reinforced intradermal hepatitis B 
vaccination in hemodialysis patients is superior 
in antibody response to intramuscular or 
subcutaneous vaccination, Am J Kidney Dis, 32 
(1998) 1041-1045.
11. H. Micozkadioglu, A. Zumrutdal, D. Torun, S. 
Sezer, F.N. Ozdemir, M. Haberal, Low dose 
intradermal vaccination is superior to high 
dose intramuscular vaccination for hepatitis B 
in unresponsive hemodialysis patients, Ren Fail, 
29 (2007) 285-288.
12. Y.C. Kim, F.S. Quan, D.G. Yoo, R.W. Compans, 
S.M. Kang, M.R. Prausnitz, Improved influenza 
vaccination in the skin using vaccine coated 
microneedles, Vaccine, 27 (2009) 6932-6938.
13. D. Holland, R. Booy, F. De Looze, P. Eizenberg, J. 
McDonald, J. Karrasch, M. McKeirnan, H. Salem, 
G. Mills, J. Reid, F. Weber, M. Saville, Intradermal 
influenza vaccine administered using a new 
microinjection system produces superior 
SUMMARY, PROSPECTS AND CONCLUSION | 175
7
immunogenicity in elderly adults: a randomized 
controlled trial, J Infect Dis, 198 (2008) 650-
658.
14. F.S. Quan, Y.C. Kim, A. Vunnava, D.G. Yoo, J.M. 
Song, M.R. Prausnitz, R.W. Compans, S.M. Kang, 
Intradermal vaccination with influenza virus-
like particles by using microneedles induces 
protection superior to that with intramuscular 
immunization, J Virol, 84 (2010) 7760-7769.
15. D.G. Koutsonanos, E.V. Vassilieva, A. 
Stavropoulou, V.G. Zarnitsyn, E.S. Esser, M.T. 
Taherbhai, M.R. Prausnitz, R.W. Compans, 
I. Skountzou, Delivery of subunit influenza 
vaccine to skin with microneedles improves 
immunogenicity and long-lived protection, Sci 
Rep, 2 (2012) 357.
16. E.V. Vassilieva, H. Kalluri, D. McAllister, M.T. 
Taherbhai, E.S. Esser, W.P. Pewin, J.A. Pulit-
Penaloza, M.R. Prausnitz, R.W. Compans, 
I. Skountzou, Improved immunogenicity of 
individual influenza vaccine components 
delivered with a novel dissolving microneedle 
patch stable at room temperature, Drug Deliv 
Transl Res, 5 (2015) 360-371.
17. R. Arakane, R. Annaka, A. Takahama, K. Ishida, 
M. Yoshiike, T. Nakayama, F. Takeshita, Superior 
immunogenicity profile of the new intradermal 
influenza vaccine compared to the standard 
subcutaneous vaccine in subjects 65 years and 
older: A randomized controlled phase III study, 
Vaccine, 33 (2015) 6650-6658.
18. J. Cadorna-Carlos, E. Vidor, M.C. Bonnet, 
Randomized controlled study of fractional 
doses of inactivated poliovirus vaccine 
administered intradermally with a needle in the 
Philippines, Int J Infect Dis, 16 (2012) e110-116.
19. S.B. Troy, D. Kouiavskaia, J. Siik, E. Kochba, 
H. Beydoun, O. Mirochnitchenko, Y. Levin, 
N. Khardori, K. Chumakov, Y. Maldonado, 
Comparison of the Immunogenicity of Various 
Booster Doses of Inactivated Polio Vaccine 
Delivered Intradermally Versus Intramuscularly 
to HIV-Infected Adults, J Infect Dis, 211 (2015) 
1969-1976.
20. J. van Smeden, M. Janssens, G.S. Gooris, J.A. 
Bouwstra, The important role of stratum 
corneum lipids for the cutaneous barrier 
function, Biochim Biophys Acta, 1841 (2014) 
295-313.
21. K. van der Maaden, W. Jiskoot, J. Bouwstra, 
Microneedle technologies for (trans)dermal 
drug and vaccine delivery, J Control Release, 
161 (2012) 645-655.
22. R. Zhang, H. Olin, Porous Gold Films-A Short 
Review on Recent Progress, Materials (Basel), 7 
(2014) 3834-3854.
23. A.D. Nisbet, R.H. Saundry, A.J. Moir, L.A. 
Fothergill, J.E. Fothergill, The complete 
amino-acid sequence of hen ovalbumin, Eur J 
Biochem, 115 (1981) 335-345.
24. S.Y. Tzeng, K.J. McHugh, A.M. Behrens, S. Rose, 
J.L. Sugarman, S. Ferber, R. Langer, A. Jaklenec, 
Stabilized single-injection inactivated polio 
vaccine elicits a strong neutralizing immune 
response, Proc Natl Acad Sci U S A, 115 (2018) 
E5269-E5278.
25. J.M. Hogle, M. Chow, D.J. Filman, Three-
dimensional structure of poliovirus at 2.9 A 
resolution, Science, 229 (1985) 1358-1365.
26. D. Gatto, S.W. Martin, J. Bessa, E. Pellicioli, P. 
Saudan, H.J. Hinton, M.F. Bachmann, Regulation 
of memory antibody levels: the role of persisting 
176 | CHAPTER 7
7
antigen versus plasma cell life span, J Immunol, 
178 (2007) 67-76.
27. U. Klein, R. Dalla-Favera, Germinal centres: role 
in B-cell physiology and malignancy, Nat Rev 
Immunol, 8 (2008) 22-33.
28. G. Du, R.M. Hathout, M. Nasr, M.R. Nejadnik, J. 
Tu, R.I. Koning, A.J. Koster, B. Slutter, A. Kros, W. 
Jiskoot, J.A. Bouwstra, J. Monkare, Intradermal 
vaccination with hollow microneedles: A 
comparative study of various protein antigen 
and adjuvant encapsulated nanoparticles, J 
Control Release, 266 (2017) 109-118.
29. M. Zaric, O. Lyubomska, O. Touzelet, C. Poux, 
S. Al-Zahrani, F. Fay, L. Wallace, D. Terhorst, 
B. Malissen, S. Henri, U.F. Power, C.J. Scott, 
R.F. Donnelly, A. Kissenpfennig, Skin dendritic 
cell targeting via microneedle arrays laden 
with antigen-encapsulated poly-D,L-lactide-
co-glycolide nanoparticles induces efficient 
antitumor and antiviral immune responses, ACS 
Nano, 7 (2013) 2042-2055.
30. P.C. Demuth, W.F. Garcia-Beltran, M.L. Ai-Ling, 
P.T. Hammond, D.J. Irvine, Composite dissolving 
microneedles for coordinated control of 
antigen and adjuvant delivery kinetics in 
transcutaneous vaccination, Adv Funct Mater, 
23 (2013) 161-172.
31. M. Leone, J. Monkare, J.A. Bouwstra, G. Kersten, 
Dissolving Microneedle Patches for Dermal 
Vaccination, Pharm Res, 34 (2017) 2223-2240.
32. J. Monkare, M. Pontier, E.E.M. van Kampen, G. 
Du, M. Leone, S. Romeijn, M.R. Nejadnik, C. 
O’Mahony, B. Slutter, W. Jiskoot, J.A. Bouwstra, 
Development of PLGA nanoparticle loaded 
dissolving microneedles and comparison with 
hollow microneedles in intradermal vaccine 
delivery, Eur J Pharm Biopharm, 129 (2018) 111-
121.
33. A.J. Mohammed, S. AlAwaidy, S. Bawikar, P.J. 
Kurup, E. Elamir, M.M. Shaban, S.M. Sharif, H.G. 
van der Avoort, M.A. Pallansch, P. Malankar, A. 
Burton, M. Sreevatsava, R.W. Sutter, Fractional 
doses of inactivated poliovirus vaccine in Oman, 
N Engl J Med, 362 (2010) 2351-2359.
34. A. Anand, K. Zaman, C.F. Estivariz, M. Yunus, 
H.E. Gary, W.C. Weldon, T.I. Bari, M. Steven 
Oberste, S.G. Wassilak, S.P. Luby, J.D. 
Heffelfinger, M.A. Pallansch, Early priming 
with inactivated poliovirus vaccine (IPV) and 
intradermal fractional dose IPV administered by 
a microneedle device: A randomized controlled 
trial, Vaccine, 33 (2015) 6816-6822.
35. S. Resik, A. Tejeda, P.M. Lago, M. Diaz, A. 
Carmenates, L. Sarmiento, N. Alemani, B. 
Galindo, A. Burton, M. Friede, M. Landaverde, 
R.W. Sutter, Randomized controlled clinical 
trial of fractional doses of inactivated poliovirus 
vaccine administered intradermally by needle-
free device in Cuba, J Infect Dis, 201 (2010) 
1344-1352.
36. S. Resik, A. Tejeda, R.W. Sutter, M. Diaz, L. 
Sarmiento, N. Alemani, G. Garcia, M. Fonseca, 
L.H. Hung, A.L. Kahn, A. Burton, J.M. Landaverde, 
R.B. Aylward, Priming after a fractional dose of 
inactivated poliovirus vaccine, N Engl J Med, 
368 (2013) 416-424.
37. D. Soonawala, P. Verdijk, A.J. Wijmenga-
Monsuur, C.J. Boog, P. Koedam, L.G. Visser, 
N.Y. Rots, Intradermal fractional booster dose 
of inactivated poliomyelitis vaccine with a jet 
injector in healthy adults, Vaccine, 31 (2013) 
3688-3694.
SUMMARY, PROSPECTS AND CONCLUSION | 177
7
38. C.F. Estivariz, H. Jafari, R.W. Sutter, T.J. John, V. 
Jain, A. Agarwal, H. Verma, M.A. Pallansch, A.P. 
Singh, S. Guirguis, J. Awale, A. Burton, S. Bahl, 
A. Chatterjee, R.B. Aylward, Immunogenicity of 
supplemental doses of poliovirus vaccine for 
children aged 6-9 months in Moradabad, India: 
a community-based, randomised controlled 
trial, Lancet Infect Dis, 12 (2012) 128-135.
39. S. Resik, A. Tejeda, O. Mach, M. Fonseca, M. Diaz, 
N. Alemany, G. Garcia, L.H. Hung, Y. Martinez, 
R. Sutter, Immune responses after fractional 
doses of inactivated poliovirus vaccine using 
newly developed intradermal jet injectors: a 
randomized controlled trial in Cuba, Vaccine, 
33 (2015) 307-313.
40. P.M. Frew, A.K. Fisher, M.M. Basket, Y. Chung, J. 
Schamel, J.L. Weiner, J. Mullen, S.B. Omer, W.A. 
Orenstein, Changes in childhood immunization 
decisions in the United States: Results from 
2012 & 2014 National Parental Surveys, Vaccine, 
34 (2016) 5689-5696.
41. C. Hough-Telford, D.W. Kimberlin, I. Aban, W.P. 
Hitchcock, J. Almquist, R. Kratz, K.G. O’Connor, 
Vaccine Delays, Refusals, and Patient Dismissals: 
A Survey of Pediatricians, Pediatrics, 138 (2016).
42. H.J. Larson, A. de Figueiredo, Z. Xiahong, W.S. 
Schulz, P. Verger, I.G. Johnston, A.R. Cook, N.S. 
Jones, The State of Vaccine Confidence 2016: 
Global Insights Through a 67-Country Survey, 
EBioMedicine, 12 (2016) 295-301.
43. N.S. Clemmons, P.A. Gastanaduy, A.P. 
Fiebelkorn, S.B. Redd, G.S. Wallace, C. Centers 
for Disease, Prevention, Measles - United 
States, January 4-April 2, 2015, MMWR Morb 
Mortal Wkly Rep, 64 (2015) 373-376.
44. J.S. Gerber, P.A. Offit, Vaccines and autism: a 
tale of shifting hypotheses, Clin Infect Dis, 48 
(2009) 456-461.
45. I.o. Medicine, Adverse Effects of Vaccines: 
Evidence and Causality, The National Academy 
Press, Washington, DC, USA, 2012.
46. M.A. Maglione, L. Das, L. Raaen, A. Smith, R. 
Chari, S. Newberry, R. Shanman, T. Perry, M.B. 
Goetz, C. Gidengil, Safety of vaccines used 
for routine immunization of U.S. children: a 
systematic review, Pediatrics, 134 (2014) 325-
337.
47. X. Chen, G.J. Fernando, M.L. Crichton, C. Flaim, 
S.R. Yukiko, E.J. Fairmaid, H.J. Corbett, C.A. 
Primiero, A.B. Ansaldo, I.H. Frazer, L.E. Brown, 
M.A. Kendall, Improving the reach of vaccines 
to low-resource regions, with a needle-
free vaccine delivery device and long-term 
thermostabilization, J Control Release, 152 
(2011) 349-355.
48. H.S. Gill, M.R. Prausnitz, Coating formulations 
for microneedles, Pharm Res, 24 (2007) 1369-
1380.
178 | CHAPTER 7
7









Een uitleg van de onderstreepte woorden is te vinden in de verklarende woordenlijst.
INLEIDING
Het belang van vaccineren
Het belang van vaccineren staat soms ter twijfel. Ten onrechte, want vaccineren 
voorkomt ernstige ziektes. Ziektes die in de vorige eeuw nog verantwoordelijk waren voor 
ziekenhuisopname, permanente schade en sterfte, voornamelijk onder kinderen, komen 
tegenwoordig weinig voor dankzij grootschalige vaccinatieprogramma’s. Behalve leed, 
worden ook medische kosten bespaard door te investeren in vaccinatieprogramma’s.
Hoe werkt een vaccin
Het afweersysteem weert ziekteverwekkers uit ons lichaam. Afweercellen zijn de 
soldaten van het afweersysteem. Zij staan op wacht en starten een afweerreactie 
als zij een ziekteverwekker ontdekken. Deze afweerreactie is zeer belangrijk om de 
ziekteverwekker uit het lichaam te weren.
Een vaccin is een spuitje met daarin een samenstelling van (i) een verzwakte of gedode 
ziekteverwekker, of een onderdeel daarvan, (ii) een adjuvans en (iii) verschillende hulpstoffen 
om het vaccin stabiel en werkzaam te houden. Een dergelijke samenstelling wordt ook wel 
een vaccinformulering genoemd. Na vaccinatie reageren de afweercellen op het vaccin 
en proberen het vaccin af te weren. Met succes, want het vaccin is immers onschadelijk. 
Omdat een vaccin in zekere mate lijkt op de echte ziekteverwekker, leren de afweercellen 
de ziekteverwekker te herkennen en af te weren. Hierdoor zijn de immuuncellen in staat bij 
een infectie de echte ziekteverwekker te herkennen en te neutraliseren.
Soms is een vaccin niet succesvol om het afweersysteem een ziekteverwekker te 
leren herkennen of afweren. In dat geval wordt de ziekteverwekker niet herkend door 
de afweercellen na vaccinatie of treden de afweercellen niet afdoende op tegen de 
ziekteverwekker na vaccinatie. In een dergelijk geval wordt een adjuvans aan het vaccin 
toegevoegd. Een adjuvans maakt de afweercellen actief en spoort deze aan tot actie. 
Een adjuvans is dus een hulpstof die het vaccin werkzamer maakt. Daarnaast is het 
mogelijk dat er meerdere vaccins worden samengevoegd tot één combinatievaccin. Het 
voordeel van een combinatievaccin is dat er minder prikken nodig zijn.
De traditionele manieren van vaccineren
De meeste vaccins worden via een injectienaald in een spier of onderhuids ingespoten. 
182 | APPENDICES
A
Deze manier van vaccineren kan als traditioneel beschouwd worden. In de afgelopen 
jaren is de belangstelling om vaccins op andere manieren toe te dienen echter 
toegenomen, omdat deze mogelijk effectiever zijn.
Eén van deze andere manieren van vaccineren is het injecteren van een vaccin in de huid. 
De huid bevat namelijk veel meer afweercellen dan spieren. Daarom zal vaccineren via de 
huid effectiever kunnen zijn dan vaccinatie via de spier. Zoveel effectiever, dat er wellicht 
een lagere dosis vaccin nodig zal zijn. Dit wordt ook wel dosisbesparing genoemd.
In de wetenschappelijke literatuur is bijvoorbeeld beschreven dat er bij vaccinatie via 
de huid van hondsdolheidsvaccin (rabiësvaccin) een 60-80% lagere dosis nodig is ten 
opzichte van toediening in de spier. Dosisbesparing is ook beschreven voor vaccinatie 
tegen hepatitis B, griep (influenza) en polio, wanneer vaccinatie via de huid werd 
vergeleken met vaccinatie via de spier.
Beschermende functies van de huid
De huid heeft een beschermende functie voor het lichaam. Eén van deze beschermende 
functies is het buiten het lichaam houden van ziekteverwekkers. Zo is er bijvoorbeeld een 
fysieke blokkade, welke wordt verzorgd door de buitenste laag van de huid, de hoornlaag. 
De hoornlaag is zeer dun, ongeveer 15-20 micrometer (ofwel ongeveer één vijftigste 
millimeter) dik. Echter, de fysieke blokkade van de hoornlaag houdt ook vaccins buiten de 
huid. Om vaccins in de huid toe te dienen, moet de hoornlaag omzeild worden. Wanneer er 
naalden gebruikt worden die lang genoeg zijn om de hoornlaag te passeren, kan het vaccin 
afgeleverd worden bij de afweercellen in de huid. Wanneer de naalden bovendien kort 
genoeg zijn, kan een pijnsensatie vermeden worden. Pijnreceptoren liggen namelijk diep in 
de huid. Micronaalden zijn dunne naaldjes met een lengte van slechts 50-1000 micrometer 
(ofwel één twintigste tot 1 millimeter) en voldoen aan deze eigenschappen. De ontwikkeling 
van micronaalden kan daarom leiden tot een manier voor pijnloze vaccinatie.
Nadelen van traditionele vaccinatie met een injectienaald
Hoewel traditionele vaccinatie door middel van een injectienaald effectief is, zijn 
er een aantal nadelen bij het gebruik van injectienaalden. Behalve dat injecties met 
injectienaalden pijnlijk zijn, is er ook een risico dat de injectienaalden hergebruikt 
worden, waardoor een risico op infectie ontstaat. Daarnaast is er een risico voor 
prikaccidenten met infectie als gevolg. Tot slot kunnen de injecties alleen uitgevoerd 
worden door personen die daarvoor geschoold zijn. Omdat micronaalden zo kort zijn, 
voor eenmalig gebruik ontworpen kunnen worden en gemakkelijk te gebruiken zijn, 




Om vaccinatie via de huid mogelijk te maken, zijn er diverse typen micronaalden 
ontwikkeld. In dit proefschrift wordt onderzoek beschreven waarin twee typen 
micronaalden gebruikt worden voor vaccinatie: holle en gecoate micronaalden. 
Holle micronaalden lijken enigszins op traditionele injectienaalden, maar hebben 
veel kleinere afmetingen. Holle micronaalden worden in de huid geprikt, waarna een 
vloeibare vaccinformulering door het holle gedeelte van de naald de huid in vloeit, met 
behulp van een injectiepomp.
In het in dit proefschrift beschreven onderzoek werd een enkele holle micronaald 
gebruikt in combinatie met een applicator- en injectiesysteem (zie figuur 1). Een 
applicatorsysteem is nodig om de holle micronaald nauwkeurig op een gewenste diepte 
in de huid aan te brengen. Een injectiesysteem is nodig om een gewenste dosis van het 
vaccin nauwkeurig toe te dienen. De diepte waarop de micronaalden in de huid gebracht 
worden is van belang, omdat het aantal en het type afweercellen in de huid afhankelijk 
is van de diepte in de huid. Zowel het aantal als het type afweercellen dat bereikt wordt 
zou de effectiviteit van de vaccinatie kunnen beïnvloeden.
Figuur 1 Beelden van het applicator- en injectiesysteem voor enkele holle micronaalden (A en B) 
met een enkele holle micronaald daaraan bevestigd (B) en een zeer sterk vergroot beeld van een 
enkele holle micronaald (C, de witte balk representeert 0,05 mm, ofwel één twintigste millimeter).
Het tweede type in dit proefschrift beschreven micronaalden voor vaccinatie zijn 
gecoate micronaalden, waarvoor massieve micronaalden gebruikt worden. Deze worden 
veelal geproduceerd in rijen welke uit een plaatje steken; dit geheel wordt gewoonlijk 




het oppervlak van de micronaalden op zo’n array gecoat met vaccin (zie figuur 2C). Na 
het inbrengen in de huid van met vaccin gecoate micronaalden-arrays, laat de coating 
van de micronaaldoppervlakken los. De vaccincoating blijft achter in de huid nadat de 
micronaalden-arrays verwijderd zijn (zie figuur 2D). De afweercellen in de huid reageren 
vervolgens op het vaccin.
Het voordeel van met vaccin gecoate micronaalden-arrays is dat zij, in vergelijking 
met een holle micronaald, zeer eenvoudig in de huid ingebracht kunnen worden. Zo 
eenvoudig dat men het in principe zelf zou kunnen doen, mits daarvoor een zeer simpel 
micronaald-toedieningsapparaatje ontworpen wordt. Het nadeel is echter dat de 
hoeveelheid vaccin dat gecoat kan worden op de micronaalden-arrays beperkt is door 
het relatief kleine beschikbare oppervlak voor vaccincoating. De hoeveelheid vaccin 
dat gecoat kan worden kan verhoogd worden door het vergroten van het beschikbare 
oppervlak voor vaccincoating.
Figuur 2 Beelden van micronaalden-arrays. Een overzichtsbeeld van een micronaalden-array met 
576 massieve micronaalden op een 5x5 mm plaatje is weergegeven in A en een 600x vergroot beeld 
daarvan is weergegeven in B (witte balk representeert 0,1 mm, ofwel één tiende millimeter). Beelden 
van de coating (groene en rode kleur) op een met vaccin gecoate micronaald-array is weergegeven 
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in C. Beelden van coating afgegeven in de huid, nadat een met vaccin gecoate micronaald-array in 
de huid is gebracht en verwijderd, is weergegeven in D.
DOELSTELLINGEN VAN HET IN DIT PROEFSCHRIFT BESCHREVEN 
ONDERZOEK
De doelstellingen van het in dit proefschrift beschreven onderzoek zijn:
•	 Inzicht verkrijgen in het effect van de injectiediepte in de huid op de afweerreactie 
tegen een vaccin.
•	 Inzicht verkrijgen in de afweerreactie na vaccinatie via de huid gedurende meerdere 
dagen, ten opzichte van een éénmalige injectie, waarbij de totale hoeveelheid 
vaccin gelijk is.
•	 Opzetten van een methode waarin vaccin en adjuvans afwisselend laag-voor-laag op 
micronaalden-arrays worden aangebracht, om de hoeveelheid aangebracht vaccin 
op de micronaalden-arrays te vergroten voor vaccinatiedoeleinden.
•	 Opzetten van methoden om goudoppervlakken te veranderen, met als doel de 
hoeveelheid te coaten vaccin op goud-gecoate micronaalden-arrays te vergroten.
SAMENVATTING
Dendritische cellen (DCs) zijn afweercellen welke gespecialiseerd zijn in het neutraliseren 
van ziekteverwekkers en het op gang brengen van verdere afweerreacties. DCs zijn 
daarom erg belangrijk bij vaccinatie. Zoals in detail is uitgelegd in de inleiding van dit 
proefschrift (hoofdstuk 1), bevinden zich drie verschillende typen DCs in de humane huid. 
Elk type DC in de huid heeft een andere functie in de afweer tegen ziekteverwekkers. 
Bovendien verblijven deze drie typen DCs in verschillende hoeveelheden op verschillende 
dieptes in de huid. Daarom is de sterkte van de verschillende afweerreacties wellicht 
afhankelijk van de diepte waarop het vaccin in de huid wordt toegediend. Het onderzoek 
dat is beschreven in hoofdstukken 2 en 3 heeft daarom tot doel om te bepalen of de 
afweerreacties op vaccinatie beïnvloed worden door de diepte waarop het vaccin in de 
huid wordt toegediend.
In hoofdstuk 2 is beschreven hoe het applicator- en injectiesysteem voor een holle 
micronaald is verbeterd ten opzichte van het initiële ontwerp. Het injectiesysteem werd 
lekkage-vrij gemaakt door kritieke onderdelen te vervangen door onderdelen bestendig 
tegen hoge druk. Door deze verbeteringen is het mogelijk met een enkele holle micronaald 
in mensen- en rattenhuid te injecteren met een precieze injectiediepte, injectievolume 
en injectiesnelheid. Vervolgens is onderzocht of specifiek tegen geïnactiveerd poliovaccin 
serotype 1 (IPV1) gerichte afweerreacties in ratten beïnvloed worden door de injectiediepte. 
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Tevens is onderzocht of de IPV1-specifieke afweerreacties versterkt kunnen worden door 
adjuvantia aan de IPV1-vaccinformulering toe te voegen. Uit dit onderzoek is gebleken dat 
IPV1-specifieke afweerreacties onafhankelijk zijn van de diepte waarop IPV1 met behulp 
van een holle micronaald in de huid wordt geïnjecteerd. Tevens is gebleken dat vaccinatie 
via de huid net zo effectief is als vaccinatie via de spier. Bovendien leidt toevoeging van 
een adjuvans (CpG oligodeoxynucleotide 1826 (CpG) of choleratoxine (CT)) aan de IPV1-
vaccinformulering tot een verhoging van IPV1-specifieke afweerreacties ten opzichte van 
een IPV1-vaccinformulering zonder adjuvans, ongeacht het type adjuvans (CpG of CT) of 
de toedieningsroute (via de huid of de spier). Beide adjuvantia zijn dus veelbelovende 
kandidaten om het effect van IPV1-vaccinatie via de huid te verbeteren.
In hoofdstuk 3 is onderzocht of de afweerreacties van de drie typen DCs in humane huid 
veranderen, wanneer verschillende doses vaccin worden geïnjecteerd of wanneer een 
vaccin op verschillende dieptes in de huid wordt geïnjecteerd. Nadat de DCs in de huid 
vaccin opnemen, worden zij geactiveerd en migreren vervolgens naar dieper gelegen 
weefsels in het lichaam om daar afweerreacties op gang te brengen. Daarom zijn er drie 
reacties van de DCs op vaccinatie onderzocht: de hoeveelheid opgenomen vaccin, de 
mate van DC-activatie en de mate van migratie van de drie typen DCs in humane huid. Uit 
deze studies is gebleken dat de drie verschillende typen DCs in humane huid van elkaar 
verschillen in de mate waarin zij het vaccin opnemen, de mate waarin zij geactiveerd 
worden en de mate van migratie. Het is gebleken dat deze uitkomsten ook afhankelijk 
zijn van de geïnjecteerde dosis. Echter, de mate van vaccinopname, DC-activatie en 
-migratie wordt niet beïnvloed door de injectiediepte in de huid. Nader onderzoek 
heeft uitgewezen dat het vaccin zich zo snel door de huid beweegt dat het alle lagen 
van de huid kan bereiken gedurende de duur van het experiment. Het injectievolume is 
echter ook van belang, voornamelijk voor de mate van irritatie en pijnsensatie in de huid 
nadat een vaccin in de huid is geïnjecteerd. Het is gebleken dat injecties in de huid met 
holle micronaalden en een zeer klein injectievolume tot vergelijkbare afweerreacties 
leiden als injecties met een normale injectienaald en een groot injectievolume.
Tijdens een natuurlijke infectie kan een ziekteverwekker de huid binnen dringen 
en exponentieel in aantal toenemen tijdens deze infectie. Door deze sterke groei in 
aantallen ziekteverwekkers kan de omvang van de afweerreactie toenemen. Daarom 
is, zoals beschreven in hoofdstuk 4, onderzocht of de afweerreactie toeneemt door 
de vaccindosis over meerdere dagen te verspreiden, al dan niet in een exponentieel 
toenemende dosis. Immers, als het toedienen van vaccin een natuurlijk verloop volgt, 
blijft de afweerreactie gestimuleerd voor langere tijd, waardoor meer afweercellen 
aangetrokken zouden kunnen worden.
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Het doel van de studies beschreven in hoofdstuk 4 is dan ook om te bepalen of IPV1-
specifieke afweerreacties worden versterkt, wanneer een dosis IPV1 in meerdere 
delen wordt opgesplitst en toegediend gedurende meerdere dagen, ten opzichte 
van een gelijke éénmalige dosis IPV1. Voor verspreide toediening zijn verschillende 
doseringsschema’s gebruikt, namelijk vaccinatie gedurende 4 of 8 dagen, om de dag 
of exponentieel toenemend (gedurende 4 dagen en al dan niet met CpG toegevoegd), 
welke zijn vergeleken met een éénmalige toediening. De doseringsschema’s waarbij 
vaccin is geïnjecteerd in de huid gedurende meerdere dagen, al dan niet met een 
exponentieel toenemende dosis, resulteert in een 10-voudige verhoging van IPV1-
specifieke afweerreacties in vergelijking met een éénmalige dosering geïnjecteerd in 
huid of spier. IPV1 gecombineerd met adjuvans CpG in een exponentieel toenemend 
doseringsschema verhoogt de IPV1-specifieke afweerreacties niet verder. Samengevat 
is gebleken dat het toedienen van IPV1 in de huid gedurende meerdere dagen tot 
superieure IPV1-specifieke afweerreacties leidt, waarbij het gebruik van een adjuvans 
geen toegevoegde waarde heeft.
Naast studies gebruikmakend van holle micronaalden zijn er ook studies uitgevoerd 
gebruikmakend van gecoate massieve micronaalden-arrays. Gecoate massieve 
micronaalden-arrays kunnen worden gemaakt door gebruik te maken van pH-gevoelige 
oppervlakken. De lading van pH-gevoelige micronaaldoppervlakken is afhankelijk van de 
pH van de omgeving waarin de oppervlakken zich bevinden. Tijdens het coaten wordt 
een relatief lage pH gebruikt. Bij een lage pH zijn de micronaaldoppervlakken positief 
geladen. Daardoor kan een negatief geladen vaccin zich aan de micronaaldoppervlakken 
hechten. Omdat de pH in de huid neutraal is en de lading van de micronaaldoppervlakken 
afhankelijk is van de pH, wordt de lading op het oppervlak minder. Daardoor verzwakt 
ook de binding tussen vaccin en micronaaldoppervlak. Hierdoor laat het vaccin los van 
de micronaaldoppervlakken nadat de micronaalden-arrays in de huid zijn ingebracht.
Zoals eerder beschreven, is de hoeveelheid vaccin die gecoat kan worden op 
massieve micronaalden-arrays beperkt door het geringe beschikbare oppervlak voor 
vaccincoating. Het in de hoofdstukken 5 en 6 beschreven onderzoek had daarom tot 
doel methoden te ontwikkelen om meer vaccin op de micronaalden-arrays te coaten, 
door gebruikmaking van pH-gevoelige oppervlakken en methoden om het beschikbare 
oppervlak voor vaccincoating te vergroten.
In het onderzoek beschreven in hoofdstuk 5 is een laag-voor-laag coatingsmethode 
ontwikkeld, gebruikmakend van micronaalden-arrays met pH-gevoelige oppervlakken. 




In de eerste stap zijn pH-gevoelige oppervlakken gecreëerd door chemische modificatie 
van micronaaldoppervlakken die bestaan uit silicium. In de tweede stap zijn deze pH-
gevoelige oppervlakken van de micronaalden-arrays afwisselend gecoat met negatief 
geladen difterietoxoïde (DT, een vaccin) en positief geladen N-trimethylchitosan (TMC, 
een polymeer met adjuvansfunctie).
Uit een dosis-responsstudie is gebleken dat de minimaal benodigde DT-dosis voor het 
opwekken van meetbare DT-specifieke afweerreacties ongeveer 300 nanogram is. 
Daarna is de methode om diverse DT/TMC-lagen op de micronaalden-arrays te coaten 
geoptimaliseerd. Hierbij is gebleken dat reproduceerbare hoeveelheden DT op de 
micronaalden-arrays gecoat kunnen worden. Bovendien is gebleken dat de hoeveelheid 
gecoat DT op de micronaalden-arrays verhoogd kan worden door een groter aantal 
DT/TMC-lagen aan te brengen. Daarnaast is gebleken dat de hoeveelheid in de huid 
afgeleverd vaccin mede bepaald wordt door het aantal gecoate DT/TMC-lagen.
In een daaropvolgende vaccinatiestudie in muizen is aangetoond dat vaccinatie met 
micronaalden-arrays gecoat met een stapsgewijs toenemend aantal DT/TMC-lagen 
resulteert in stapsgewijs toenemende DT-specifieke afweerreacties. Vaccinatie met 
behulp van micronaalden-arrays gecoat met 10 DT/TMC-lagen (overeenkomend met 
ongeveer 0,6 microgram in de huid toegediend DT) resulteert in vergelijkbare DT-
specifieke afweerreacties als onderhuidse vaccinatie met 5 microgram DT gecombineerd 
met adjuvans. Dit is een 8-voudige dosisbesparing. Uit de resultaten beschreven in 
hoofdstuk 5 blijkt dat de laag-voor-laag DT/TMC-coatingsmethode op pH-gevoelige 
micronaaldoppervlakken een veelbelovende manier is om DT-vaccinatie via de huid 
mogelijk te maken.
Een andere methode om het beschikbare oppervlak voor vaccincoating op micronaalden-
arrays te vergroten, is het creëren van een sponsachtig goudoppervlak bovenop het 
siliciumoppervlak van de micronaalden-arrays. Om dit vergrote oppervlak te benutten, 
is in hoofdstuk 6 tot doel gesteld om methoden op te zetten voor chemische modificatie 
van goudoppervlakken, zodat pH-gevoelige oppervlakken gecreëerd kunnen worden.
Zoals eerder beschreven, bepaalt de pH van de omgeving of en wanneer een pH-
gevoelig oppervlak in staat is om vaccin te binden en in de huid af te geven, als 
gevolg van een samenspel tussen pH en pKa-waarde. De pH waarbij 50% van de 
oppervlakmoleculen een lading heeft en de andere helft neutraal is, wordt de pKa-
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waarde genoemd. Om te bepalen bij welke pH een oppervlak geladen is, is het van belang 
deze pKa-waarde te meten. Daarom is in het in hoofdstuk 6 beschreven onderzoek 
de pKa-waarde van de gemodificeerde goudoppervlakken bepaald. Uit deze studies is 
gebleken dat goudoppervlakken met succes gemodificeerd kunnen worden met vier 
verschillende moleculen, die na chemische reactie met het goudoppervlak resulteren in 
goudoppervlakken met vier verschillende pKa-waarden.
CONCLUSIE
Met het in dit proefschrift beschreven onderzoek is meer inzicht verkregen in 
verschillende aspecten van vaccinatie via de huid met behulp van micronaalden. Vaccin-
specifieke afweerreacties blijken niet afhankelijk te zijn van de diepte waarop het vaccin 
in de huid wordt toegediend. Vaccin-specifieke afweerreacties blijken daarentegen 
aanzienlijk te worden verhoogd, wanneer het vaccin gedurende meerdere dagen in de huid 
wordt toegediend. Verder bieden zowel holle micronaalden als laag-voor-laag gecoate 
massieve micronaalden met pH-gevoelige micronaaldoppervlakken mogelijkheden om 




•	 Adjuvans (meervoud: adjuvantia): een stof die de afweerreactie tegen een vaccin 
kan versterken.
•	 Afweercellen: lichaamscellen betrokken bij het neutraliseren van ziekteverwekkers.
•	 Afweerreactie: reactie van het lichaam gericht op het neutraliseren van 
ziekteverwekkers.
•	 Afweersysteem: systeem van reacties van het lichaam betrokken bij de neutralisatie 
van ziekteverwekkers.
•	 Applicator- en injectiesysteem: een combinatie van een applicatorsysteem, welke 
nodig is om een holle micronaald op een nauwkeurige manier in de huid te brengen, 
en een injectiesysteem, welke nodig is om de gewenste dosis van het vaccin 
nauwkeurig toe te dienen (zie figuur 1).
•	 Chemische modificatie (van een oppervlak): het aanpassen van de eigenschappen 
van een oppervlak door chemische reacties uit te voeren op het oppervlak, met als 
doel het oppervlak een functie uit te kunnen laten voeren (bijvoorbeeld een pH-
gevoelig oppervlak).
•	 Dendritische cellen (DCs): afweercellen betrokken bij eerste reacties van 
het lichaam op ziekteverwekkers door de binnendringende ziekteverwekkers 
onschadelijk te maken en verdere afweerreacties op gang te brengen.
•	 Difterie: een ziekte veroorzaakt door Corynebacterium diphtheriae, een bacterie 
die gifstoffen maakt welke kunnen leiden tot beschadiging van de hartspier en 
zenuwstelsel. Onbehandeld is de ziekte vaak dodelijk: difterie was één van de 
meest voorkomende doodsoorzaken bij kinderen, totdat vaccinatie tegen difterie 
routinematig werd toegepast.
•	 Difterietoxoïde: het werkzame bestandsdeel in een vaccin tegen difterie.
•	 Dosis-responsstudie: studie waarbij de relatie wordt onderzocht tussen een 
gegeven dosis en het effect daarvan.
•	 DT-specifieke afweerreacties: afweerreacties van het lichaam, welke specifiek 
gericht zijn tegen DT (difterietoxoïde). De hoogte van deze afweerreacties zegt iets 
over de mate van bescherming tegen difterie.
•	 Geïnactiveerd polio vaccin serotype 1 (IPV1): vaccin tegen polio, gebaseerd op 
gedood (geïnactiveerd) poliovirus (sero-)type 1.
•	 Griep (influenza): een ziekte veroorzaakt door het influenzavirus. Infectie van 
de luchtwegen met influenzavirus leidt bij de meeste mensen tot aanzienlijke 
ziekteverschijnselen en soms zelfs tot sterfte.
•	 Hepatitis B: een leverontsteking die wordt veroorzaakt door het hepatitis B-virus, 
welke kan leiden tot levercirrose en leverkanker.
•	 Hondsdolheid (rabiës): een ernstige ziekte als gevolg van een infectie met het 
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rabiësvirus, meestal door een beet van een door rabiës besmet dier (onder andere 
honden, vossen, vleermuizen en katten). Hondsdolheid is uiterst gevaarlijk voor 
mensen en het leidt onbehandeld tot de dood.
•	 Infectie: het binnendringen en zich vestigen van een ziekteverwekker in een levend 
wezen.
•	 IPV1-specifieke afweerreacties: afweerreacties van het lichaam, welke specifiek 
gericht zijn op de afweer van IPV1 (geïnactiveerd polio vaccin serotype 1). De hoogte 
van deze afweerreacties zegt iets over de mate van bescherming tegen polio.
•	 Microgram: één microgram is gelijk aan één miljoenste gram.
•	 Micrometer: één micrometer is een duizendste van een millimeter.
•	 Micronaalden-array: één of meerdere rijen van micronaalden, welke uit een plaatje 
steken (zie figuur 2).
•	 Nanogram: één nanogram is gelijk aan één miljardste gram.
•	 N-trimethylchitosan (TMC): een polymeer met adjuvansfunctie.
•	 Polio (poliomyelitis): een virusziekte welke een ontsteking van de grijze stof in het 
ruggenmerg veroorzaakt. Dit leidt tot ongeneeslijke verlammingen en blijvende 
spierzwakte, bij groeiende kinderen ook tot misvormingen of soms tot de dood als 
de ademhalingsspieren verlamd raken.
•	 Polymeer: aaneenschakeling van identieke of soortgelijke moleculen die chemisch 
aan elkaar zijn gekoppeld.
•	 Vaccin: (farmaceutisch) preparaat waarmee tegen een ziekte wordt gevaccineerd.
•	 Vaccinatieprogramma: een schema waarmee een overheid een aantal als essentieel 
beoordeelde vaccinaties aanbeveelt of verplicht stelt.
•	 Vaccineren: het toedienen van een vaccin.
•	 Vaccinformulering: een samenstelling van (i) een verzwakte of gedode 
ziekteverwekker, of een onderdeel daarvan, (ii) een adjuvans en (iii) verschillende 
hulpstoffen om het vaccin stabiel en werkzaam te houden.
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4 x 1/4th (4 d) four 1/4th doses administered over four consecutive days





8 x 1/8th (8 d) eight 1/8th doses administered over eight consecutive days
APC antigen-presenting cell
BSA bovine serum albumin
CI 95% confidence interval
CLSM confocal laser scanning microscopy





DC-shMN-iSystem digitally-controlled single hollow microneedle injection 
system 
DDC dermal dendritic cell
DT diphtheria toxoid
DT-AF488 diphtheria toxoid conjugated with Alexa Fluor® 488
DT-ALUM aluminum phosphate-adsorbed diphtheria toxoid
DT-IRDYE800 diphtheria toxoid conjugated with near-infrared 




Exp four exponentially increasing doses administered over four 
consecutive days
Exp-CpG four exponentially increasing doses combined with adjuvant 
CpG administered over four consecutive days
FCS fetal calf serum




FRAP fluorescence recovery after photobleaching
FT Fourier transform
FT-SERS Fourier transform surface enhanced Raman scattering




ID-bolus intradermal bolus immunization
IM intramuscular
IM-bolus intramuscular bolus immunization
IMDM Iscove’s modified Dulbecco’s medium
IPV inactivated polio vaccine
IPV1 monovalent inactivated polio vaccine serotype 1
LC Langerhans cell
LSD least significant difference
MFI median fluorescence intensity
MN microneedle
MQ ultrapure deionized Milli-Q water
NaOH sodium hydroxide
OPV oral polio vaccine
OVA ovalbumin
OVA-AF488 ovalbumin conjugated with Alexa Fluor® 488
OVA-FITC ovalbumin conjugated with FITC
PBS phosphate buffered saline
PDI polydispersity index
SC subcutaneous
SDS sodium dodecyl sulfate
SEM scanning electron microscopy
SERS surface enhanced Raman scattering
TMB 3,3’5,5’-tetramethylbenzidine
TMC N,N,N-trimethyl chitosan
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